Browse Biomarkers Based on Biomarker Basis

This page shows data for Expression Based biomarker basis.
Total Entries Retrieved: 1266
IDBiomarkerBiomoleculeSubjectsRegulationTypeExperimentLevel of SignificanceSourcePMID
1 p4036+ p4361+ p4413+p4639+p4749+p5666+p28422 (PSA) Protein Humans Upregulated in PCa: [p4036; p4361; p4413; p4639; p4749; p28422 (PSA)] Downregulated in PCa: [p5666] Diagnostic Prostate Cancer or Prostatic intraepithelial neoplasia Vs Benign Prostatic Hyperplasia or Normal Prostate NA Tissue 12171882
2 p4036 Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Normal Prostate NA Tissue 12171882
3 p4361 Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Normal Prostate NA Tissue 12171882
4 p4639 Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Normal Prostate NA Tissue 12171882
5 p4749 Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Normal Prostate NA Tissue 12171882
6 p4036+p4361 Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Normal Prostate NA Tissue 12171882
7 p4036+p4639 Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Normal Prostate NA Tissue 12171882
8 p4361+p4639 Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Normal Prostate NA Tissue 12171882
9 p4036+p4749 Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Normal Prostate NA Tissue 12171882
10 p4361+p4749 Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Normal Prostate NA Tissue 12171882
11 p4639+p4749 Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Normal Prostate NA Tissue 12171882
12 p4036+p4361+p4639 Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Normal Prostate NA Tissue 12171882
13 p4036+p4361+p4749 Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Normal Prostate NA Tissue 12171882
14 MGC5466+Wnt5A+KIAA0476+ITPR1+TCF2 mRNA Humans Differentially Expressed in Recurrent Cancer Prognostic Recurrence Vs No Recurrence p<0.0001 Tissue 15067324
15 MGC5466+CHAF1A+CDS2+IER3 mRNA Humans Differentially Expressed in Recurrent Cancer Prognostic Recurrence Vs No Recurrence p<0.0001 Tissue 15067324
16 PPFIA3+COPEB+FOS+JUNB+ZFP36 mRNA Humans Differentially Expressed in Recurrent Cancer Prognostic Recurrence Vs No Recurrence p=0.001 Tissue 15067324
17 MGC5466+Wnt5A+KIAA0476+ITPR1+TCF2+CHAF1A+CDS2+IER3+PPFIA3+COPEB+FOS+JUNB+ZFP36 mRNA Humans Differentially Expressed in Recurrent Cancer Prognostic Recurrence Vs No Recurrence p<0.0001 Tissue 15067324
19 XLKD1/LYVE1 mRNA Humans Downregulated in PCa(atleast 2 fold) Diagnostic Normal Prostate vs Prostate Cancer p<0.05 Tissue 14654526
20 CGA mRNA Humans Downregulated in PCa(atleast 2 fold) Diagnostic Normal Prostate vs Prostate Cancer p<0.05 Tissue 14654526
21 F2R/PAR1 mRNA Humans Downregulated in PCa(atleast 2 fold) Diagnostic Normal Prostate vs Prostate Cancer p<0.05 Tissue 14654526
22 BCL-G mRNA Humans Downregulated in PCa(atleast 2 fold) Diagnostic Normal Prostate vs Prostate Cancer p<0.05 Tissue 14654526
23 XLKD1/LYVE1+CGA+ F2R/PAR1+ BCL-G mRNA Humans Differentially Expressed Prognostic Patients with Relapse Vs Without Relapse p<0.05 Tissue 14654526
24 Caveolin-1 Protein Humans Upregulated in African American Men (AA: 39% vs WA: 17%) Prognostic African Americans vs White American men with Prostate Cancer p=0.0048 Tissue 10999725
27 BCL-2 Protein Humans Upregulated in High Gleason Score Prognostic High (8-10) vs Low (2-4) Gleason Score p<0.001 Tissue 11500787
29 Alpha Methylacyl Coenzyme A Racemase (AMACR) mRNA Humans Upregulated in Localised Prostate Cancer (3.1 fold) Diagnostic Benign Prostate vs Localised Prostate Cancer p<0.001 Tissue 11926890
30 Alpha Methylacyl Coenzyme A Racemase (AMACR) mRNA Humans Upregulated in Metastatic Prostate Cancer (1.67 fold) Diagnostic Benign Prostate vs Metastatic Prostate Cancer p<0.004 Tissue 11926890
31 Alpha Methylacyl Coenzyme A Racemase (AMACR) Protein Humans Upregulated in Localised Prostate Cancer [Mean expression Value: (Localised Prostate Cancer: 3.2 vs Normal Prostate: 1.3)] Diagnostic Benign Prostate vs Localised Prostate Cancer p<0.001 Tissue 11926890
36 Lycopene Protein Humans Downregulated (41% fold) Diagnostic Normal vs Cancerous p<0.05 Serum 12497123
37 Lycopene Protein Humans Downregulated (36% fold) Diagnostic Normal vs Cancerous p<0.05 Tissue 12497123
38 Annexin 1 Protein Humans Downregulated in Metastatic hormone refractory PCa (2.23 fold) Prognostic Localized Prostate Cancer VS Metastatic Hormone Refractory Prostate cancer p<0.001 Tissue 12507908
39 Annexin 2 Protein Humans Downregulated in Metastatic hormone refractory PCa (1.51 fold) Prognostic Localized Prostate Cancer VS Metastatic Hormone Refractory Prostate cancer p=0.009 Tissue 12507908
40 Annexin 4 Protein Humans Downregulated in Metastatic hormone refractory PCa (1.3 fold) Prognostic Localized Prostate Cancer VS Metastatic Hormone Refractory Prostate cancer p=0.001 Tissue 12507908
41 Annexin 7 Protein Humans Downregulated in Metastatic hormone refractory PCa (1.42 fold) Prognostic Localized Prostate Cancer VS Metastatic Hormone Refractory Prostate cancer p<0.001 Tissue 12507908
42 Annexin 11 Protein Humans Downregulated in Metastatic hormone refractory PCa (1.81 fold) Prognostic Localized Prostate Cancer VS Metastatic Hormone Refractory Prostate cancer p<0.001 Tissue 12507908
43 Fatty Acid Synthase (FAS) mRNA Humans Upregulated in PCa (3 fold) [Mean Value: PCa:158 Vs Normal: 53] Diagnostic Prostate Cancer Vs Normal Adjacent p<0.00000029 Tissue 12939396
44 Fatty Acid Synthase (FAS) mRNA Humans Upregulated in Metastatic PCa (12 fold) [Mean Value: GS7 :149.2 Vs Metastatic: 1960.8] Prognostic Gleason Score 7 Vs Metastatic Tumor p<0.00000029 Tissue 12939396
45 Fatty Acid Synthase (FAS) Intensity Protein Humans Upregulated in Metastatic PCa (12 fold) [Mean Value: GS7 :149.2 Vs Metastatic: 1960.8] Diagnostic Prostate Cancer Vs Normal Adjacent p<0.00000000857 Tissue 12939396
46 alpha-Methylacyl Coenzyme A Racemase (AMACR) Protein Humans Upregulated in PCa (Prostate Cancer: 3.14 Vs Benign Prostate: 1.3) Diagnostic Benign Prostate Vs Localised Prostate Cancer p<0.00001 Tissue 14982837
47 alpha-Methylacyl Coenzyme A Racemase (AMACR) Protein Humans Upregulated in PCa (Prostate Cancer: 21.6 Vs Benign Prostate: 7.3) Diagnostic Benign Prostate Vs Localised Prostate Cancer p<0.05 Tissue 14982837
48 phosphorylated Akt (pAkt) Protein Humans Upregulated in PSA failures (PSA Failure: [222.18±33.9 vs PSA Non-Failure: 108.79±104.57) Prognostic PSA failure versus PSA non failure p<0.001 Tissue 15289328
49 phosphorylated Akt (pAkt) + phosphorylated ERK (extracellular signal-regulated kinase) (pERK) Protein Humans pAKT: Upregulated in PSA failures; pERK: Downregulated in PSA failures Prognostic PSA failure versus PSA non failure NA Tissue 15289328
50 GalNAc-T3+PSMA+Hepsin+DD3 mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs benign prostatic hyperplasia NA Tissue 15609297
51 PSMA+Hepsin+DD3 mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs benign prostatic hyperplasia NA Tissue 15609297
52 GalNAc-T3+Hepsin+DD3 mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs benign prostatic hyperplasia NA Tissue 15609297
53 GalNAc-T3,+Hepsin+PSMA mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs benign prostatic hyperplasia NA Tissue 15609297
54 GalNAc-T3+PSMA+DD3 mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs benign prostatic hyperplasia NA Tissue 15609297
55 DDR/PCA3 mRNA Humans Upregulated (140 fold) Diagnostic Prostate Cancer Vs benign prostatic hyperplasia p=0.007 Tissue 15609297
56 HEPSIN mRNA Humans Upregulated (21 fold) Diagnostic Prostate Cancer Vs benign prostatic hyperplasia p=0.049 Tissue 15609297
57 PSMA mRNA Humans Upregulated (66 fold) Diagnostic Prostate Cancer Vs benign prostatic hyperplasia p=0.047 Tissue 15609297
58 GalNAc-T3 mRNA Humans Upregulated (4.6 fold) Diagnostic Prostate Cancer Vs benign prostatic hyperplasia p=0.005 Tissue 15609297
59 Kallikrein 4 (KLK4/hK4) Protein Humans Upregulated in PCa Diagnostic Benign prostatic hyperplasia Vs Prostate Cancer p<0.05 Tissue 16172196
60 BCL-2 Protein Humans Upregulated in PCa Patients: PSA >10 ng/ml Prognostic PSA ≤10 ng/ml Vs PSA >10 ng/ml p<0.01 Tissue 15655565
61 COX-2 Protein Humans Upregulated in PCa Patients: PSA >10 ng/ml Prognostic PSA ≤10 ng/ml Vs PSA >10 ng/ml p<0.01 Tissue 15655565
62 BCL-2 Protein Humans Upregulated in Patients with relapse Prognostic PCa Relapse Vs No Relapse p<0.01 Tissue 15655565
63 COX-2 Protein Humans Upregulated in Patients with relapse Prognostic PCa Relapse Vs No Relapse p<0.01 Tissue 15655565
64 Heat Shock Protein (Hsp70) Protein Mice Upregulated in PCa (2 fold) Diagnostic Wild-type mouse dorsal prostate Vs Transgenic Adenocarcinoma Mouse Prostate (TRAMP) dorsal prostate p<0.05 Tissue 15666362
65 Proliferating cell nuclear antigen (PCNA) Protein Mice Upregulated in PCa (1.44 fold) Diagnostic Wild-type mouse dorsal prostate Vs Transgenic Adenocarcinoma Mouse Prostate (TRAMP) dorsal prostate p<0.05 Tissue 15666362
66 Apoliprotein A-1 Protein Mice Upregulated in PCa (1.65 fold) Diagnostic Wild-type mouse dorsal prostate Vs Transgenic Adenocarcinoma Mouse Prostate (TRAMP) dorsal prostate p<0.05 Tissue 15666362
67 Phospholipase C Protein Mice Upregulated in PCa (1.95 fold) Diagnostic Wild-type mouse dorsal prostate Vs Transgenic Adenocarcinoma Mouse Prostate (TRAMP) dorsal prostate p<0.05 Tissue 15666362
68 Glucose regulated protein (GRP 58) Protein Mice Upregulatd in PCa (2 fold) Diagnostic Wild-type mouse dorsal prostate Vs Transgenic Adenocarcinoma Mouse Prostate (TRAMP) dorsal prostate p<0.05 Tissue 15666362
69 Enolase 1, Non-Neuron Protein Mice Upregulatd in PCa (1.8 fold) Diagnostic Wild-type mouse dorsal prostate Vs Transgenic Adenocarcinoma Mouse Prostate (TRAMP) dorsal prostate p<0.05 Tissue 15666362
70 AMACR (o-methylacyl-CoA racemaÌŠse) mRNA Humans Upregulated in PCa (3.3 fold) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
71 SIM2 (single-minded homolog 2) mRNA Humans Upregulated in PCa (2.3 fold) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
72 EST (similar to cDS4 retroviral related polyprotein) mRNA Humans Upregulated in PCa (2.3 fold) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
73 EST (weakly similar to protease) mRNA Humans Upregulated in PCa (2.2 fold) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
74 TRGV9 (Tcell receptory variable 9) mRNA Humans Upregulated in PCa (2.1 fold) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
75 EST (AGR2 anterior gradient 2 homolog) mRNA Humans Upregulated in PCa (2.1 fold) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
76 HPN (hepsin transmembrane protease, serine I) mRNA Humans Upregulated in PCa (2.0 fold) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
77 KCNA5 (potassium voltage-gated channel), mRNA Humans Upregulated in PCa (2.0 fold) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
78 TM4SF13 (transmembrane 4 superfamily member 13) mRNA Humans Upregulated in PCa (2.0 fold) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
79 SOX9 (SRY sex determining region Y-box 9) mRNA Humans Upregulated in PCa (2.0 fold) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
80 SOX4 (SRY sex determining region Y-box 4) mRNA Humans Upregulated in PCa (1.9 fold) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
81 SLC26A2 (solute carrier family 26 member 2) mRNA Humans Upregulated in PCa (1.9 fold) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
82 SYNP02 (synaptopodin) mRNA Humans Downregulated in PCa (4.2 fold ) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
83 SLC18A2 (solute carrier family 18 member 2) mRNA Humans Downregulated in PCa (3.0 fold ) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
84 CALD1 (caldesmon 1) mRNA Humans Downregulated in PCa (2.8 fold ) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
85 MRE11A (meiotic recombination 11 homologue A) mRNA Humans Downregulated in PCa (2.8 fold ) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
86 KRT15 (keratin 15) mRNA Humans Downregulated in PCa (2.7 fold ) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
87 ACTG2 (actin gamma 2 smooth muscle, enteric) mRNA Humans Downregulated in PCa (2.5 fold) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
88 DSIPI (delta sleep inducing peptide, immunoreactor) mRNA Humans Downregulated in PCa (2.5 fold) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
89 SLC18A2 (solute carrier family 18 member 2) mRNA Humans Downregulated in PCa (2.5 fold ) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
90 MME [membrane metallo-endopeptidase] mRNA Humans Downregulated in PCa (2.4 fold ) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
91 KRT17 (similar to keratin 17) mRNA Humans Downregulated in PCa (2.4 fold ) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
92 LY96 (lymphocyte antigen 96) mRNA Humans Downregulated in PCa (2.4 fold ) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
93 SYNP02 (synaptopodin) mRNA Humans Downregulated in PCa (2.4 fold ) Diagnostic Malignant Vs Benign Tissue p<0.05 Tissue 15645116
99 Ghrelin Protein Humans Upregulated in PCa Diagnostic Benign Prostatic Hypertrophy Vs Prostate Cancer p<0.05 Tissue 16322288
100 Preproghrelin Protein Humans Upregulated in PCa Diagnostic Benign Prostatic Hypertrophy Vs Prostate Cancer p<0.05 Tissue 16322288
101 bromo domain containing protein 2 (BRD2),+eukaryotic translation initiation factor 4 gamma 1 (EIF4G1)+ribosomal protein L22 (RPL22)+ribosomal protein L13a (RPL13a)+17 other autoantibodies mRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs Controls p<0.05 Serum 16177248
107 18 proteins with Mass (Da) M3700 + M3904 + M3978 + M4300 + M5085 + M5923 + M6250 + M6569+ M6652 + M7121 + M7782 +M7850 + M7991 + M95031+ M5265 +M15878 + M16003 + M16068 Protein Humans Downregulated in PCa: [M3700 + M3904 + M3978 + M4300 + M5085 + M5923 + M6250 + M6569+ M6652 + M7121 + M7782 +M7850 + M7991 + M95031Upregulated in PCa: [M5265 +M15878 + M16003 + M16068] Diagnostic Prostate Cancer Vs Controls p<0.01 Serum 16372118
108 FPA Protein Humans Downregulated (0.58 fold) Diagnostic Normal vs Prostate Cancer p=0.000108 Serum 16395409
109 Fibrogen alpha Protein Humans Downregulated (0.33 fold) Diagnostic Normal vs Prostate Cancer p=0.00000000000763 Serum 16395409
110 inter-α-trypsin inhibitor heavy chain H4 (ITIH4) Protein Humans Upregulated (121 fold) Diagnostic Normal vs Prostate Cancer p=0.0000108 Serum 16395409
111 Clusterin Beta Protein Humans Upregulated (251 fold) Diagnostic Normal vs Prostate Cancer p=0.00000000481 Serum 16395409
112 factor X111a Protein Humans Upregulated (2.84 fold) Diagnostic Normal vs Prostate Cancer p=0.0000000143 Serum 16395409
113 PCaP Polypeptide Panel (PCAPP) Protein Humans Differentially Expressed in Prostate Cancer Diagnostic Prostate Cancer Vs Healthy Controls p<0.05 Urine 19759844
114 PCDH7, NRXN3, TPTE/ PTEN2, EPHA3, TSPY, HGF, PKIA, PRLR, NR2F1, TNS, MET, CALN1, ADAM-TS3, NPL4, MYO3A, GNA11, GAGEB1/PA GE1, AKAP9, TCF4, MYLK, KLK2, HOXA10, DDR2, EGF, TEM8, XAGE-1, GAS2. mRNA Humans Upregulated (Log2 fold change: 2-7.9 fold) Prognostic Androgen Independent PCa Vs Androgen Dependent PCa NA Cell Lines 17977648
115 ANGPT2, THBS1, CCL5, PTK6, CXCL11, S100P, PSMD5, CDKN2B, PEG3, HTATIP2, CXCL2, RND1, NK4, ACPP, ICAM1, FOSL2, SFN, PLAT, INHBE, CDKN1C, TP73, SOCS2, BMPR1B, CCL2, VIM, SPRY2, CXCL10, LCN2, AKAP12, KLF4, ATF3, FBN1, TWIST1, ALCAM, MSX2, LOX, BTG1, SOCS1, PPP3CA, PPP3CA mRNA Humans Downregulated (Log2 fold change: 1.3-7.8 fold) Prognostic Androgen Independent PCa Vs Androgen Dependent PCa NA Cell Lines 17977648
116 PP2A mRNA Humans Downregulated in PCa Diagnostic Benign Prostatic Hyperplasia (BPH) vs Prostate Cancer (PCa) p=0.0073 Tissue 17977648
123 Neuropeptide Y (NPY) Protein Humans Upregulated in PCa Diagnostic Benign Prostate Vs Prostate Cancer p<0.0001 Tissue 16614113
124 Neuropeptide Y (NPY) Protein Humans Upregulated in PCa Diagnostic HGPIN vs PCa p=0.0108 Tissue 16614113
125 Neuropeptide Y (NPY) Protein Humans Upregulated in Gleason Pattern 4 Prognostic Gleason Pattern 3 Vs Gleason Pattern 4 p=0.042 Tissue 16614113
126 Neuropeptide Y (NPY) Protein Humans Upregulated in Gleason Pattern 5 Prognostic Gleason Pattern 4 Vs Gleason Pattern 5 p=0.037 Tissue 16614113
127 Neuropeptide Y (NPY) Protein Humans Increased expression with increase in relapse Prognostic Relapse Vs No Relapse after Radical Prosteactomy p=0.037 Tissue 16614113
128 Macrophage Inhibitory Cytokine-1 (MIC-1) Protein Humans Upregulated in PCa Diagnostic Benign Prostate Vs Prostate Cancer p<0.0001 Tissue 16614113
129 Macrophage Inhibitory Cytokine-1 (MIC-1) Protein Humans Upregulated in PCa Diagnostic HGPIN vs PCa p<0.0001 Tissue 16614113
130 Macrophage Inhibitory Cytokine-1 (MIC-1) Protein Humans Increased expression with increase in relapse Prognostic Relapse Vs No Relapse after Radical Prosteactomy p=0.037 Tissue 16614113
133 PTGS2 Other Humans Increased expression with increase in relapse Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p = 0.0395 Serum 17764114
135 PCA3 mRNA Humans Upregulated in Positive Biopsy PCa Prognostic Positive Vs Negative Biopsies for PCa NA Urine 17785564
138 CCNE2+CDC6+FBP1+HOXC6+MKI67+MYBL2+PTTG1+DTL+UBE2C+WNT5A+ALCAM+AZGP1+CCK+MYLK+PPAP2B+PROK1 mRNA Humans Upregulated GEX score in PCa Patients (PCa: 7.38 ± 0.35 Vs Non Cancer: 7.2±0.16) Diagnostic No Cancer Vs Prostate Cancer p=0.0013 Tissue 17459658
139 CCNE2+CDC6+FBP1+HOXC6+MKI67+MYBL2+PTTG1+DTL+UBE2C+WNT5A+ALCAM+AZGP1+CCK+MYLK+PPAP2B+PROK1 mRNA Humans Increased GEX Score with relapse Prognostic Relapse Vs No Relapse p=0.007 Tissue 17459658
140 PARP Protein Humans Upregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Native Japanese p=0.02 Tissue 15491717
141 BCL-2 Protein Humans Downregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Native Japanese p=0.01 Tissue 15491717
142 EGFR Protein Humans Upregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Native Japanese p=0.01 Tissue 15491717
143 BAD Protein Humans Upregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Native Japanese p=0.01 Tissue 15491717
144 H3 Protein Humans Upregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Native Japanese p=0.01 Tissue 15491717
145 Lipoxygenase Protein Humans Upregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Native Japanese p=0.01 Tissue 15491717
146 p27 Protein Humans Downregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Native Japanese p=0.01 Tissue 15491717
147 Racemase 3 Protein Humans Upregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Native Japanese p=0.01 Tissue 15491717
148 Ki-67 Protein Humans Upregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Native Japanese p=0.01 Tissue 15491717
149 PARP Protein Humans Upregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Japanese American p=0.01 Tissue 15491717
150 BCL-2 Protein Humans Downregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Japanese American p=0.01 Tissue 15491717
151 EGFR Protein Humans Upregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Japanese American p=0.01 Tissue 15491717
152 BAD Protein Humans Upregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Japanese American p=0.01 Tissue 15491717
153 Lipoxygenase Protein Humans Upregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Japanese American p=0.01 Tissue 15491717
154 p27 Protein Humans Downregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Japanese American p=0.01 Tissue 15491717
155 Racemase 3 Protein Humans Upregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Japanese American p=0.01 Tissue 15491717
156 Ki-67 Protein Humans Upregulated in PCa Diagnostic Benign Vs Cancerous Tissue in Japanese American p=0.01 Tissue 15491717
157 Lipoxygenase Protein Humans Downregulated (in JA compared to NJ) Diagnostic Cancerous Tissue in Japanese American (JA) Vs Native Japanese (NJ) p=0.01 Tissue 15491717
158 Caspase-3 Protein Humans Downregulated (in JA compared to NJ) Diagnostic Cancerous Tissue in Japanese American (JA) Vs Native Japanese (NJ) p=0.01 Tissue 15491717
159 AMACR (α-methylacyl-CoA racemåse) [AMACR 2094, 2097, 2098, 2095] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 2.12E-08 Tissue 16618727
160 PYCR1 (Pyroline 5 - Carboxylate reductase1) mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 8.58E-10 Tissue 16618727
161 MYO6 (Myosin VI) [MYO6-0041] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.15E-08 Tissue 16618727
162 SMPDL3B (Sphingomyelinase like phosphodiesterase 3B) [SMPDL3B 2030] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 2.32E-08 Tissue 16618727
163 NOX4 (NADPH oxidase 4) [NOX4 1355] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.57E-07 Tissue 16618727
164 FASN (Fatty Acid Synthase) [FASN 1432,1433, 1435] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 4.78E-05 Tissue 16618727
165 CACNA1D (Voltage-dep. L-type Calcium Channel Alpha 1D Subunit) [CACNA1D 2040, 2039] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 3.32E-06 Tissue 16618727
166 FBP1 (Fructose 1,6 Bisphosphatase 1) [FBP1 0807] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.46E-07 Tissue 16618727
167 IMPDH2 (Inosine-5′-monophosphate dehydrogenase 2) [IMPDH2 0144,0145] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.68E-05 Tissue 16618727
168 ABCC4 (Multidrug Resistance-Associated Protein 4) [ABCD4 2013] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.09E-05 Tissue 16618727
169 GART (Phosphoribosylglycinamide Formyltransferase) [GART 0310, 0307] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.57E-05 Tissue 16618727
170 CLN3 (ceroid lipofuscinosis, neuronal 3, juvenile) [CLN3 1132] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.50E-05 Tissue 16618727
171 DHPS (Deoxyhypusine Synthase) [DHPS 2028] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.68E-05 Tissue 16618727
172 BIRC5 (Baculoviral IAP Repeat Containing 5 (survivin)) [BIRC5 0847] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.73E-05 Tissue 16618727
173 REPS2 (RALBP1 Associated Eps Domain Containing 2) [REPS2 0732, 0733] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 2.18E-05 Tissue 16618727
174 RPS2 (40S Ribosomal Protein S2) [RPS2-0809] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.051607 Tissue 16618727
175 TMSNB (Thymosin, Beta, identified in neuroblastoma cells) [TMSNB 0227] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 2.34E-05 Tissue 16618727
176 EPB41 (Erythrocyte Membrane Protein Band 4.1) [EPB41 1096,1092] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 2.69E-05 Tissue 16618727
177 GCNT1 (Core 2 Beta1,6 N-Acetylglucosaminyltransferase-I) [GCNT1 0981, 0982,0985] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 8.15E-05 Tissue 16618727
178 LYPLA1 (Lysophospholipase 1) [LYPLA1 0862, 0860] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.006744 Tissue 16618727
179 RET1 (Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret) [RET1 0252 0250] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.008659 Tissue 16618727
180 HSPD1 (Heat Shock 60kDa Protein 1 (Chaperonin)) [HSPD1 0152, 0154] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.033554 Tissue 16618727
181 MAPT (Microtubule Associated Protein Tau) [MAPT 1060] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.000885 Tissue 16618727
182 C7ORF24 (Chromosome 7 Open Reading Frame 24) [C7ORF24 0.001028] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.001028 Tissue 16618727
183 ERBB3 (Erb-B2 Receptor Tyrosine Kinase 3) [ERBB3 1431] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.001238 Tissue 16618727
184 PLA2G2A (Phospholipase A2 Group IIA) [PLA2G2A 1380] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.001569 Tissue 16618727
185 NME1 (Nucleoside Diphosphate Kinase A) [NME1 0827] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.001945 Tissue 16618727
186 CDK7 (Cyclin Dependent Kinase 7) [CDK7 0899] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.002319 Tissue 16618727
187 MMP9 (Matrix Metallopeptidase 9) [MMP9 1185] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.00262 Tissue 16618727
188 BGN (Biglycan) [BGN 1274] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.002956 Tissue 16618727
189 PPIB (Peptidylprolyl Isomerase B (Cyclophilin B)) [PPIB 0969] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.006963 Tissue 16618727
190 IQGAP2 (IQ Motif Containing GTPase Activating Protein 2) [IQGAP2 0234] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.010253 Tissue 16618727
191 DKFZP564B167 (DKFZP564B167 Protein) [DKFZP564B167 0717] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.015526 Tissue 16618727
192 TMEPAI (Transmembrane Prostate Androgen- Induced Protein) [TMEPAI 2074] mRNA Humans Upregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.023696 Tissue 16618727
193 STAC (SH3 And Cysteine Rich Domain) [STAC 1045, 1044, 1047] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 4.42E-07 Tissue 16618727
194 FGFR2 (Fibroblast Growth Factor Receptor 2) [FGFR2 0101,0095,0100,0106, 0107, 0097] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.42E-07 Tissue 16618727
195 CDC42BPA (CDC42 Binding Protein Kinase Alpha) [CDC42BPA 1051] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.56E-08 Tissue 16618727
196 KRT15 (keratin 15) [KRT15 1335, 1333, 1334,1341] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.60E-06 Tissue 16618727
197 TRIM29 (Tripartite Motif Containing 29) [TRIM29 1353, 1348, 1346] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 4.38E-06 Tissue 16618727
198 CES1 (Carboxylesterase ) [CES1 0942, 0937] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.43E-05 Tissue 16618727
199 CLU (Clusterin) [CLU 0196, 0192, 0191] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.000272 Tissue 16618727
200 ALDH1A2 (Aldehyde Dehydrogenase 1A2) [ALDH1A2 0004,0001, 0006] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.000266 Tissue 16618727
201 DRR1 (Collagen and Wnt5a regulated receptor tyrosin kinase) [DRR1 - 0753] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.88E-07 Tissue 16618727
202 ROBO1 (Roundabout, Axon Guidance Receptor, Homolog 1) [ROBO1 1419] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 2.26E-07 Tissue 16618727
203 LTBP4 (Latent TFG Beta Binding Protein 4) [LTBP4 0752, 0747, 0742, 1519, 1518, 0745, 0748, 0746] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.002361 Tissue 16618727
204 PGR (Progesterone Receptor) [PGR 1161, 1162] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 3.77E-06 Tissue 16618727
205 EDNRB (Endothelin Receptor Type B) [EDNRB 1187] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.88E-06 Tissue 16618727
206 ANGPT1 (Angiopoietin 1) [ANGPT1 1032, 1031] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 3.72E-05 Tissue 16618727
207 IGF1 (Insulin like Growth Factor 1 Somatomedin C) [IGF1 0025] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 3.77E-06 Tissue 16618727
208 COL6A2 (Collagen, Type VI, Alpha 2) [COL6A2 1489] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 8.16E-06 Tissue 16618727
209 PTGDS (Prostaglandin D2 Synthase 21kDa) [PTGDS 0787] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.09E-05 Tissue 16618727
210 ANGPTL2 (Angiopoietin-related Protein 2) [ANGPTL2 0950] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 1.20E-05 Tissue 16618727
211 VCL (Vinculin) [VCL 1534, 0933, 0936] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.011744 Tissue 16618727
212 GSTP1 (Glutathione S-transferase P) [GSTP1 0927, 0923] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.030854 Tissue 16618727
213 SAT (Spermidine/Spermine N1-acetyltransferase) [SAT 0840, 0842] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.052888 Tissue 16618727
214 TGFB2 (Transforming Growth Factor, Beta 2) [TGFB2 0085] mRNA Humans Downregulated Diagnostic Cancerous Tissue Vs Normal Tissue 0.095398 Tissue 16618727
215 Endothelial cell-specific molecule 1; Protein tyrosine phosphatase receptor type-Q, CD24 antigen; Gap junction membrane channel protein alpha 1; Transmembrane 4 superfamily member 3; Serpine2; Activated leukocyte cell adhesion molecule; Fibromodulin; Plasminogen activator inhibitor 2 type A; Kelch repeat and BTB (POZ) domain containing 10 (krp1); Preproenkephalin, related sequence; Sialophorin; Thymosin beta-4; Glutamate receptor interacting protein 1; Synuclein, gamma; Hypoxanthine guanine phosphoribosyl transferase; Phosphoribosyl pyrophosphate synthetase 1; Phosphoribosyl pyrophosphate synthetase 2; UDP-Gal:betaGlcNAc beta1,4-galactosyltransferase, polypeptide 6; Dual specificity phosphatase 5; Cytochrome P450, family 3, subfamily a, polypeptide 13; 3-hydroxy-3-methylglutaryl-Coenzyme A reductase ; Branched chain keto acid dehydrogenase E1, beta polypeptide; Cytochrome P450, subfamily 24; Plasminogen activator, urokinase; Caveolin 1; Cyclin D1; High mobility group AT-hook 1; Cxxc5; HNF-3/forkhead homolog-1; Fatty acid binding protein 4, adipocyte; Fatty acid binding protein 5, epidermal; Rabin 3; Phospholipase C, delta 4; Decay-accelarating factor; Coagulation factor II (thrombin) receptor-like 1; Nerve growth factor receptor associated protein 1; Asparagine synthetase; Dual specificity phosphatase 6; Protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), beta isoform; Protein tyrosine phosphatase, receptor type, N1; UDP glycosyltransferase 1 family polypeptide A2; Adenosine monophosphate deaminase 3; Stearoyl-Coenzyme A desaturase 1; Hypothetical LOC290595 (LOC290595), mRNA; Similar to Tubulin alpha-4 chain (Alpha-tubulin 4) (LOC316531), mRNA; Similar to chromosome 14 open reading frame 50 (LOC299153), mRNA; Guanine nucleotide binding protein beta 4 subunit mRNA, partial cds; mRNA Rat Upregulated (Endothelial cell-specific molecule 1 (26.5 fold); Protein tyrosine phosphatase receptor type Q (19.72 fold); CD24 antigen (15.56 fold); Gap junction membrane channel protein alpha 1 (10.53 fold); Transmembrane 4 superfamily member 3 (10.4 fold); Serpine2 (8.61 fold); Activated leukocyte cell adhesion molecule (6.65 fold) ; Fibromodulin (2.62 fold); Plasminogen activator inhibitor 2 type A (2.11 fold); Kelch repeat and BTB (POZ) domain containing 10 (krp1) (36.21 fold); Preproenkephalin, related sequence (24.63 fold); Sialophorin1 (24.14 fold); Thymosin beta-4 (19.82 fold) ; Glutamate receptor interacting protein 1 (8.4 fold) ; Synuclein, gamma (6.62 fold); Hypoxanthine guanine phosphoribosyl transferase (11.45 fold); Phosphoribosyl pyrophosphate synthetase 1 (8.25 fold) ; Phosphoribosyl pyrophosphate synthetase 2 (5.37 fold); UDP-Gal:betaGlcNAc beta1,4-galactosyltransferase, polypeptide 6 (3.4 fold); Dual specificity phosphatase 5 (2.35 fold); Cytochrome P450, family 3, subfamily a, polypeptide 13 (14.28 fold); 3-hydroxy-3-methylglutaryl-Coenzyme A reductase (3.49 fold) ; Branched chain keto acid dehydrogenase E1, beta polypeptide (2.14 fold); Cytochrome P450, subfamily 24 (2.11 fold); Plasminogen activator, urokinase (4.68 fold); Caveolin 1 (31.05 fold) ; Cyclin D1 (7.95 fold); High mobility group AT-hook 1 (15.41 fold) ; Cxxc5 (4.25 fold); HNF-3/forkhead homolog-1 (3.08 fold); Fatty acid binding protein 4, adipocyte (34.02 fold); Fatty acid binding protein 5, epidermal (15.38 fold) ; Rabin 3 (6.46 fold); Phospholipase C, delta 4 (2.64 fold); Decay-accelarating factor (4.02 fold); Coagulation factor II (thrombin) receptor-like 1 (4.96 fold); Nerve growth factor receptor associated protein 1 (8.75 fold); Asparagine synthetase (14.65 fold); Dual specificity phosphatase 6 (11.08 fold); Protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), beta isoform (2.31 fold) ; Protein tyrosine phosphatase, receptor type, N1 (2.22 fold); UDP glycosyltransferase 1 family polypeptide A21 (5.93 fold); Adenosine monophosphate deaminase 3 (2.14 fold); Stearoyl-Coenzyme A desaturase 1 (25.92 fold); Hypothetical LOC290595 (LOC290595), mRNA (8.46 fold); Similar to Tubulin alpha-4 chain (Alpha-tubulin 4) (LOC316531), mRNA (4.76 fold); Similar to chromosome 14 open reading frame 50 (LOC299153), mRNA (3.58 fold); Guanine nucleotide binding protein beta 4 subunit mRNA, partial cds (3.38 fold); Prognostic MAT-LyLu Vs G Cell Lines p<0.005 Cell Lines 17713630
216 Procollagen, type XII, alpha 1; Glycoprotein Ib (platelet), beta polypeptide; Macrophage stimulating 1 (hepatocyte growth factor-like); Alpha-2-macroglobulin; Hyaluronan and proteoglycan link protein 1; Glycoprotein 38; Decorin; Vascular cell adhesion molecule 1; Clusterin; Elastin; Biglycan; Selenoprotein P, plasma, 1; T-cell receptor gamma chain; Myxovirus (influenza virus) resistance 2; Major histocompatibility complex, class II, DM alpha; MHC class Ib RT1.S3; RT1 class Ib, locus Aw2; Similar to interferon regulatory factor 7 (LOC293624), mRNA; Late gestation lung protein 1; Transgelin; Ectonucleoside triphosphate diphosphohydrolase 2; Dual specificity phosphatase 1; Cytochrome b-245, alpha polypeptide; 3-alpha-hydroxysteroid dehydrogenase; Cathepsin S; Alanyl (membrane) aminopeptidase; Dipeptidase 1 (renal); Caspase 1; B-cell translocation gene 3; CD 81 antigen; Similar to RIKEN cDNA 4930415K17 (LOC291670), mRNA; Similar to RIKEN cDNA 4930415K17 (LOC291670), mRNA; LIM homeobox protein 2; Lectin, galactose binding, soluble 9; apolipoprotein E; Ubiquitin carboxy-terminal hydrolase L1; Parvalbumin; Purkinje cell protein 4; Carboxylesterase 1; O-6-methylguanine-DNA methyltransferase; UDP glycosyltransferase 1 family, polypeptide A6; Endothelial differentiation, sphingolipid G-protein-coupled 29415 -2.27 0.003533 receptor, 5; Growth hormone receptor; Insulin-like growth factor 1; Insulin-like growth factor binding protein 5; Peripherin 1; Arginosuccinate synthetase; Lactate dehydrogenase B; Calcium/calmodulin-dependent serine protein kinase; Aminolevulinic acid synthase 1; 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2; Alcohol Dehydrogenase 1; Phosphodiesterase 3B; Similar to kelch domain containing 3; testis intracellular 363192 -2.17 0.03046 mediator protein (LOC363192), mRNA; Similar to cornichon-like protein (LOC361705), mRNA; Similar to RNA-binding protein with multiple splicing 361161 -2.81 0.024735 (RBP-MS) (LOC361161), mRNA; Similar to CLN6 protein (LOC315746), mRNA; Reticulocalbin 3; Similar to CG31613-PA (LOC364716), mRNA; mRNA Rat Downregulated (Procollagen, type XII, alpha 1 (2.18 fold); Glycoprotein Ib (platelet), beta polypeptide (2.5 fold); Macrophage stimulating 1 (hepatocyte growth factor-like) (2.61 fold); Alpha-2-macroglobulin (3.8 fold); Hyaluronan and proteoglycan link protein 1 (3.82 fold); Glycoprotein 38 (3.87 fold); Decorin (5.74 fold); Vascular cell adhesion molecule 1 (7.82 fold); Clusterin (8.84 fold); Elastin (12.76 fold); Biglycan (13.23 fold); Selenoprotein P, plasma, 1 (23.08 fold); T-cell receptor gamma chain (2.2 fold); Myxovirus (influenza virus) resistance 2 (2.22 fold) ; Major histocompatibility complex, class II, DM alpha (2.37 fold); MHC class Ib RT1.S3 (4.8 fold) ; RT1 class Ib , locus Aw2 (5.18 fold); Similar to interferon regulatory factor 7 (LOC293624), mRNA (6.14 fold); Late gestation lung protein 1 (2.26 fold); Transgelin (5.72); Ectonucleoside triphosphate diphosphohydrolase 2 (2.7 fold); Dual specificity phosphatase 1 (2.3 fold); Cytochrome b-245, alpha polypeptide (3.64 fold); 3-alpha-hydroxysteroid dehydrogenase (4.86 fold); Cathepsin S (2.33 fold); Alanyl (membrane) aminopeptidase (3.18 fold); Dipeptidase 1 (renal) (6.82 fold); Caspase 1 (11.12 fold); B-cell translocation gene 3 (17.35 fold); CD 81 antigen (36 fold); Similar to RIKEN cDNA 4930415K17 (LOC291670), mRNA (2.28 fold); Similar to RIKEN cDNA 4930415K17 (LOC291670), mRNA (2.62 fold); LIM homeobox protein 2 (5.43 fold); Lectin, galactose binding, soluble 9 (2.46 fold); apolipoprotein E (29.52 fold); Ubiquitin carboxy-terminal hydrolase L1 (16.29 fold); Parvalbumin (3.85 fold); Purkinje cell protein 4 (6.82 fold); Carboxylesterase 1 (2.16 fold); O-6-methylguanine-DNA methyltransferase (4.62 fold); UDP glycosyltransferase 1 family, polypeptide A6 (3.25 fold); Endothelial differentiation, sphingolipid G-protein-coupled 29415 -2.27 0.003533 receptor, 5 (2.27 fold); Growth hormone receptor (3.12 fold); Insulin-like growth factor 1 (4.85 fold); Insulin-like growth factor binding protein 5 (5.25 fold); Peripherin 1 (7.17 fold); Arginosuccinate synthetase (12.75 fold); Lactate dehydrogenase B (15.07 fold); Calcium/calmodulin-dependent serine protein kinase (4.13 fold); Aminolevulinic acid synthase 1 (2.39 fold); 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 (3.17 fold); Alcohol Dehydrogenase 1 (6.38 fold); Phosphodiesterase 3B (4.76 fold); Similar to kelch domain containing 3 testis intracellular 363192 -2.17 0.03046 mediator protein (LOC363192), mRNA (2.17 fold); Similar to cornichon-like protein (LOC361705), mRNA (2.35 fold); Similar to RNA-binding protein with multiple splicing 361161 -2.81 0.024735 (RBP-MS) (LOC361161), mRNA (2.81 fold); Similar to CLN6 protein (LOC315746), mRNA (3.68 fold); Reticulocalbin 3 (3.94 fold); Similar to CG31613-PA (LOC364716), mRNA (8.61 fold); Prognostic MAT-LyLu Vs G Cell Lines p<0.005 Cell Lines 17713630
217 Kelch repeat and BTB (POZ) domain containing 10 (krp1) mRNA Rat Upregulated in MAT-LyLu (48 fold) Prognostic MAT-LyLu Vs G Cell Lines p=0.01816 Cell Lines 17713630
218 Endothelial cell-specific molecule 1 mRNA Rat Upregulated in MAT-LyLu (23 fold) Prognostic MAT-LyLu Vs G Cell Lines p=0.00995283 Cell Lines 17713630
219 Caveolin 1 mRNA Rat Upregulated in MAT-LyLu (45 fold) Prognostic MAT-LyLu Vs G Cell Lines p=0.0009527 Cell Lines 17713630
220 VEGF (Vascular Endothelial Growth Factor) Protein Humans Downregulated in Prostate Cancer Diagnostic Cancerous Vs Normal Patients p=0.01 Serum 17932343
221 Resistin Protein Humans Downregulated in Prostate Cancer Diagnostic Cancerous Vs Normal Patients p=0.04 Serum 17932343
222 IL-1Ra (Interleukin 1Ra) Protein Humans Downregulated in Prostate Cancer Diagnostic Cancerous Vs Normal Patients p=0.03 Serum 17932343
223 MMP-3 (Matrix Metalloproteinase-3) Protein Humans Downregulated in Prostate Cancer Diagnostic Cancerous Vs Normal Patients p=0.01 Serum 17932343
224 PAI-1(active) (Plasminogen Activator Inhibitor) Protein Humans Downregulated in Prostate Cancer Diagnostic Cancerous Vs Normal Patients p=0.01 Serum 17932343
225 AFP (α- Fetoprotein) Protein Humans Upregulated in Prostate Cancer Diagnostic Cancerous Vs Normal Patients p=0.02 Serum 17932343
226 Kallikrein-8 Protein Humans Downregulated in Prostate Cancer Diagnostic Cancerous Vs Normal Patients p=0.02 Serum 17932343
227 PSA Protein Humans Upregulated in Prostate Cancer Diagnostic Cancerous Vs Normal Patients p=0.0001 Serum 17932343
228 G-CSF (Granulocyte Colony-Stimulating Factor) Protein Humans Downregulated in Prostate Cancer Diagnostic Cancerous Vs Normal Patients p=0.005 Serum 17932343
229 ENC1 + GJB1 mRNA Humans Differentially Expressed Diagnostic Benign Prostate Vs Prostate Cancer p<0.0005 Tissue 17460773
230 MYO6 + AMACR mRNA Humans Differentially Expressed Diagnostic Benign Prostate Vs Prostate Cancer p<0.0005 Tissue 17460773
231 TSPAN13 + PRKCBP1 mRNA Humans Differentially Expressed Diagnostic Benign Prostate Vs Prostate Cancer p<0.0005 Tissue 17460773
232 C20ORF74 + DAPK1 mRNA Humans Differentially Expressed Diagnostic Benign Prostate Vs Prostate Cancer p<0.0005 Tissue 17460773
233 IMAGE:396839 + ENC1 mRNA Humans Differentially Expressed Diagnostic Benign Prostate Vs Prostate Cancer p<0.0005 Tissue 17460773
234 Metaclassifier: ENC1+GJB1+MYO6+AMACR+TSPAN13+PRKCBP+C20ORF74+DAPK1+IMAGE:396839 + ENC1 mRNA Humans Differentially Expressed Prognostic Benign Prostate Vs Prostate Cancer p<0.0005 Tissue 17460773
235 ARL6IP+MYH11 mRNA Humans Differentially Expressed Prognostic Primary Vs Metastatic Prostate Cancer NA Tissue 17460773
236 Cytokeratin 5 (CK5) mRNA Humans Upregulated in Dasatinib Sensitive Cell Lines (>3 fold) Potential Predictive Dasatinib Sensitive Vs Dasatinib Resistant Cell Lines p<0.05 Cell Lines 18047674
237 Prostate Specific Antigen (PSA) mRNA Humans Downregulated in Dasatinib Sensitive Cell Lines (>3 fold) Potential Predictive Dasatinib Sensitive Vs Dasatinib Resistant Cell Lines p<0.05 Cell Lines 18047674
238 Androgen Receptor (AR) mRNA Humans Downregulated in Dasatinib Sensitive Cell Lines (>3 fold) Potential Predictive Dasatinib Sensitive Vs Dasatinib Resistant Cell Lines p<0.05 Cell Lines 18047674
239 Anterior Gradient 2 Homolog AGR2 Protein Humans Upregulatated in PCa (3.8 fold) Diagnostic Normal Vs Prostate Cancer p=0.0021 Serum 18061988
242 CXCL12 Protein Humans Upregulated in Biopsy Positive Patients Diagnostic Biopsy Negative Patients And Biopsy Positive Patients for Prostate Cancer p=0.05 Serum 18196514
243 SPINK1 mRNA Humans Upregulated in PCa Diagnostic Normal Vs Prostate Cancer p=0.0002 Urine 18245462
244 GOLPH2 mRNA Humans Upregulated in PCa Diagnostic Normal Vs Cancer p=0.0002 Urine 18245462
245 PCA3 mRNA Humans Upregulated in PCa Diagnostic Normal Vs Cancer p=0.001 Urine 18245462
246 SPINK1, PCA3, GOLPH2, TMPRSS2:ERG mRNA Humans Upregulated in PCa Diagnostic Normal Vs Cancer p=1.91E-11 Urine 18245462
247 SPINK1, PCA3, GOLPH2, TMPRSS2:ERG mRNA Humans Upregulated in PCa Diagnostic Normal Vs Cancer p=1.91E-11 Urine 18245462
248 PI3-K p85 α mRNA Humans Downregulated in Gleason Score 7-10 Prognostic Gleason Score 5-6 Vs Gleason Score 7-10 p<0.05 Tissue 18336616
249 ILK mRNA Humans Downregulated in Gleason Score 7-11 Prognostic Gleason Score 5-6 Vs Gleason Score 7-10 p<0.05 Tissue 18336616
250 PTEN mRNA Humans Downregulated in Gleason Score 7-12 Prognostic Gleason Score 5-6 Vs Gleason Score 7-10 p<0.05 Tissue 18336616
251 PHLPP mRNA Humans Downregulated in Gleason Score 7-13 Prognostic Gleason Score 5-6 Vs Gleason Score 7-10 p<0.05 Tissue 18336616
252 FOXO1A mRNA Humans Downregulated in Gleason Score 7-14 Prognostic Gleason Score 5-6 Vs Gleason Score 7-10 p<0.05 Tissue 18336616
253 AMACR (Alpha-methylacyl-coA racemase ) Protein Humans Upregulated in PCa Diagnostic High Grade Prostatic Intraepithelial Neoplasia Vs Prostate Cancer p=0.0044 Tissue 18343427
256 TOP2A mRNA Humans Upregulated in PCa (≥2 fold) Diagnostic Prostate Cancer Vs Nonneoplastic Sample p<0.05 Tissue 18347174
257 ERG mRNA Humans Upregulated in PCa (≥2 fold) Diagnostic Prostate Cancer Vs Nonneoplastic Sample p<0.05 Tissue 18347174
258 NRP1 mRNA Humans Upregulated in Aggressive Prostate Cancer Prognostic Non Aggressive Vs Aggressive prostate cancer phenotype p=0.007 Tissue 18347174
259 TOP2A mRNA Humans Upregulated in Aggressive Prostate Cancer Prognostic Non Aggressive Vs Aggressive prostate cancer phenotype p<0.0001 Tissue 18347174
260 RRM2 mRNA Humans Upregulated in Aggressive Prostate Cancer Prognostic Non Aggressive Vs Aggressive prostate cancer phenotype p<0.0001 Tissue 18347174
261 KHRDSB3 mRNA Humans Upregulated in Aggressive Prostate Cancer Prognostic Non Aggressive Vs Aggressive prostate cancer phenotype p=0.015 Tissue 18347174
262 SSTR1 mRNA Humans Upregulated in Aggressive Prostate Cancer Prognostic Non Aggressive Vs Aggressive prostate cancer phenotype p=0.006 Tissue 18347174
280 Golgi phosphoprotein 2 (GOLPH2) mRNA Humans Upregulated in Prostate Cancer(3.04 fold) Diagnostic prostate cancer Vs normal prostate p<0.001 Tissue 18543251
281 Golgi phosphoprotein 2 (GOLPH2) Protein Humans Upregulated in Prostate Cancer Diagnostic prostate cancer Vs normal prostate p<0.01 Tissue 18543251
282 Golgi phosphoprotein 2 (GOLPH2) Protein Humans Upregulated in Prostate Cancer Diagnostic prostate cancer Vs normal prostate epithelium p<0.001 Tissue 18543251
283 Myosin VI (MYO6) mRNA Humans Upregulated in Prostate Cancer Diagnostic Tumor and adjacent normal prostate tissues NA Tissue 18543251
284 %[-2]proPSA Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs No Cancer p=0.001 Serum 18550118
285 PSA+BPSA+%fPSA+%[-2] proPSA+[-2]proPSA/BPSA Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs No Cancer p<0.05 Serum 18550118
286 %fPSA Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs No Cancer p=0.008 Serum 18550118
287 40S ribosomal protein S25 Protein Humans Upregulated (Mean Ratio: 2.13 ±0.44) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
288 40S ribosomal protein S7 Protein Humans Upregulated (Mean Ratio: 5.24 ±0.66) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
289 α-1-antitrypsin precursor (α-1protease inhibitor) Protein Humans Upregulated (Mean Ratio: 3.19 ±0.97) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
290 Cellular nucleic acid-binding protein (CNBP) (Zinc finger protein 9) Protein Humans Upregulated (Mean Ratio: 2.33 ±0.79) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
291 Chondroitin sulfate proteoglycan 2 (Versican) variant (Fragment) Protein Humans Upregulated (Mean Ratio: 2.28 ±0.58) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
292 Chromobox protein homologue 1 (Heterochromatin protein 1 homologue β) Protein Humans Upregulated (Mean Ratio: 3.36 ±0.50) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
293 Cofilin-1 (Cofilin, nonmuscle isoform) (18 kDa phosphoprotein) (p18) Protein Humans Upregulated (Mean Ratio: 3.29 ± 1.2) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
294 Complement component 1 Q subcomponent-binding protein (p33) Protein Humans Upregulated (Mean Ratio: 4.55 ± 1.70) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
295 Elongation factor 1-R 2 (Elongation factor 1 A-2) (Statin S1) Protein Humans Upregulated (Mean Ratio: 2.68 ±0.73) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
296 Ezrin (p81) (Cytovillin) (Villin-2) Protein Humans Upregulated (Mean Ratio: 2.26 ±0.0.49) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
297 FASN variant protein (Fragment) Protein Humans Upregulated (Mean Ratio: 2.78 ±0.91) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
298 FK506-binding protein 4 (Peptidyl-prolyl cis-trans isomerase) (Rotamase) Protein Humans Upregulated (Mean Ratio: 2.46 ±0.29) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
299 Glutamate carboxypeptidase 2 (Folate hydrolase 1) (Prostate- specific membrane antigen) Protein Humans Upregulated (Mean Ratio: 2.82 ±0.95) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
300 Glutathione peroxidase 3 precursor Protein Humans Upregulated (Mean Ratio: 2.19 ±0.57) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
301 Glutathione S-transferase ω-1 Protein Humans Upregulated (Mean Ratio: 2.36 ±0.58) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
302 Heat shock protein HSP90-β Protein Humans Upregulated (Mean Ratio: 3.2 ±0.61) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
303 Histone cluster 1, H1e Protein Humans Upregulated (Mean Ratio: 3.5 ±0.82) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
304 Histone H1.2 (Histone H1d) Protein Humans Upregulated (Mean Ratio: 2.98 ±1.07) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
305 Lactoylglutathione lyase (Aldoketomutase) (Glyoxalase I) Protein Humans Upregulated (Mean Ratio: 2.06 ±0.56) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
306 α-methylacyl-CoA racemase (AMAC) Protein Humans Upregulated (Mean Ratio: 2.51 ±0.62) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
307 Nucleophosmin (NPM) (Nucleolar phosphoprotein B23) (Numatrin) Protein Humans Upregulated (Mean Ratio: 2.6 ±1.01) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
308 Periostin, osteoblast specific factor Protein Humans Upregulated (Mean Ratio: 3.38 ± 1.59) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
309 Prostaglandin E synthase 3 (Telomerase-binding protein p23) (Hsp90 co-chaperone) (Progesterone receptor complex p23) Protein Humans Upregulated (Mean Ratio: 3.14 ±0.56) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
310 Proteasome subunit alpha type 5 (Multicatalytic endopeptidase complex ?-chain) Protein Humans Upregulated (Mean Ratio: 2.07 ±1.70) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
311 Protein mago nashi homologue 2 Protein Humans Upregulated (Mean Ratio: 2.18 ±0.43) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
312 Protein-glutamine γ-glutamyltransferase 4 (Prostate transglutaminase) (Prostate-specific transglutaminase) Protein Humans Upregulated (Mean Ratio: 3.45 ±1.00) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
313 Thioredoxin domain-containing protein 4 precursor Protein Humans Upregulated (Mean Ratio: 2.54 ±0.45) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
314 Ubiquinol-cytochrome c reductase complex 11 kDa protein Protein Humans Upregulated (Mean Ratio: 2.90 ±0.59) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
315 14-3-3 protein β/α Protein Humans Downregulated (Mean Ratio: 0.52 ±0.1) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
316 Androgen receptor-associated protein of 55 kDa (ARA 55) Protein Humans Downregulated (Mean Ratio: 0.38 ±0.11) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
317 α-parvin (Calponin-like integrin-linked kinase-binding protein) (CH-ILKBP) Protein Humans Downregulated (Mean Ratio: 0.53 ±0.08) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
318 Angiotensin-converting enzyme, somatic isoform (precursor) (CD143 antigen) Protein Humans Downregulated (Mean Ratio: 0.32 ±0.09) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
319 Ankyrin repeat domain-containing protein 25 (SRC-1-interacting protein) Protein Humans Downregulated (Mean Ratio: 0.46 ±0.11) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
320 BCL2-associated athanogene 3 variant (Fragment) Protein Humans Downregulated (Mean Ratio: 0.32 ±0.11) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
321 CD44 antigen precursor (Phagocytic glycoprotein I) (Hyaluronate receptor) (Epican) Protein Humans Downregulated (Mean Ratio: 0.23 ±0.07) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
322 Cell surface glycoprotein MUC18 precursor (Melanoma cell adhesion molecule) (CD146 antigen) Protein Humans Downregulated (Mean Ratio: 0.49 ±0.08) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
323 Ciliary dynein heavy chain 10 (Axonemal beta dynein heavy chain 10) (Fragment) Protein Humans Downregulated (Mean Ratio: 0.35 ±0.05) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
324 Collagen α-1(V) chain precursor Protein Humans Downregulated (Mean Ratio: 0.41 ±0.19) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
325 Collagen α-1(VI) chain precursor Protein Humans Downregulated (Mean Ratio: 0.43 ±0.15) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
326 Flotillin-1 Protein Humans Downregulated (Mean Ratio: 0.33 ±0.10) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
327 G antigen family C member 1 (Prostate-associated gene 4 protein) Protein Humans Downregulated (Mean Ratio: 0.25 ±0.09) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
328 γ-synuclein (Persyn) (Breast cancer-specific gene 1 protein) (Synoretin) Protein Humans Downregulated (Mean Ratio: 0.18 ±0.07) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
329 Glutathione S-transferase μ-1 Protein Humans Downregulated (Mean Ratio: 0.42 ±0.09) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
330 Glutathione S-transferase π-1 Protein Humans Downregulated (Mean Ratio: 0.29 ±0.10) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
331 Hsc70-interacting protein (Hip) (Putative tumor suppressor ST13) (Progesterone receptor-associated p48 protein) Protein Humans Downregulated (Mean Ratio: 0.33 ±0.11) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
332 Insulin-degrading enzyme (Insulysin) (Insulinase) (Insulin protease) Protein Humans Downregulated (Mean Ratio: 0.38 ±0.12) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
333 Insulin-like growth factor-binding protein 7 precursor (IGFBP-7) (Prostacyclin-stimulating factor) (PGI2-stimulating factor) Protein Humans Downregulated (Mean Ratio: 0.42 ±0.10) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
334 Kallikrein-11 precursor (Hippostasin) Protein Humans Downregulated (Mean Ratio: 0.41 ±0.09) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
335 Keratin, type I cytoskeletal 17 (Cytokeratin-17) Protein Humans Downregulated (Mean Ratio: 0.38 ±0.14) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
336 Leiomodin-1 (64 kDa autoantigen 1D) Protein Humans Downregulated (Mean Ratio: 0.21 ±0.07) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
337 Microtubule-associated protein 1B (MAP 1B) Protein Humans Downregulated (Mean Ratio: 0.46 ±0.11) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
338 Olfactomedin-like protein 1 precursor Protein Humans Downregulated (Mean Ratio: 0.33 ±0.09) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
339 Phosphoglucomutase-like protein 5 (Aciculin) Protein Humans Downregulated (Mean Ratio: 0.47 ±0.10) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
340 Platelet-activating factor acetylhydrolase IB subunit α Protein Humans Downregulated (Mean Ratio: 0.42 ±0.09) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
341 Prostatic acid phosphatase [Precursor] Protein Humans Downregulated (Mean Ratio: 0.42 ±0.14) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
342 Ras-related protein R-Ras (p23) Protein Humans Downregulated (Mean Ratio: 0.31 ±0.10) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
343 Retinol binding protein I, cellular Protein Humans Downregulated (Mean Ratio: 0.28 ±0.12) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
344 Selenium binding protein 1 (SELENBP1 protein) Protein Humans Downregulated (Mean Ratio: 0.36 ±0.11) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
345 TFIIH basal transcription factor complex helicase XPB subunit (DNA-repair protein complementing XP-B) Protein Humans Downregulated (Mean Ratio: 0.32 ±0.13) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
346 Ubiquitin carboxyl-terminal hydrolase isozyme L1 (Ubiquitin thioesterase L1 Protein Humans Downregulated (Mean Ratio: 0.38 ±0.12) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
347 Vinculin (Metavinculin) Protein Humans Downregulated (Mean Ratio: 0.46 ±0.12) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
348 Zinc-α-2-glycoprotein precursor Protein Humans Downregulated (Mean Ratio: 0.43 ±0.13) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
349 Zyxin Protein Humans Downregulated (Mean Ratio: 0.45 ±0.13) Diagnostic Prostate cancer Vs Benign Prostatic Hyperplasia p≤0.01 Tissue 18553995
360 IL-8 Protein Humans Upregulated in Recurrent Group (Recurrent Group: 181.1 ± 89.3; Non Recurrent Group: 96.4 ± 85.6) Prognostic Reccurance Free Survival Vs Recurrance in 5 years p<0.001 Tissue 18593988
361 Osteopontin Protein Humans Upregulated in Recurrent Group (Recurrent Group: 203.2 ± 78.4; Non Recurrent Group: 127.76 ± 76.6) Prognostic Reccurance Free Survival Vs Recurrance in 5 years p<0.001 Tissue 18593988
362 IL8 + Osteopontin Protein Humans Upregulated in Recurrent Group Prognostic Reccurance Free Survival Vs Recurrance in 5 years p<0.001 Tissue 18593988
365 CD31 Protein Humans Differentially Expressed Prognostic Progression Vs No Progression p=0.009 Tissue 18767028
366 Ki67 Protein Humans Differentially Expressed Prognostic Progression Vs No Progression p=0.003 Tissue 18767028
367 Her-2/neu Protein Humans Differentially Expressed Prognostic Progression Vs No Progression p=0.006 Tissue 18767028
368 CD31 Protein Humans Differentially Expressed Prognostic Progression Vs No Progression p=0.001 Tissue 18767028
369 Ki67 Protein Humans Differentially Expressed Prognostic Progression Vs No Progression p=0.03 Tissue 18767028
370 PCNA Protein Humans Differentially Expressed Prognostic Progression Vs No Progression p=0.03 Tissue 18767028
371 Her-2/neu Protein Humans Differentially Expressed Prognostic Progression Vs No Progression p=0.049 Tissue 18767028
372 CD31 Protein Humans Differentially Expressed Prognostic Progression Vs No Progression p=0.028 Tissue 18767028
373 Her-2/neu Protein Humans Differentially Expressed Prognostic Progression Vs No Progression p=0.025 Tissue 18767028
374 Ki67 Protein Humans Differentially Expressed Prognostic Progression Vs No Progression p=0.027 Tissue 18767028
375 Her-2/neu Protein Humans Negative Staining in Patients with Progression Free Survival Prognostic Progression Free Survival Vs No Progression Survival p=0.001 Tissue 18767043
376 Her-2/neu Protein Humans Negative Staining in Patients with Metastatic Free Survival Prognostic Metastatic Vs Non Metastatic Prostate cancer p=0.002 Tissue 18767043
377 Her-2/neu Protein Humans Negative Staining in Patients with PCa Death Free Survival Prognostic PCa Specific Death Vs No PCa Specific Death p=0.021 Tissue 18767043
383 Serum PSA + DRE + PCA3 mRNA Humans NA Diagnostic Benign vs. PCA p<0.01 Expressed Prostatic Secretion 18948370
384 Serum PSA + DRE + TMPRSS:ERG mRNA Humans NA Diagnostic Benign vs. PCA p<0.001 Expressed Prostatic Secretion 18948370
391 Serum PSA + DRE + PCA3 mRNA Humans NA Diagnostic (Benign Samples + Gleason sums < 7) Vs ≥ 7 p<0.01 Expressed Prostatic Secretion 18948370
393 Ornithine Decarboxylase (ODC) + Ornithine Decarboxylase antizyme (OAZ) +Adenosylmethionine Decarboxylase (AdoMetDC)+ Spermidine/Spermine N(1)-acetyltransferase (SSAT)+ histone H3 (H3)+ growth arrest specific gene (GAS1)+glyceraldehyde 3-phosphate dehydrogenase (GAPDH) + Clusterin (CLU) mRNA Humans Downgregulated in PCa: (GAS1,SSAT, CLU, OAZ, GAPDH); Upregulated in PCa (H3, ODC) Diagnostic Benign Vs Prostate Cancer Clusterin: p<0.01 Tissue 18974881
394 Ornithine Decarboxylase (ODC) + Ornithine Decarboxylase antizyme (OAZ) +Adenosylmethionine Decarboxylase (AdoMetDC)+ Spermidine/Spermine N(1)-acetyltransferase (SSAT)+ histone H3 (H3)+ growth arrest specific gene (GAS1)+glyceraldehyde 3-phosphate dehydrogenase (GAPDH) + Clusterin (CLU) mRNA Humans Downgregulated in PCa: (GAS1,SSAT, CLU, OAZ, GAPDH); Upregulated in PCa (H3, ODC) Prognostic Gleason Score <7 Vs Gleason Score ≥ 7 NA Tissue 18974881
400 Ki-67 Protein Humans Upregulated in PCa Diagnostic Localized prostate cancer Vs benign prostate p<0.01 Tissue 19050681
401 p53 Protein Humans Upregulated in PCa Diagnostic Localized prostate cancer Vs benign prostate p<0.01 Tissue 19050681
402 BCL-2 Protein Humans Upregulated in PCa Diagnostic Localized prostate cancer Vs benign prostate p<0.01 Tissue 19050681
403 Ki-67 Protein Humans Downregulated with Flaxseed supplemented Diet [ Control Diet: 3.23 (95% CI: 2.42-3.92), Flaxseed Supplementation: 1.66 (95% CI: 1.13-2.64)] Predictive Controls Vs Flaxseed Supplementation in Patients with PCa p=0.0013 Tissue 19064574
406 Androgen Receptor (AR) mRNA Humans Upregulated in Hormone Refactory Prostate Cancer (11 fold) Prognostic Hormone Naive Vs Hormone Refractory Prostate Cancer p<0.0001 Tissue 19117982
407 Androgen Receptor AR-V1 mRNA Humans Upregulated in Hormone Refactory Prostate Cancer (22 fold) Prognostic Hormone Naive Vs Hormone Refractory Prostate Cancer p<0.0001 Tissue 19117982
408 Androgen Receptor AR-V7 mRNA Humans Upregulated in Hormone Refactory Prostate Cancer (20 fold) Prognostic Hormone Naive Vs Hormone Refractory Prostate Cancer p<0.0001 Tissue 19117982
409 Androgen Receptor AR-V7 mRNA Humans Higher expression in patients with biochemical recurrence Prognostic PSA Recurrence Vs No PSA Recurrence p=0.012 Tissue 19117982
413 PSA +C4a lacking the C-terminal arginine (C4a des-Arg) + N-terminal fragment of PCI Protein Humans Upregulated in PCa: [C4a lacking the C-terminal arginine (C4a des-Arg)];Downregulated in PCa: [N-terminal fragment of PCI] Prognostic Recurrence Vs No recurrence for 5 years Training: p=0.012 Testing: p=0.011 Serum 19157448
417 Transforming growth factor-b1 Protein Humans Increased Expression with Biochemical Recurrence Prognostic Recurrence Vs No recurrence for 5 years Univariate: p<0.001; Multivariate: p=0.003 Plasma 19229851
418 Interleukin-6 soluble receptor ((IL-6sR) Protein Humans Increased Expression with Biochemical Recurrence Prognostic Recurrence Vs No recurrence for 5 years Univariate: p<0.001; Multivariate: p=0.001 Plasma 19229851
419 Interleukin-6 (IL-6) Protein Humans Increased Expression with Biochemical Recurrence Prognostic Recurrence Vs No recurrence for 5 years Univariate: p<0.001 Plasma 19229851
420 Vascular cell adhesion molecular 1 (VCAM 1) Protein Humans Increased Expression with Biochemical Recurrence Prognostic Recurrence Vs No recurrence for 5 years p<0.001 Plasma 19229851
421 Vascular endothelial growth factor (VEGF) Protein Humans Increased Expression with Biochemical Recurrence Prognostic Recurrence Vs No recurrence for 5 years p=0.002 Plasma 19229851
422 Endoglin Protein Humans Increased Expression with Biochemical Recurrence Prognostic Recurrence Vs No recurrence for 5 years p<0.001 Plasma 19229851
423 Urokinase-type plasminogen activator (uPA) Protein Humans Increased Expression with Biochemical Recurrence Prognostic Recurrence Vs No recurrence for 5 years Univariate: p<0.001; Multivariate: p=0.036 Plasma 19229851
424 Urokinase-type plasminogen activator receptor (uPAR) Protein Humans Increased Expression with Biochemical Recurrence Prognostic Recurrence Vs No recurrence for 5 years p<0.001 Plasma 19229851
425 Gleason sum +TGFB1+ IL-6sR +VCAM1+uPA Protein Humans Increased Expression with Biochemical Recurrence Prognostic Recurrence Vs No recurrence for 5 years NA Plasma 19229851
426 p53 Protein Humans Increased Expression with PCa Specific Death Prognostic Prostate Cancer Specific Survival Vs No Survival Univariate: p<0.001; Multivariate: p=0.03; Tissue 19239456
427 p53 Protein Humans Increased Expression with Overall Death Prognostic Overall Survival Vs No Survival Univariate: p<0.001; Multivariate: p=0.001; Tissue 19239456
428 p53 Protein Humans Increased Expression with PCa Specific Death Prognostic Prostate Cancer Specific Survival Vs No Survival Univariate: p=0.01; Multivariate: p=0.01; Tissue 19239456
429 p53 Protein Humans Increased Expression with Overall Death Prognostic Overall Survival Vs No Survival Univariate: p=0.001; Multivariate: p=0.004; Tissue 19239456
430 TMPRSS2 mRNA Humans Upregulated in PCa: (Normal: 0.26 ± 0.04 vs PCa: 3.91 ± 0.78) Diagnostic prostate cancer Vs Adjacent Normal p=0.001 Tissue 19242826
431 TMPRSS2 mRNA Humans Upregulated (Clinical Stage 1&2: 3.43 ± 0.62 ; Vs Clinical Stage 3: 5.45 ± 0.92) Prognostic Clincal Stage (1-2) Vs Clinical Stage 3 p=0.02 Tissue 19242826
432 TMPRSS2 mRNA Humans Upregulated (GS<6 4.64 ± 0.35 vs GS>6: 8.34 ± 1.53) Prognostic Gleason Score ≤6, Vs Gleason Score>6 p=0.008 Tissue 19242826
433 TMPRSS2 mRNA Humans Upregulated (Tumor Grade 1-2: 2.35 ± 1.45 vs Tumor Grade 3: 3.41 ± 2.31) Prognostic Tumor Grade (1-2) Vs Tumor Grade 3 p=0.016 Tissue 19242826
434 KLK11 mRNA Humans Upregulated in PCa: (Normal: 0.49 ± 0.07 vs PCa: 3.63 ± 0.42) Diagnostic prostate cancer Vs Adjacent Normal p=0.003 Tissue 19242826
435 KLK11 mRNA Humans Upregulated (CS: (1-2) 6.05 ± 1.34 vs CS 3: 3.93 ± 0.45) Prognostic Clincal Stage (1-2) Vs Clinical Stage 3 p=0.009 Tissue 19242826
436 KLK11 mRNA Humans Upregulated (GS<6 4.64 ± 0.35 vs GS>6: 8.34 ± 1.53) Prognostic Gleason Score ≤6, Vs Gleason Score>6 p=0.01 Tissue 19242826
437 KLK11 mRNA Humans Upregulated (Tumor Grade 1-2 : 2.35 ± 1.45 vs Tumor Grade 3: 3.41 ± 2.31) Prognostic Tumor Grade (1-2) Vs Tumor Grade 3 p=0.006 Tissue 19242826
440 Ki-67 Protein Humans Differentially Expressed Prognostic Cause Specific Survival Vs No Survival p<0.001 Tissue 19293807
441 Ki-67 Protein Humans Differentially Expressed [Cause Specific Survial (Δχ2 = 24.6) and overall survival (Δχ2 = 20.5)] Prognostic Overall Survival Vs No Survival p<0.001 Tissue 19293807
442 ACPP; AD-017; AMIGO2; APPBP2; ASNS; ATAD2; ATP6V0E; ATXN1; AURKB; B3GALT4; BANK1; BCAP29; BIRC5; BM039 (CENPN); BRE; BUB1; BUB1B; C18orf10; C1orf9; C22orf18 (CENPM); C5orf13; C6orf111; C6orf210; C9orf116; C9orf127; CATSPER2; CCNA2; CCNB1; CCNB2; CCNE2; CD24; CDC16; CDC2; CDC20; CDC25C; CDC6; CDC7; CDKN3; CENPA; CENPC1; CENPF; CHEK1; CHEK1; CITED2; CITED2; CLUL1; COH1; CPT2; CRADD; CTSL2; CYFIP2; DEPDC1; DGKA; DMXL1; DSCR1L1; EFNB2; ESPL1; F2R; FEN1; FLJ10036; FLJ10534; FLJ22624; GABARAPL1; GALNT7; GFPT1; GGA2; GTSE1; GTSE1; H2AFX; H2AFY; HCAP-G; HCAP-G; HECA; HMGB2; HMMR; HMMR; HPS1; IL13RA1; INSIG1; KIAA0999; KIAA1608; KIF14; KIF20A; KIF4A KLK2; KLK2; KLK3; KNS2; KNTC2; LAMB2; LMAN1; LOC54103; MAC30; MALT1; MAPK8IP1; MCM5 ; MID1; MLF1IP; MLLT3; MTHFD2; MTMR1; MYCBP2; MYH10; MYRIP; NAP1L3; NAV3; NEK2; NEK2 NLGN1; NUSAP1; OIP5; OSR2; PBEF1; PCLO; PDE9A; PDIR; PER3; PIK3R1;PINK1; PIR51; PLCB4; PLK1; PMAIP1; PMS2L11; PMSCL1; PRC1; PRKWNK1; PTBP1; PTBP2; PTCD1 ; PTPN13; PTPRR; RAB3B; RACGAP1; RBM30; RFC3; RRM1 ; RRM2; RRM2; SAS; SDC2 ; SDC2 ; SDC4; SEC6L1; SHCBP1 ; SI; SLC29A1; SLC7A6; SMARCA2; SMC4L1; SMC4L1; SOCS2; SOD2; SOS1; Spc25; SS18; STC2; STK3; STK6 ; TM4SF1; TMPO; TNFRSF10B ; TNFSF13; TNFSF12-TNFSF13; TWE-PRIL; TOPK; TPBG; TPX2; TRIB1; TTC3; TUBA3; TYMS; UAP1; UBE3B; USP3; VEGF; ZNF175; ZNF292; ZNF45; ZWINT mRNA Humans Differentially Expressed Prognostic Metastatic Vs Localised Prostate Cancer p=0.0000121714 Cell Lines 19351846
443 ACPP; AD-017 ; AMIGO2; APPBP2; ASNS ; ATAD2; ATP6V0E; ATXN1; AURKB; B3GALT4; BANK1; BCAP29; BIRC5; BM039 (CENPN); BRE; BUB1; BUB1B; C18orf10 ; C1orf9; C22orf18 (CENPM) ; C5orf13; C6orf111 ; C6orf210; C9orf116 ; C9orf127; CATSPER2 ; CCNA2; CCNB1; CCNB2; CCNE2; CD24; CDC16; CDC2 ; CDC20; CDC25C ; CDC6 ; CDC7; CDKN3; CENPA; CENPC1; CENPF; CHEK1; CHEK1; CITED2; CITED2; CLUL1; COH1; CPT2; CRADD; CTSL2; CYFIP2; DEPDC1; DGKA; DMXL1; DSCR1L1 ; EFNB2 ; ESPL1; F2R; FEN1; FLJ10036; FLJ10534; FLJ22624; GABARAPL1 ; GALNT7; GFPT1 ; GGA2; GTSE1; GTSE1 ; H2AFX ; H2AFY; HCAP-G; HCAP-G ; HECA; HMGB2; HMMR ; HMMR; HPS1; IL13RA1; INSIG1; KIAA0999; KIAA1608; KIF14; KIF20A; KIF4A; KLK2 ; KLK2 ; KLK3; KNS2 KNTC2 LAMB2; LMAN1; LOC54103; MAC30; MALT1; MAPK8IP1; MCM5; MID1; MLF1IP; MLLT3; MTHFD2; MTMR1; MYCBP2; MYH10 MYRIP; NAP1L3; NAV3 ; NEK2; NEK2; NLGN1; NUSAP1; OIP5; OSR2; PBEF1; PCLO; PDE9A ; PDIR; PER3 ; PIK3R1 ; PINK1 ; PIR51; PLCB4; PLK1; PMAIP1; PMS2L11; PMSCL1; PRC1; PRKWNK1; PTBP1; PTBP2; PTCD1 ; PTPN13; PTPRR; RAB3B ; RACGAP1;RBM30; RFC3; RRM1; RRM2; RRM2; SAS ; SDC2; SDC2 ; SDC4; SEC6L1; SHCBP1; SI; SLC29A1; SLC7A6; SMARCA2; SMC4L1; SMC4L1; SOCS2; SOD2; SOS1; Spc25; SS18; STC2 ; STK3; STK6; TM4SF1 ; TMPO; TNFRSF10B; TNFSF13; TNFSF12-TNFSF13; TWE-PRIL; TOPK ; TPBG; TPX2; TRIB1 ; TTC3; TUBA3; TYMS; UAP1;UBE3B; USP3; VEGF; ZNF175; ZNF292; ZNF45; ZWINT mRNA Humans Differentially Expressed Prognostic Androgen Dependent Vs Androgen Independent Prostate Cancer p=0.0056 Cell Lines 19351846
447 CTC (Circulating Tumor Cells) Others Humans Increased expression in overall survival Prognostic Overall Survival Vs No Survival p<0.001 Blood 19505924
448 Alkaline Phosphatase Metabolites Humans Increased expression in overall survival Prognostic Overall Survival Vs No Survival p<0.001 Blood 19505924
449 LDH Metabolites Humans Increased expression in overall survival Prognostic Overall Survival Vs No Survival p<0.001 Blood 19505924
450 Prostatic Acid Phosphatase (PAP) Metabolites Humans Increased expression in overall survival Prognostic Overall Survival Vs No Survival p<0.001 Blood 19505924
451 Total Acid Phosphatase (TAP) Metabolites Humans Increased expression in overall survival Prognostic Overall Survival Vs No Survival p<0.001 Blood 19505924
452 Albumin Metabolites Humans Increased expression in overall survival Prognostic Overall Survival Vs No Survival p=0.002 Blood 19505924
453 Hemoglobin Metabolites Humans Increased expression in overall survival Prognostic Overall Survival Vs No Survival p<0.001 Blood 19505924
454 MIC-1 (Macrophage inhibitory cytokine 1); A1BG a-1B-glycoprotein1 precursor; VTNC (Vitronectin precursor); RNPEP (Arginyl aminopeptidase); FETUA (Fetuin A) Protein Humans Upregulated in Docetaxel- resistant PC3-Rx cells [(MIC-1 Macrophage inhibitory cytokine 1 (2.4 fold); A1BG a-1B-glycoprotein1 precursor (1.9 fold) ; VTNC Vitronectin precursor (1.7 fold); RNPEP Arginyl aminopeptidase (1.6 fold); FETUA Fetuin A (1.6 fold)] Potential Predictive Docetaxel-sensitive PC3 cells Vs Docetaxel- resistant PC3-Rx cells p<0.05 Cell Lines 19773444
455 CYR61 (Angiogenic inducer 61); MASPIN (Serpin peptidase inhibitor); AGR2 (Anterior gradient 2 homologue); Protein Humans Downgregulated in Docetaxel- resistant PC3-Rx cells [(CYR61 Angiogenic inducer 61 (1.5 fold); MASPIN Serpin peptidase inhibitor (1.5 fold); AGR2 Anterior gradient 2 homologue (2.4 fold)]; Potential Predictive Docetaxel-sensitive PC3 cells Vs Docetaxel- resistant PC3-Rx cells p<0.05 Cell Lines 19773444
456 MIC-1 (Macrophage inhibitory cytokine 1) Protein Humans Downregulated after one round of chemotherapy Predictive Metastatic HRPC patients Pre Vs Post One round of Docetaxel chemotherapy p=0.02 Blood 19773444
457 MIC-1 (Macrophage inhibitory cytokine 1) Protein Humans Downregulated after one round of chemotherapy Predictive Overall survival Vs No survival in patients Post One round of Docetaxel chemotherapy p=0.002 Blood 19773444
459 IGF1 Protein Humans Higher concentrations in patients with increased risk of prostate cancer Diagnostic NA p=0.049 NA 19491931
460 IGF1 Protein Humans Higher concentrations in patients with decreased risk of advanced prostate cancer Prognostic Localised Vs Advanced Prostate Cancer p<0.001 NA 19491931
461 IGFBP3 Protein Humans Higher concentrations in patients with decreased risk of advanced prostate cancer Prognostic Localised Vs Advanced Prostate Cancer p=0.004 NA 19491931
474 CCNB1 (cyclin B1); CENPF (centromere protein F, 350/400 ka (mitosin)); BUB1B (BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast)); CLDN4 (claudin 4); KIAA0101 (KIAA0101); LOC400879 (Hypothetical gene supported by AK096951); SLC39A6 (solute carrier family 39 (zinc transporter), member 6); SOX4 (SRY (sex determining region Y)-box 4); TOP2A (topoisomerase (DNA) II alpha 170 kDa) mRNA Humans Upregulated: CCNB1 (cyclin B1) [1.8 fold]; CENPF (centromere protein F, 350/400 ka (mitosin)) [1.4 fold]; BUB1B (BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast)) [1.4 fold]; CLDN4 (claudin 4) [2.4 fold]; KIAA0101 (KIAA0101) [1.6 fold]; LOC400879 (Hypothetical gene supported by AK096951) [1.7 fold]; SLC39A6 (solute carrier family 39 (zinc transporter), member 6) [1.6 fold]; SOX4 (SRY (sex determining region Y)-box 4) [1.8 fold]; TOP2A (topoisomerase (DNA) II alpha 170 kDa) [1.7 fold] Diagnostic Tumor Vs Adjacent To Tumor p=0.05 Tissue 19652763
475 ABLIM3 (actin binding LIM protein family, member 3); AOX1 (aldehyde oxidase 1); CES1 (carboxylesterase 1 (monocyte/macrophage serine esterase 1)); DSCR1 (Down syndrome critical region gene 1); GLRX (glutaredoxin (thioltransferase)); IGFBP4 (insulin-like growth factor binding protein 4); MT1B (metallothionein 1B); MT1E (metallothionein 1E); MT1F (metallothionein 1F); MT1H (metallothionein 1H); C1QB (complement component 1, q subcomponent, B chain); CYB5R3 (cytochrome b5 reductase 3); DARC (Duffy blood group, chemokine receptor); DUSP3 (dual specifi city phosphatase 3 (vaccinia virus phosphatase VH1−related)); F13A1 (coagulation factor XIII, A1 polypeptide); FEZ1 (fasciculation and elongation protein zeta 1 (zygin I)); G0S2 (G0/G1switch 2); GAS6 (growth arrest-specifi c 6); IFITM2 (interferon induced transmembrane protein 2 (1–8D)); ITGA1 (integrin, alpha 1); MAP4 (microtubule-associated protein 4); MT1A (metallothionein 1A); MT2A (metallothionein 2A); PCMT1 (protein-L-isoaspartate (D-aspartate) O-methyltransferase); PROS1 (protein S (alpha)); RBPMS (RNA binding protein with multiple splicing); RDX (Radixin); RNF11 (ring finger protein 11); S100A8 (S100 calcium binding protein A8); SERINC1 (serine incorporator 1); SERPING1 (serpin peptidase inhibitor, clade G (C1 inhibitor), member 1, (angioedema, hereditary)); STOM (stomatin); TGFBR3 (transforming growth factor, beta receptor III); TGM2 (transglutaminase 2 (C polypeptide, protein-glutamine-gamma-glutamyltransferase)); WDR47 (WD repeat domain 47) mRNA Humans Downregulated: ABLIM3 (actin binding LIM protein family, member 3) [1.6 fold]; AOX1 (aldehyde oxidase 1) [2.6 fold]; CES1 (carboxylesterase 1 (monocyte/macrophage serine esterase 1)) [1.7 fold]; DSCR1 (Down syndrome critical region gene 1) [1.6 fold]; GLRX (glutaredoxin (thioltransferase)) [1.7 fold]; IGFBP4 (insulin-like growth factor binding protein 4) [2.5 fold]; MT1B (metallothionein 1B) [2.3 fold]; MT1E (metallothionein 1E) [1.9 fold]; MT1F (metallothionein 1F) [2.3 fold]; MT1H (metallothionein 1H) [2.4 fold]; C1QB (complement component 1, q subcomponent, B chain) [1.4 fold]; CYB5R3 (cytochrome b5 reductase 3) [1.4 fold]; DARC (Duffy blood group, chemokine receptor) [2.9 fold]; DUSP3 (dual specifi city phosphatase 3 (vaccinia virus phosphatase VH1−related)) [1.4 fold]; F13A1 (coagulation factor XIII, A1 polypeptide) [2.1 fold]; FEZ1 (fasciculation and elongation protein zeta 1 (zygin I)) [1.6 fold]; G0S2 (G0/G1switch 2) [2.2 fold]; GAS6 (growth arrest-specifi c 6) [2 fold]; IFITM2 (interferon induced transmembrane protein 2 (1–8D)) [2 fold]; ITGA1 (integrin, alpha 1) [1.4 fold]; MAP4 (microtubule-associated protein 4) [1.6 fold]; MT1A (metallothionein 1A) [2.6 fold]; MT2A (metallothionein 2A) [2.5 fold]; PCMT1 (protein-L-isoaspartate (D-aspartate) O-methyltransferase) [1.3 fold]; PROS1 (protein S (alpha)) [1.7 fold]; RBPMS (RNA binding protein with multiple splicing) [2.4 fold]; RDX (Radixin) [1.4 fold]; RNF11 (ring finger protein 11) [1.4 fold]; S100A8 (S100 calcium binding protein A8) [2.3 fold]; SERINC1 (serine incorporator 1) [1.5 fold]; SERPING1 (serpin peptidase inhibitor, clade G (C1 inhibitor), member 1, (angioedema, hereditary)) [2.2 fold]; STOM (stomatin) [1.8 fold]; TGFBR3 (transforming growth factor, beta receptor III) [1.7 fold]; TGM2 (transglutaminase 2 (C polypeptide, protein-glutamine-gamma-glutamyltransferase)) [1.8 fold]; WDR47 (WD repeat domain 47) [1.5 fold] Diagnostic Tumor Vs Adjacent To Tumor p=0.05 Tissue 19652763
476 GLUT1 Protein Humans Increased expression in Biochemical Recurrence Prognostic PSA recurrence Vs No PSA recurrence p=0.005 Tissue 19854473
477 PHD1 (prolyl-4-hydroxylases 1) Protein Humans Increased expression in Biochemical Recurrence Prognostic PSA recurrence Vs No PSA recurrence p <0.001 Cell Lines 19854473
486 PSGR (Prostate-Specific G-protein Coupled Receptor) mRNA Humans Upregulated Diagnostic Benign Vs Prostate Cancer p=0.008 Urine 20672322
487 PCA3 (Prostate Cancer Gene 3) mRNA Humans Upregulated Diagnostic Benign Vs Prostate Cancer p<0.001 Urine 20672322
488 PSGR + PCA3 mRNA Humans Upregulated Diagnostic Benign Vs Prostate Cancer NA Urine 20672322
489 PCA3 (Prostate Cancer Gene 3) mRNA Humans Upregulated in Positive Biopsy Diagnostic Positive PCa Biopsy Vs Negative PCa Biopsy p <0.0001 Urine 20850153
490 Age+ Family History+ PCA3 + %fPSA+ Prostate Volume+ sPSA mRNA Humans Upregulated in Positive Biopsy Diagnostic Positive PCa Biopsy Vs Negative PCa Biopsy p <0.0001 Urine 20850153
491 Age+ Family History+ PCA3 + %fPSA+ Prostate Volume+ sPSA mRNA Humans Upregulated in Positive Biopsy Diagnostic Positive PCa Biopsy Vs Negative PCa Biopsy p <0.0001 Urine 20850153
492 ezrin; lamin B1; succinate dehydrogenase complex, subunit A, flavoprotein precursor; succinate dehydrogenase complex, subunit A, flavoprotein precursor; acute morphine dependence related protein 2; methylcrotonoyl Coenzyme A carboxylase 2 (beta); 3-oxoacid CoA transferase 1 precursor; CCT2; CCT2; CCT2; keratin 8; lamin A/C transcript variant 1; Chain A, X-ray Structure Of The Human mitogen activated protein kinase kinase 2 (Mek2)in A Complex; Stomatin (EPB72)-like 2; Heterogeneous nuclear ribonucleoprotein C (C1/C2), hnRNP; Heterogeneous nuclear ribonucleoprotein C (C1/C2); SEC13 homologue (S. cerevisiae); HSPC124; Enoyl Coenzyme A hydratase 1, peroxisomal; Chain A, Structure Of Inositol Monophosphatase the Putative Target Of Lithium Therapy; cathepsin D preproprotein; chloride intracellular channel 4; endoplasmic reticulum protein 29 isoform 1 precursor; heat shock 27 kDa protein 1; Chain A, Native Human Lysosomal Beta-Hexosaminidase Isoform B; thioredoxin peroxidase, peroxiredoxin 4; Chain A, Human Glyoxalase I With Benzyl-Glutathione inhibitor; Chain A, Human Glyoxalase I With Benzyl-Glutathione inhibitor; hypothetical protein LOC79017; ATP synthase, H+ transporting, mitochondrial F0; Ferritin, light polypeptide; nonmetastatic cells 1, protein (NM23A) expressed in isoform a; keratin-10; ubiquitin-conjugating enzyme E2N; fatty acid binding protein 5 (psoriasis-associated); Protein Humans Upregulated ratio in LNMPCA: ezrin [2.4]; lamin B1 [2.76]; succinate dehydrogenase complex, subunit A, flavoprotein precursor [2.22]; succinate dehydrogenase complex, subunit A, flavoprotein precursor [1.86]; acute morphine dependence related protein 2 [1.94]; methylcrotonoyl Coenzyme A carboxylase 2 (beta) [5.27]; 3-oxoacid CoA transferase 1 precursor [1.90]; CCT2 [2.74]; CCT2 [2.22]; CCT2 [1.82]; keratin 8 [4.19]; lamin A/C transcript variant 1 [3.66]; Chain A, X-ray Structure Of The Human mitogen activated protein kinase kinase 2 (Mek2)in A Complex [2.95]; Stomatin (EPB72)-like 2 [2.10]; Heterogeneous nuclear ribonucleoprotein C (C1/C2), hnRNP [2.25]; Heterogeneous nuclear ribonucleoprotein C (C1/C2) [2.01]; SEC13 homologue (S. cerevisiae) [2.62]; HSPC124 [4.70]; Enoyl Coenzyme A hydratase 1, peroxisomal [3.79]; Chain A, Structure Of Inositol Monophosphatase the Putative Target Of Lithium Therapy [2.39]; cathepsin D preproprotein [2.49]; chloride intracellular channel 4 [2.16]; endoplasmic reticulum protein 29 isoform 1 precursor [2.54]; heat shock 27 kDa protein 1 [3.47]; Chain A, Native Human Lysosomal Beta-Hexosaminidase Isoform B [4.62]; thioredoxin peroxidase, peroxiredoxin 4 [2.12]; Chain A, Human Glyoxalase I With Benzyl-Glutathione inhibitor [4.19]; Chain A, Human Glyoxalase I With Benzyl-Glutathione inhibitor [4.56]; hypothetical protein LOC79017 [3.15]; ATP synthase, H+ transporting, mitochondrial F0 [2.46]; Ferritin, light polypeptide [2.49]; nonmetastatic cells 1, protein (NM23A) expressed in isoform a [2.99]; keratin-10 [3.84]; ubiquitin-conjugating enzyme E2N [2.23]; fatty acid binding protein 5 (psoriasis-associated) [20.86]; Prognostic Lymph Node Metastatic Prostate Cancer Vs Localised PCA p<0.05 Tissue 19894759
493 collagen, type VI, alpha 1 precursor; vinculin isoform meta-VCL; FLNA protein; gelsolin isoform b; transferrin; transferrin; lamin A/C transcript variant 1; archain; Dihydropyrimidinase-like 3; mutant desmin; PREDICTED: similar to actin, alpha 1, skeletal muscle isoform 2; Chain A, human B lactate dehydrogenase complexed with NAD+ and Hydroxy-1,2,5-Oxadiazole-3-Carbox; splicing factor, arginine/ serine-rich 1 isoform 1; Unknown (protein for IMAGE:3906970); ubiquitin carboxy-terminal hydrolase L1; Chain A, Ligand-Free Human Glutathione S-Transferase M2–2; Chain A, Crystal Structure Of Human Glutathione S-Transferase P1-1 Complexed With (9r,10r)-9; regulatory myosin light chain long version; smooth muscle protein (SM22); haptoglobin-related protein precursor; smooth muscle protein (SM22); smooth muscle protein (SM22); Chain A, X-ray Crystal Structure Of Human Galectin-1; Protein Humans Downregulated ratio in LNMPCA: collagen, type VI, alpha 1 precursor [2.15]; vinculin isoform meta-VCL [3.47]; FLNA protein [1.99]; gelsolin isoform b [2.15]; transferrin [2.04]; transferrin [2.15]; lamin A/C transcript variant 1 [2.06]; archain [1.63]; Dihydropyrimidinase-like 3 [1.86]; mutant desmin [2.38]; PREDICTED: similar to actin, alpha 1, skeletal muscle isoform 2 [2.89]; Chain A, human B lactate dehydrogenase complexed with NAD+ and Hydroxy-1,2,5-Oxadiazole-3-Carbox [2.68]; splicing factor, arginine/ serine-rich 1 isoform 1 [2.6]; Unknown (protein for IMAGE:3906970) [2.04]; ubiquitin carboxy-terminal hydrolase L1 [2.78]; Chain A, Ligand-Free Human Glutathione S-Transferase M2–2 [3.32]; Chain A, Crystal Structure Of Human Glutathione S-Transferase P1-1 Complexed With (9r,10r)-9 [2.85]; regulatory myosin light chain long version [4.25]; smooth muscle protein (SM22) [13.98]; haptoglobin-related protein precursor [6.16]; smooth muscle protein (SM22) [5.08]; smooth muscle protein (SM22) [3.30]; Chain A, X-ray Crystal Structure Of Human Galectin-1 [2.46]; Prognostic Lymph Node Metastatic Prostate Cancer Vs Localised PCA p<0.05 Tissue 19894759
494 transglutaminase 2 isoform a; TPM1 protein; FTH1 protein; S100 calcium binding protein A9; splicing factor, arginine/ serine-rich 1 isoform 1; chromatin modifying protein 4B; Protein Humans Upregulated ratio in Localised PCA: transglutaminase 2 isoform a [2.03]; TPM1 protein [4.18]; FTH1 protein [2.28]; S100 calcium binding protein A9 [3.81]; splicing factor, arginine/ serine-rich 1 isoform 1 [2.07]; chromatin modifying protein 4B [2.16]; Diagnostic Localized PCa and BPH p<0.05 Tissue 19894759
495 keratin 5; mutant desmin; histone cluster 2, H2bf; Protein Humans Downregulated ratio in Localised PCA: keratin 5 [2.08]; mutant desmin [2.03]; histone cluster 2, H2bf [2.02]; Diagnostic Localized PCa and BPH p<0.05 Tissue 19894759
496 e-FABP5 Protein Humans Upregulated in LNM PCa Prognostic Lymph Node Metastatic Prostate Cancer Vs Localised PCA p<0.01 Serum 19894759
497 e-FABP5 Protein Humans Upregulated in Localised PCA Diagnostic Localized PCa and BPH p<0.01 Serum 19894759
498 e-FABP5, MCCC2, PPA2, Ezrin, and SLP2 Protein Humans Upregulated in LNM PCa Prognostic Lymph Node Metastatic Prostate Cancer Vs Localised PCA p<0.01 Tissue 19894759
499 SM22 Protein Humans Downregulated in LNM PCa Prognostic Lymph Node Metastatic Prostate Cancer Vs Localised PCA p<0.01 Tissue 19894759
500 Genomic Evaluators of Metastatic Prostate Cancer (GEMCaP)[Fixed DNA (Gene) Humans Differentially Expressed Prognostic Biochemical recurrence (within 1 year ) Vs No recurrence (24 months) NA Tissue 20028763
501 Genomic Evaluators of Metastatic Prostate Cancer (GEMCaP) [Floating] DNA (Gene) Humans Differentially Expressed Prognostic Biochemical recurrence (within 1 year ) Vs No recurrence (24 months) NA Tissue 20028763
502 Genomic Evaluators of Metastatic Prostate Cancer (GEMCaP) [Integrated] DNA (Gene) Humans Differentially Expressed Prognostic Biochemical recurrence (within 1 year ) Vs No recurrence (24 months) NA Tissue 20028763
503 ANXA5; APLP2; COL1A2; CRIM1; ECHS1; HMGB1; MAP3K5; NGFRAP1; NPM1; NUB1; PDIA3; PLA2G2A; ROCK1; TEGT; TMEM16G; TMEM69; TRAF4; VCAN; VCP; VDAC1; mRNA Humans Differentially Expressed: ANXA5 [1.47 fold]; APLP2 [1.22 fold]; COL1A2 [1.18 fold]; CRIM1 [1.20 fold]; ECHS1 [1.18 fold]; HMGB1 [1.40 fold]; MAP3K5 [1.35 fold]; NGFRAP1 [1.32 fold]; NPM1 [1.30 fold]; NUB1 [1.12 fold]; PDIA3 [1.43 fold]; PLA2G2A [1.75 fold]; ROCK1 [1.17 fold]; TEGT [1.32 fold]; TMEM16G [0.66 fold]; TMEM69 [1.08 fold]; TRAF4 [1.26 fold]; VCAN [1.31 fold]; VCP [1.18 fold]; VDAC1 [1.51 fold]; Prognostic Gleason Score 6 Vs Gleason Score (8-10) p<0.05 Tissue 20035634
504 ANXA5; APLP2; COL1A2; CRIM1; ECHS1; HMGB1; MAP3K5; NGFRAP1; NPM1; NUB1; PDIA3; PLA2G2A; ROCK1; TEGT; TMEM16G; TMEM69; TRAF4; VCAN; VCP; VDAC1; mRNA Humans Differentially Expressed: ANXA5 [4.28 fold]; APLP2 [2.83 fold]; COL1A2 [2.02 fold]; CRIM1 [3.23 fold]; ECHS1 [1.89 fold]; HMGB1 [4.68 fold]; MAP3K5 [2.98 fold]; NGFRAP1 [3.95 fold]; NPM1 [3.07 fold]; NUB1 [1.62 fold]; PDIA3 [2.40 fold]; PLA2G2A [3.00 fold]; ROCK1 [9.76 fold]; TEGT [2.77 fold]; TMEM16G [0.35 fold]; TMEM69 [2.77 fold]; TRAF4 [2.59 fold]; VCAN [2.92 fold]; VCP [2.75 fold]; VDAC1 [5.41 fold]; Prognostic Gleason Score 6 Vs Gleason Score (8-10) p<0.05 Tissue 20035634
505 MAP3K5 mRNA Humans Upregulated in Gleason Score 8-10 Prognostic Gleason Score 6 Vs Gleason Score (8-10) qRT-PCR: p=0.0129 Tissue 20035634
506 PDIA3 mRNA Humans Upregulated in Gleason Score 8-10 Prognostic Gleason Score 6 Vs Gleason Score (8-10) qRT-PCR: p=0.00167 Tissue 20035634
507 TRPM8 (transient receptor potential member 8) mRNA Humans Upregulated in PCa Diagnostic Tumors Vs patient matched non-tumor NA Tissue 20043080
508 TRPM8 (transient receptor potential member 8) mRNA Humans Upregulated in PCa (ratio = 1.94±0.256) Diagnostic Tumors Vs patient matched non-tumor p<0.01 Tissue 20043080
509 TRPM8 (transient receptor potential member 8) mRNA Humans Upregulated in Metastatis (Metastatis: 1.81±0.153; Healthy: 1.0 ± 0.132) Diagnostic Healthy Vs Metastatic p<0.001 Blood 20043080
510 TRPM8 (transient receptor potential member 8) mRNA Humans Upregulated in Metastatis Diagnostic Healthy Vs Metastatic p<0.0001 Urine 20043080
512 ERG expression in TMPRSS2–ERG mRNA Humans Upregulated in Fusion (3.07-fold) Prognostic ERG Fusion Vs No Fusion p=3.48E-11 Tissue 20068566
513 CSPG2+ WNT10B+E2F3+CDKN2A+TYMS+TGFB3+ALOX12+CD44+LAF4 mRNA Humans Upregulated with Biochemical Recurrence Prognostic Biochemical recurrence Vs No recurrence Univariate: p=0.0000002; Multivariate: p=0.0270 Tissue 20068566
514 Enhancer of Zeste 2 (EZH2) mRNA Humans Overexpression leads to aggressive behaviour in Cell Lines Prognostic Overexpression Vs No Overexpression in Cell Lines NA Cell Lines 20087897
520 CB:SA ratio: (cathepsin B/stefin A) Protein Humans Upregulated in Cancer: (BPH Geometric Mean : 1.448 Vs Cancer Geometric Mean : 2.990) Diagnostic benign prostatic hyperplasia Vs Prostate Cancer p=0.0001 Tissue 20392989
521 CB:SA ratio: (cathepsin B/stefin A) Protein Humans Upregulated in Cancer (Gleason Score 6): (BPH Geometric Mean : 1.448 Vs GS6 Geometric Mean : 3.452) Diagnostic benign prostatic hyperplasia Vs Prostate Cancer (Gleason Score 6) p=0.0003 Tissue 20392989
522 CB:SA ratio: (cathepsin B/stefin A) Protein Humans Upregulated in Cancer (Gleason Score 7): (BPH Geometric Mean : 1.448 Vs GS7: Geometric Mean : 2.756) Diagnostic benign prostatic hyperplasia Vs Prostate Cancer (Gleason Score 7) p=0.0052 Tissue 20392989
523 hsa-miR-375-4373027; hsa-miR-9*-4395342; hsa-miR-141-4373137; hsa-miR-516a-3p-4373183; hsa-miR-629-4395547; hsa-miR-203-4373095; hsa-miR-429-4373203; hsa-miR-618-4380996; hsa-miR-212-4373087; hsa-miR-21-4373090; hsa-miR-545-4395378; hsa-miR-218-4373081; hsa-miR-422a-4395408; hsa-miR-656-4380920; hsa-miR-655-4381015; hsa-miR-29c-4395171; hsa-miR-200b-4395362; hsa-miR-200c-4395411; hsa-miR-502-5p-4373227; miRNA Humans Upregulated in Metastatis (Log Fold Change): hsa-miR-375-4373027 [-4.3]; hsa-miR-9*-4395342 [-3.8]; hsa-miR-141-4373137 [-4.5]; hsa-miR-516a-3p-4373183 [-3.9]; hsa-miR-629-4395547 [-2.1]; hsa-miR-203-4373095 [-2.5]; hsa-miR-429-4373203 [-3.4]; hsa-miR-618-4380996 [-3.7]; hsa-miR-212-4373087 [-2.6]; hsa-miR-21-4373090 [-1.8]; hsa-miR-545-4395378 [-2.3]; hsa-miR-218-4373081 [-2.8]; hsa-miR-422a-4395408 [-2.1]; hsa-miR-656-4380920 [-2.8]; hsa-miR-655-4381015 [-2.4]; hsa-miR-29c-4395171 [-1.7]; hsa-miR-200b-4395362 [-3.1]; hsa-miR-200c-4395411 [-1.8]; hsa-miR-502-5p-4373227 [-3.1]; Prognostic Localised Vs Metastatic Prostate Cancer p<0.0098 Serum 20473869
524 miRNA-375, miRNA-141 and miRNA-200b miRNA Humans Differentially Expressed Prognostic Pathoglical Stage pt3 vs pt2 p<0.05 Serum 20473869
525 miRNA-375, miRNA-141 and miRNA-200b miRNA Humans Upregulated Prognostic Gleason Score 6 Vs Gleason Score 7 p<0.05 Serum 20473869
526 miRNA-375 miRNA Humans Upregulated in PCa Prognostic Lymph Node Status: NO Vs N1 p<0.01 Serum 20473869
527 miRNA-141 miRNA Humans Upregulated in PCa Prognostic Lymph Node Status: NO Vs N1 p<0.05 Serum 20473869
528 miRNA-141 miRNA Humans Upregulated in PCa Prognostic Gleason Score >8 Vs Gleason Score 7 p<0.01 Serum 20473869
529 miRNA-375 miRNA Humans Upregulated in PCa Diagnostic Tumor Vs Normal p<0.001 Tissue 20473869
530 miRNA-141 miRNA Humans Upregulated in PCa Diagnostic Tumor Vs Normal p<0.001 Tissue 20473869
531 KLK15 (kallikrein-related peptidase) mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Normal Adjacent p = 0.045 Tissue 20473923
532 KLK15 (kallikrein-related peptidase) Protein Humans High levels associated with shorter progression-free survival. Prognostic PSA recurrence Vs No PSA recurrence Univariate: p = 0.002; Multivariate: p=0.037; StepWise Inclusion: p=0.032 Tissue 20473923
538 SPATA19 mRNA Humans Upregulated in PCa (Increased Prostate cancer risk with High expression) Diagnostic Benign Prostatic Hyperplasia Vs Prostate Cancer p<0.0001 Tissue 20682177
539 LEMD1 mRNA Humans Upregulated in PCa (Increased Prostate cancer risk with High expression) Diagnostic Benign Prostatic Hyperplasia Vs Prostate Cancer p=0.012 Tissue 20682177
540 MMP-9 % Protein Humans Increased expression in Recurrence free survival Prognostic Biochemical Recurrence Vs No Recurrence p=0.03 Tissue 20889560
541 MMP-9 intensity Protein Humans Increased expression in Disease Specific Mortality Prognostic Disease Specific Mortality Vs No Mortality p<0.001 Tissue 20889560
542 MMP-9 intensity Protein Humans Increased expression in Overall Mortality Prognostic Overall Mortality Vs No Mortality p<0.001 Tissue 20889560
543 PCA3 mRNA Humans Differentially Expressed Diagnostic Cancer Vs No Malignancy (PSA Range: 4-10) Univariate: p=0; Multivariate: p=0.02 Urine 20957673
544 TMPRSS2: ERG mRNA Humans Differentially Expressed Diagnostic Cancer Vs No Malignancy (PSA Range: 4-10) Univariate: p=0.002; Multivariate: p=0.028 Urine 20957673
545 Annexin A3 Protein Humans Differentially Expressed Diagnostic Cancer Vs No Malignancy (PSA Range: 4-10) Univariate: p=0; Multivariate: p=0.027 Urine 20957673
546 Sarcosine Metabolites Humans Differentially Expressed Diagnostic Cancer Vs No Malignancy (PSA Range: 4-10) Univariate: p=0.011; Multivariate: p=0.015 Urine 20957673
547 PCA3 mRNA Humans Differentially Expressed Diagnostic Cancer Vs No Malignancy Univariate: p=0; Multivariate: p=0.02 Urine 20957673
548 TMPRSS2: ERG mRNA Humans Differentially Expressed Diagnostic Cancer Vs No Malignancy Univariate: p=0.002; Multivariate: p=0.028 Urine 20957673
549 Annexin A3 Protein Humans Differentially Expressed Diagnostic Cancer Vs No Malignancy Univariate: p=0.002; Multivariate: p=0.027 Urine 20957673
550 Sarcosine Metabolites Humans Differentially Expressed Diagnostic Cancer Vs No Malignancy Univariate: p=0.011; Multivariate: p=0.015 Urine 20957673
555 Fructose-bisphosphate aldolase A; Isocitrate dehydrogenase; Citrate synthase; L-Lactate dehydrogenase A; ATP synthase gamma chain; Alpha-enolase; Phosphoglycerate mutase 1; Malate dehydrogenase; Core protein II; Transketolase; 60 kDa heat shock protein; Flotillin 1; 26S protease regulatory subunit 8; Annexin A2; Protein Humans Upregulated (with Regulation Coefficient): Fructose-bisphosphate aldolase A [1.15]; Isocitrate dehydrogenase [1.09]; Citrate synthase [1.18]; L-Lactate dehydrogenase A [1.40]; ATP synthase gamma chain [1.28]; Alpha-enolase [1.48]; Phosphoglycerate mutase 1 [1.56]; Malate dehydrogenase [1.64]; Core protein II [1.19]; Transketolase [1.31]; 60 kDa heat shock protein [1.83]; Flotillin 1 [1.07]; 26S protease regulatory subunit 8 [1.14]; Annexin A2 [1.29]; Diagnostic Gleason 6 Vs Benign Prostate p<0.05 Tissue 20977276
556 Lamin A; Cytokeratin-1; Mimecan; Prostatic acid phosphatase; Prostate-specific antigen; Protein Humans Downregulated (with Regulation Coefficient): Lamin A [-1.52]; Cytokeratin-1 [-1.09]; Mimecan [-1.08]; Prostatic acid phosphatase [-2.85]; Prostate-specific antigen [-1.15]; Diagnostic Gleason 6 Vs Benign Prostate p<0.05 Tissue 20977276
557 Fructose-bisphosphate aldolase A; Isocitrate dehydrogenase; Citrate synthase; L-Lactate dehydrogenase A; ATP synthase gamma chain; Alpha-enolase; Phosphoglycerate mutase 1; Malate dehydrogenase; Core protein II; Transketolase; 60 kDa heat shock protein; Lamin A; Flotillin 1; Cytokeratin-1; Mimecan; 26S protease regulatory subunit 8; Annexin A2; Protein Humans Upregulated (with Regulation Coefficient): Fructose-bisphosphate aldolase A [1.85]; Isocitrate dehydrogenase [1.79]; Citrate synthase [1.76]; L-Lactate dehydrogenase A [1.75]; ATP synthase gamma chain [1.7]; Alpha-enolase [1.67]; Phosphoglycerate mutase 1 [1.65]; Malate dehydrogenase [1.64]; Core protein II [1.61]; Transketolase [1.59]; 60 kDa heat shock protein [2.13]; Lamin A [2.08]; Flotillin 1 [1.85]; Cytokeratin-1 [1.65]; Mimecan [1.58]; 26S protease regulatory subunit 8 [1.47]; Annexin A2 [1.46]; Prognostic Gleason Score 6 Vs Gleason Score 8 and above p<0.05 Tissue 20977276
558 Prostatic acid phosphatase; Prostate-specific antigen; Protein Humans Downregulated (with Regulation Coefficient): Prostatic acid phosphatase [-1.84]; Prostate-specific antigen [-3.04]; Prognostic Gleason Score 6 Vs Gleason Score 8 and above p<0.05 Tissue 20977276
559 HSP60 Protein Humans Upregulated in PCa Diagnostic Gleason 6 Vs Benign Prostate p<0.05 Tissue 20977276
560 Lamin A Protein Humans Upregulated in GS 8 and above Prognostic Gleason Score 6 Vs Gleason Score 8 and above p<0.05 Tissue 20977276
561 C8orf4; TMC5; PDLIM5; JAG1; HOXA9; C4A; STEAP4; HLA-DMB; COL12A1; DHRS8; C10orf137; SLC7A1; PDZRN3; F3; ACER3; POLB; PXDN; PROM2; GUCY1A3; SOX4; mRNA Humans Upregulated (Fold Change): [C8orf4 (5.14 fold); TMC5 (4.83 fold) ; PDLIM5 (4.51 fold); JAG1 (4.36 fold); HOXA9 (4.25 fold) ; C4A (3.98 fold); STEAP4 (3.92 fold); HLA-DMB (3.85fold); COL12A1 (3.81 fold); DHRS8 (3.81 fold); C10orf137 (3.62 fold); SLC7A1 (3.44 fold); PDZRN3 (3.30 fold); F3 (3.26 fold) ; ACER3 (3.17fold); POLB (3.16 fold); PXDN (3.12 fold); PROM2 (3.11 fold); GUCY1A3 (3.10 fold); SOX4 (3.02 fold);] Diagnostic High BMI Tumor Vs High BMI Normal p<0.05 Tissue 21060327
562 ACADL; PHLDA2; GPD1; L; NTAN1; LOC389048; SFN; HSRG1; PAK1IP1; EBP; ANPEP; ANTXR2; COL4A6; LOC400880; RHOU; GREB1; FLJ30428; C3orf14; ZNF532; SCD; PTN; SC4MOL; MAF; NPAL3; CYP3A5; NOV; ALOX15B; LOC399959; VGL-3; INSIG1; Rcan3; Poteg; P704P; EFS; mRNA Humans Downregulated (Fold Change): [ACADL (0.33 fold); PHLDA2 (0.33 fold); GPD1L (0.33 fold); NTAN1 (0.33 fold); LOC389048 (0.32 fold); SFN (0.32 fold); HSRG1 (0.32 fold); PAK1IP1 (0.32 fold); EBP (0.31 fold); ANPEP (0.31 fold); ANTXR2 (0.29 fold); COL4A6 (0.29 fold); LOC400880 (0.29 fold); RHOU (0.29 fold); GREB1 (0.28 fold); FLJ30428 (0.27 fold); C3orf14 (0.27 fold); ZNF532 (0.26 fold); SCD (0.25 fold); PTN (0.24 fold); SC4MOL (0.24 fold); MAF (0.22 fold); NPAL3 (0.22 fold); CYP3A5 (0.21 fold); NOV (0.20 fold); ALOX15B (0.17 fold); LOC399959 (0.17 fold); VGL-3 (0.16 fold); INSIG1 (0.16 fold); Rcan3 (0.15 fold); Poteg (0.14 fold); P704P (0.13 fold); EFS (0.13 fold)] Diagnostic High BMI Tumor Vs High BMI Normal p<0.05 Tissue 21060327
563 freePSA (free prostate specific antigen) Protein Humans Upregulated in PCa Diagnostic Control Vs Cancer p<0.05 Serum 21074193
564 [-2]proPSA ([-2]proenzyme prostate specific antigen) Protein Humans Upregulated in PCa Diagnostic Control Vs Cancer p<0.05 Serum 21074193
565 %fPSA (%free prostate specific antigen) Protein Humans Downregulated in PCa Diagnostic Control Vs Cancer p<0.05 Serum 21074193
566 DKK1 (Dickkopf-1) Protein Humans Upregulated in PCa Diagnostic Control Vs Cancer p<0.05 Serum 21074193
567 NEM (neuroendocrine marker) Protein Humans Upregulated in PCa Diagnostic Control Vs Cancer p<0.05 Serum 21074193
568 Prostate Health Index (phi) Protein Humans Upregulated in PCa Diagnostic Control Vs Cancer p<0.05 Serum 21074193
569 D-Dimer Protein Humans Upregulated in Progressive Disease Prognostic progressive disease (PD) Vs nonprogressive disease (non-PD) p<0.024 Blood 21088161
570 miR-874, -1274a, -1207-5p, -93, and -106a miRNA Humans Upregulated in PCa Diagnostic Healthy Vs Prostate Cancer miR-874 p<0.00; miR-1274a p<0.001; miR-1207-5p p<0.001; miR-93 p<0.001; miR-106a p<0.001 Serum 21098088
571 miR- 223, -26b, -30c, and -24 miRNA Humans Downregulated in PCa Diagnostic Healthy Vs Prostate Cancer miR-30c p= 0.01; miR-26b p<0.001; miR-223 p<0.001; miR-24 p= 0.005; Serum 21098088
572 miR-106a, miR-93 and -1274a; miR-451; miR-1207-5p; miR-874 miRNA Humans Upregulated in PCa Diagnostic Healthy Vs High Risk (CAPRA>5) miR-106a p<0.001, miR-93 p<0.001; miR-1274a p<0.001; miR-451 p= 0.02; miR-1207-5p p<0.001; miR-874 p= 0.003 Serum 21098088
573 miR-223; miR-24; miRNA Humans Downregulated in PCa Diagnostic Healthy Vs High Risk (CAPRA>5) miR-223 p= 0.002; miR-24 p=0.02 Serum 21098088
574 Apolipoprotein A-IV + Serum amyloid P-component + Gluthathione peroxidase 3 Protein Humans Upregulated in PCa Diagnostic BPH vs Prostate Cancer NA Serum 21166384
575 Kininogen-1+ Protein AMBP + Coagulation factor XIII B chain + Complement factor H + Gluthathione peroxidase 3 Protein Humans Differentially Expressed Prognostic Gleason Score 5 vs Gleason Score 7 NA Serum 21166384
576 Protein AMBP; Haptoglobin (R chain) ; Pigment Epithelium-Derived Factor 207 Kininogen-1 Protein Humans Downregulated in Non Organ Confined: [Haptoglobin (R chain) ]; Upregulated in Non Organ Confined: [Protein AMBP; Pigment Epithelium-Derived Factor 207 Kininogen-1] Prognostic Organ Confined vs Non-Organ Confined NA Serum 21166384
577 Apolipoprotein A-IV + Serum amyloid P-component + Gluthathione peroxidase 3 Protein Humans Upregulated Diagnostic BPH vs Prostate Cancer NA Serum 21166384
578 Kininogen-1+ Protein AMBP + Coagulation factor XIII B chain + Complement factor H +Gluthathione peroxidase 3 Protein Humans Differentially Expressed Prognostic Gleason Score 5 vs Gleason Score 7 NA Serum 21166384
579 Protein AMBP; Haptoglobin (R chain) ; Pigment Epithelium-Derived Factor 207 Kininogen-1 Protein Humans Downregulated in Non Organ Confined: [Haptoglobin (R chain) ]; Upregulated in Non Organ Confined: [Protein AMBP; Pigment Epithelium-Derived Factor 207 Kininogen-1] Prognostic Organ Confined vs Non-Organ Confined NA Serum 21166384
582 GSTP1, BCL2, ADCY4, CACNA1G, LOC63928, and D4S234E mRNA Humans Downregulated Diagnostic Tumor Vs Tumor Adjacent p<0.05 Tissue 21237555
583 β-microseminoprotein (MSMB) Protein Humans increased expression with decreased biochemical recurrence-free survival Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.001 Tissue 21240253
584 SLCO1B1; SLCO1B3; SLCO2A1; SLCO3A1; mRNA Humans Upregulated in CRPC metastases: SLCO1B1 (5.5 fold); SLCO1B3( 3.6 fold); SLCO2A1 (3.2 fold); SLCO3A1 (5.4 fold); Prognostic CRPC metastases versus untreated prostate cancer p<0.053 Tissue 21266523
587 Tropomyosin β chain fibroblast and epithelia, Keratin type II cytoskeletal 8 Cytokeratin 8 K, 14-3-3 protein γ protein kinase C inhibitor p, Protein disulfide isomerase precursor PDI EC 5, Keratin type I cytoskeletal 19 Cytokeratin 19, Actin muscle type A2, Desmin, α1 antitrypsin precursor, Tubulin β2 chain, 78 kDa glucose regulated protein prec GRP 78, Rho GDP dissociation inhibitor 1, Creatine kinase B chain EC 2 7 3 2 B CK, Fibrinogen γ chain precursor, Heat shock cognate 71 kDa protein, Stress 70 protein mitochondrial precursor 75 kD, Heat shock 70 kDa protein 1 HSP70 1a, Enoyl CoA hydratase mitochprecursor EC 4, Prohibitin, Apolipoprotein A I precursor Apo AI, ATP synthase β chain mitochondrial precursor, Small nuclear ribonucleoprotein 200 kDa helicas, Glycerol 3 phosphate acyltransferase EC 2 3 1 15, Keratin type I cytoskeletal 18 Cytokeratin 18, Serum albumin precursor, Annexin A4 Lipocortin IV Endonexin, Serum albumin precursor, 60 kDa heat shock protein mitochondrial precursor. Protein Humans Differentially Expressed Diagnostic BPH Vs Prostate Cancer p<0.05 Tissue 21305254
588 Annexin A4 (ANXA4); Apolipoprotein A-I (APOA1); ATP synthase, H+ transporting, mitochondrial F1 complex, β polypeptide (ATP5B); Creatine kinase, brain (CKB); Desmin (DES); Enoyl CoA hydratase, short chain, 1, mitochondrial (ECHS1); Fibrinogen γ chain (FGG); Heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa) (HSPA5); Heat shock 60 kDa protein 1 (chaperonin) (HSPD1); Prolyl 4-hydroxylase, β polypeptide (P4HB); Prohibitin (PHB); Serpin peptidase inhibitor, clade A (α-1 antiproteinase, antitrypsin), member 1) (SERPINA1); Protein Humans Upregulated in Gleason Score 7(Fold Change) : Annexin A4 (ANXA4) [1.000]; Apolipoprotein A-I (APOA1) [2.691]; ATP synthase, H+ transporting, mitochondrial F1 complex, β polypeptide (ATP5B) [7.440]; Creatine kinase, brain (CKB) [1.000]; Desmin (DES) [2.059]; Enoyl CoA hydratase, short chain, 1, mitochondrial (ECHS1) [2.335]; Fibrinogen γ chain (FGG) [7.634]; Heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa) (HSPA5) [2.339]; Heat shock 60 kDa protein 1 (chaperonin) (HSPD1) [1.000]; Prolyl 4-hydroxylase, β polypeptide (P4HB) [11.540]; Prohibitin (PHB) [1.000]; Serpin peptidase inhibitor, clade A (α-1 antiproteinase, antitrypsin), member 1) (SERPINA1) [2.992]; Prognostic Gleason Score 5 Vs Gleason Score 7 p<0.05 Tissue 21305254
589 Albumin (ALB); Rho GDP dissociation inhibitor (GDI) α (ARHGDIA); Keratin 18 (KRT18); Keratin 19 (KRT19); Keratin 8 (KRT8); Protein Humans Downregulated in Gleason Score 7(Fold Change) : Albumin (ALB) [2.155]; Rho GDP dissociation inhibitor (GDI) α (ARHGDIA) [2.571]; Keratin 18 (KRT18) [3.322]; Keratin 19 (KRT19) [4.950]; Keratin 8 (KRT8) [4.950]; Prognostic Gleason Score 5 Vs Gleason Score 7 p<0.05 Tissue 21305254
590 Albumin (ALB); Annexin A4 (ANXA4); Apolipoprotein A-I (APOA1); ATP synthase, H+ transporting, mitochondrial F1 complex, β polypeptide (ATP5B); Fibrinogen γ chain (FGG); Protein Humans Upregulated in Stage T3 (Fold Change) : Albumin (ALB) [2.684]; Annexin A4 (ANXA4) [1.000]; Apolipoprotein A-I (APOA1) [2.691]; ATP synthase, H+ transporting, mitochondrial F1 complex, β polypeptide (ATP5B) [1.000]; Fibrinogen γ chain (FGG) [1.000]; Prognostic Stage T2 Vs Stage T3 p<0.05 Tissue 21305254
591 Rho GDP dissociation inhibitor (GDI) α (ARHGDIA); Desmin (DES); Enoyl CoA hydratase, short chain, 1, mitochondrial (ECHS1); Heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa) (HSPA5); Keratin 18 (KRT18); Keratin 19 (KRT19); Keratin 8 (KRT8); Protein Humans Downregulated in Stage T3(Fold Change) : Rho GDP dissociation inhibitor (GDI) α (ARHGDIA) [2.165]; Desmin (DES) [8.929]; Enoyl CoA hydratase, short chain, 1, mitochondrial (ECHS1) [7.407]; Heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa) (HSPA5) [1.613]; Keratin 18 (KRT18) [3.322]; Keratin 19 (KRT19) [4.950]; Keratin 8 (KRT8) [4.950]; Prognostic Stage T2 Vs Stage T3 p<0.05 Tissue 21305254
592 placental growth factor (PIGF) Protein Humans Downregulated in Docetaxel + Imatinib arm Predictive Docetaxel + placebo VS Docetaxel + imatinib p<0.001 Plasma 21323568
593 soluble c-kit Protein Humans Downregulated in Docetaxel + Imatinib arm Predictive Docetaxel + placebo VS Docetaxel + imatinib p<0.001 Plasma 21323568
594 VEGF Protein Humans Downregulated in Docetaxel + Imatinib arm Predictive Docetaxel + placebo VS Docetaxel + imatinib p<0.001 Plasma 21323568
595 sVEGFR1 Protein Humans Downregulated in Docetaxel + Imatinib arm Predictive Docetaxel + placebo VS Docetaxel + imatinib p=0.001 Plasma 21323568
596 Engrailed-2 (EN2) Protein Humans Upregulated in PCa Diagnostic Biopsy Positive Vs Biopsy Negative p<0.05 Tissue 21364037
597 Engrailed-2 (EN2) mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Controls p<0.05 Cell Lines 21364037
599 vascular endothelial growth factor (VEGF) Protein Humans Upregulated in PCa Diagnostic BPH Vs Prostate Cancer p<0.001 Tissue 21367627
600 matrix metalloproteinase-9 (MMP-9) Protein Humans Upregulated in PCa Diagnostic BPH Vs Prostate Cancer p=0.004 Tissue 21367627
601 vascular endothelial growth factor (VEGF) Protein Humans Upregulated in Lymph Node Metastatis Prognostic Lymph Node Metastatis Posititve Lymph Node Metastatis Negative p<0.001 Tissue 21367627
602 matrix metalloproteinase-9 (MMP-9) Protein Humans Upregulated in Lymph Node Metastatis Prognostic Lymph Node Metastatis Posititve Lymph Node Metastatis Negative p<0.001 Tissue 21367627
603 Stromal cell-derived factor-1 (SDF-1) Protein Humans Upregulated in Lymph Node Metastatis Prognostic Lymph Node Metastatis Posititve Lymph Node Metastatis Negative p<0.001 Tissue 21367627
604 Stromal cell-derived factor-1 (SDF-1) Protein Humans Patients with low levels survived longer than those with high levels Prognostic Prostate Cancer Specific Survival VS No Survival Univariate: p<0.001; Multivariate: p=0.017 Tissue 21367627
605 vascular endothelial growth factor (VEGF) Protein Humans Patients with low levels survived longer than those with high levels Prognostic Prostate Cancer Specific Survival VS No Survival Univariate: p<0.001; Multivariate: p<0.001 Tissue 21367627
606 matrix metalloproteinase-9 (MMP-9) Protein Humans Patients with low levels survived longer than those with high levels Prognostic Prostate Cancer Specific Survival VS No Survival p<0.001 Tissue 21367627
607 let-7a; miR-101; miR-106a; miR-106b; miR-1274; miR-141; miR-17; miR-182; miR-1826; miR-200b; miR-200c; miR-20a; miR-20b; miR-21; miR-375; miR-720; miR-768-3p; miR-93 miRNA Humans Upregulated in PCa(Fold Change): let-7a(1.53 fold) ; miR-101(1.13 fold) ; miR-106a(2.41 fold); miR-106b(1.70 fold); miR-1274(1.87 fold); miR-141(1.44 fold); miR-17(2.69 fold); miR-182(2.39 fold) ; miR-1826(1.73 fold) ; miR-200b( 1.54 fold) ; miR-200c( 2.92 fold); miR-20a(2.67 fold); miR-20b(2.81 fold); miR-21( 1.40 fold); miR-375(3.90 fold) ; miR-720(1.41 fold); miR-768-3p(1.67 fold); miR-93(2.52 fold) Diagnostic Prostate Cancer Vs Normal p<0.001 Tissue 21400514
608 miR-136-star; miR-145; miR-214; miR-221; miR-222; miR-302d-star; miR-378-star miRNA Humans Downregulated in PCa (Fold Change): miR-136-star(1.18 fold) ; miR-145(1.44 fold); miR-214(1.74 fold); miR-221(2.16 fold) ; miR-222(2.91 fold) ; miR-302d-star(1.13 fold); miR-378-star(1.30 fold) Diagnostic Prostate Cancer Vs Normal p<0.001 Tissue 21400514
609 miRNA- 375; miRNA-143; miRNA-145 (Individual assesment) miRNA Humans Upregulated in PCa: miRNA-375; Downregulated in PCa: miRNA-143, miRNA 145 Diagnostic Prostate Cancer Vs Normal miRNA- 375 (p=0.002) ; miRNA-143 (p=0.001); miRNA-145 (p<0.0001); Tissue 21400514
610 miRNA- 375 + miRNA-143+ miRNA-145 (Combined assesment) miRNA Humans Upregulated in PCa: miRNA-375; Downregulated in PCa: miRNA-143, miRNA 146 Diagnostic Prostate Cancer Vs Normal p<0.0001 Tissue 21400514
611 miRNA- 375; miRNA-143; miRNA-145 (Individual assesment) miRNA Humans Upregulated in PCa: miRNA-375; Downregulated in PCa: miRNA-143, miRNA 147 Diagnostic Prostate Cancer Vs Normal miRNA- 375 (p=0.005) ; miRNA-143 (p=0.005); miRNA-145 (p<0.0001); Tissue 21400514
612 miRNA- 375 + miRNA-143+ miRNA-145 (Combined assesment) miRNA Humans Upregulated in PCa: miRNA-375; Downregulated in PCa: miRNA-143, miRNA 148 Diagnostic Prostate Cancer Vs Normal p<0.0001 Tissue 21400514
613 miRNA- 375; miRNA-143; miRNA-145 (Individual assesment) miRNA Humans Upregulated in PCa: miRNA-375; Downregulated in PCa: miRNA-143, miRNA 149 Diagnostic Prostate Cancer Vs Normal miRNA- 375 (p<0.0001) ; miRNA-143 (p<0.0001); miRNA-145 (p<0.0001); Tissue 21400514
614 miRNA- 375 + miRNA-143+ miRNA-145 (Combined assesment) miRNA Humans Upregulated in PCa: miRNA-375; Downregulated in PCa: miRNA-143, miRNA 150 Diagnostic Prostate Cancer Vs Normal p<0.0001 Tissue 21400514
626 fPSA Protein Humans NA Diagnostic Prostate Cancer Vs Controls p=0.024 Serum 21482022
627 %fPSA Protein Humans NA Diagnostic Prostate Cancer Vs Controls p=0.008 Serum 21482022
628 PSA Density Protein Humans NA Diagnostic Prostate Cancer Vs Controls p=0.001 Serum 21482022
629 %p2PSA Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Controls p < 0.001 Serum 21482022
630 Prostat Health Index (phi) Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Controls p < 0.001 Serum 21482022
631 Base Model (Age+ Prostate Volume + tPSA+ fPSA) Protein Humans NA Diagnostic Prostate Cancer Vs Controls Not significant Serum 21482022
632 Base Model + %p2PSA Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Controls p < 0.001 Serum 21482022
633 Base Model + phi Protein Humans Upregulated in PCa (phi) Diagnostic Prostate Cancer Vs Controls p < 0.001 Serum 21482022
634 NY-ESO-1 + XAGE-1b + SSX-2,4 + AMACR + p90 + LEDGF + PSA Index Protein Humans Differentially Expressed Diagnostic Prostate Cancer Vs BPH LEDGF, p90, SSX-2, 4, XAGE-1b: p<0.001; NY-ESO-1: p=0.029; AMACR: NS Serum 21504557
635 PSA Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs BPH p<0.05 Serum 21504557
636 40S ribosomal protein S8; Heterogeneous nuclear ribonucleoprotein H; 78 kDa glucose-regulated protein; Cytochrome c oxidase polypeptide VIc; Cytochrome c oxidase subunit 5B, mitochondrial ATP synthase subunit beta, mitochondrial Stress-70 protein, mitochondrial Biglycan; Elongation factor Tu mitochondrial; Ubiquitin-like modifier-activating enzyme 1; Protein disulfide-isomerase A4; Heterochromatin protein 1-binding protein 3; Tumor protein D52 Prohibitin-2; Protein disulfide-isomerase; EH domain-containing protein 2; 60 kDa heat shock protein mitochondrial; Nucleophosmin Periostin; Sorbitol dehydrogenase Protein Humans Upregulated in PCA(Fold Change) : Diagnostic Prostate Cancer Vs BPH p<0.05 Tissue 21504578
637 Desmin; Serum deprivation-response protein 3; Sorbin and SH3 domain-containing protein 1; Vimentin; Calponin-1; Heat shock protein beta-1; Actin, gamma-enteric smooth muscle; Protein kinase C delta-binding protein; Collagen alpha-1(VI) chain Laminin subunit gamma-1; Sorbin and SH3 domain-containing protein 2; Tenascin; Zyxin; Talin-1; Collagen alpha-1(I) chain; Vinculin; Mimecan; Lipoma-preferred partner; Neuroblast differentiation-associated protein AHNAK; Decorin; Basement membrane-specific heparan sulfate proteoglycan core protein; Phosphatidylethanolamine-binding protein 1 Protein Humans Downregulated in PCA(Fold Change): Diagnostic Prostate Cancer Vs BPH p<0.05 Tissue 21504578
638 Neuroblast differentiation-associated protein AHNAK; Glutamate dehydrogenase 1, mitochondrial; Protein disulfide-isomerase A4; Cytochrome c oxidase subunit 5B, mitochondrial; Collagen alpha-3(VI) chain; Heterogeneous nuclear ribonucleoprotein H; 10 kDa heat shock protein, mitochondrial; Elongation factor Tu, mitochondrial; 78 kDa glucose-regulated protein; Myosin-9; Protein disulfide-isomerase; Biglycan; Nucleoside diphosphate kinase B; 60 kDa heat shock protein, mitochondrial; Periostin; 60S ribosomal protein L10a Nucleophosmin; Asporin; Sorbitol dehydrogenase; Protein Humans Upregulated in PCA(Fold Change) : Diagnostic Prostate Cancer Vs BPH with Local PIN p<0.05 Tissue 21504578
639 Desmin; Myosin regulatory light polypeptide 9; Serum deprivation-response protein 3; Sorbin and SH3 domain- containing protein 1; Tropomyosin alpha-1 chain; Protein kinase C delta-binding protein; Calponin-1; Vinculin; Prostatic acid phosphatase; Zyxin; Fibrinogen alpha chain; Histone H1.0; Talin-1; Protein disulfide-isomerase A3; Protein Humans Downregulated in PCA(Fold Change): Diagnostic Prostate Cancer Vs BPH with Local PIN p<0.05 Tissue 21504578
640 Periostin Protein Humans Upregulated in PCA Diagnostic Prostate Cancer Vs BPH with Local PIN p<0.01 Tissue 21504578
641 Ki-67 Protein Humans Upregulated in Black men Prognostic Prostate Cancer in Black Men Vs Prostate Cancer in White Men Univariate: p=0.02; Multivariate: =0.002 Tissue 21519348
642 Norm AR (Androgen Receptor) Protein Humans Upregulated in Black men Prognostic Prostate Cancer in Black Men Vs Prostate Cancer in White Men Univariate: p=0.006; Multivariate: p=0.001 Tissue 21519348
643 Ki-67/lum Protein Humans Upregulated in Black men Prognostic Prostate Cancer in Black Men Vs Prostate Cancer in White Men p=0.022 Tissue 21519348
644 PSMA mRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Benign p=0.016 Urine 21520154
645 PSGR mRNA Humans Upregulted in PCa Diagnostic Prostate Cancer Vs Benign p<0.001 Urine 21520154
646 PCA3 mRNA Humans Upregulted in PCa Diagnostic Prostate Cancer Vs Benign p=0.018 Urine 21520154
647 PSMA + PSGR + PCA3 mRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs Benign NA Urine 21520154
648 PSMA + PSGR + PCA3 + PSA mRNA Humans Differentially Expressed Diagnostic (Prostate Cancer Vs Benign) with PSA in range 4-10ng/ml NA Urine 21520154
649 PSMA mRNA Humans Downregulated in PCa Diagnostic (Prostate Cancer Vs Benign) with PSA in range 4-10ng/ml p=0.003 Urine 21520154
650 PSGR mRNA Humans Upregulted in PCa Diagnostic (Prostate Cancer Vs Benign) with PSA in range 4-10ng/ml p= 0.009 Urine 21520154
651 PCA3 mRNA Humans Upregulted in PCa Diagnostic (Prostate Cancer Vs Benign) with PSA in range 4-10ng/ml p=0.025 Urine 21520154
652 PSMA + PSGR + PCA3 mRNA Humans Differentially Expressed Diagnostic (Prostate Cancer Vs Benign) with PSA in range 4-10ng/ml NA Urine 21520154
655 enhancer of zeste homologue 2 (EZH2) Protein Humans Progression Vs No Progression Prognostic Progression Free Survival Vs No Progression Free Survival p=0.004 Tissue 21592298
656 minichromosome maintenance protein 7 (MCM7) Protein Humans Progression Vs No Progression Prognostic Progression Free Survival Vs No Progression Free Survival p<0.001 Tissue 21592298
657 Ki-67 Protein Humans Increased expression in patients with Progression Prognostic Progression Free Survival Vs No Progression Free Survival p<0.001 Tissue 21592298
658 PCA3 mRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs No Prostate cancer p=0.001 Urine 21600800
660 TMPRSS2:ERG mRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs No Prostate cancer p=0.001 Urine 21600800
661 PSA +PCA3 + TMPRSS2:ERG mRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs No Prostate cancer NA Urine 21600800
662 TMPRSS2:ERG+ PCA3 mRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs No Prostate cancer NA Urine 21600800
663 Propenoic acid+ Pyrimidine+ Dihyroxybutanoic acid+Creatinine+ Purine+ Glucopyranoside+ Ribofuranoside+Xylonic acid=Xylopyranose Metabolites Humans Upregulated in PCA: (Propenoic acid, Dihyroxybutanoic acid, Creatinine and Xylonic acid); Downregulated in PCA: (Pyrimidine, Creatinine, Purine, Glucopyranoside, Ribofuranoside, Xylopyranose) Diagnostic Prostate Cancer Vs Healthy Men p<0.05 Urine 21626193
664 Dihyroxybutanoic acid + Pyrimidine + Xylonic acid + Xylopyranose + Ribofuranoside Metabolites Humans Upregulated in PCA: (Dihyroxybutanoic acid, Xylonic acid); Downregulated in PCA: (Pyrimidine, Xylopyranose, Ribofuranoside) Diagnostic PCa Vs Non Cancerous (healthy+BPH) p<0.05 Urine 21626193
665 MKI67 (Ki-67) + TOP2A (DNA topoisomerase II, alpha) + E2F1 (E2F transcription factor 1) Genes Humans TOP2A, E2F1: Increased expression with earlier Biochemical Recurrence, Prognostic PSA Reccurence Vs No Recurrence for 8 years p=0.001 Tissue 21629784
666 PSA+ Grade + Stage +MKI67 (Ki-67) + TOP2A (DNA topoisomerase II, alpha) + E2F1 (E2F transcription factor 1) Genes Humans TOP2A, E2F1: Increased expression with earlier Biochemical Recurrence, Prognostic PSA Reccurence Vs No Recurrence for 8 years p=0.005 Tissue 21629784
667 NA miRNA Humans Downregulated in Bone Metastatis: Prognostic Primary vs Bone Metastatis p<0.05 Tissue 21647377
668 NA miRNA Humans Upregulated in Bone Metastatis: Prognostic Primary vs Bone Metastatis p<0.05 Tissue 21647377
669 miR-143 miRNA Humans Downregulated in Bone Metastatis: 12.9 fold Prognostic Primary vs Bone Metastatis p=0.012 Tissue 21647377
670 miR-145 miRNA Humans Downregulated in Bone Metastatis: 17.3 fold Prognostic Primary vs Bone Metastatis p=0.014 Tissue 21647377
671 miR-143 miRNA Humans Downregulated in Bone Metastatis Prognostic Bone Metastatis Vs No Bone Metastasis p=0.039 Tissue 21647377
672 miR-145 miRNA Humans Downregulated in Bone Metastatis Prognostic Bone Metastatis Vs No Bone Metastasis p=0.041 Tissue 21647377
673 Androgen Receptor mRNA Humans Downregulated in PCa Diagnostic Tumor Vs Normal Tissues p=0.018 Tissue 21667031
674 Circulating Tumor Cells (Base Line) Others Humans NA Predictive Progression to Hormone-sensitive Prostate Cancer after ADT p<0.001 Blood 21705286
675 Circulating Tumor Cells (Post Base Line) Others Humans NA Potential Predictive Progression to Hormone-sensitive Prostate Cancer after ADT p<0.001 Blood 21705286
676 Alkaline Phosphate Others Humans NA Potential Predictive Progression to Hormone-sensitive Prostate Cancer after ADT p=0.006 Blood 21705286
677 Lactate Dehydrogenase (LDH) Others Humans NA Potential Predictive Progression to Hormone-sensitive Prostate Cancer after ADT p<0.001 Blood 21705286
678 Testosterone Others Humans NA Potential Predictive Progression to Hormone-sensitive Prostate Cancer after ADT p=0.005 Blood 21705286
679 miR-141 miRNA Humans Upregulated with increasing PSA Prognostic progression Vs No Progression p<0.001 Plasma 21723797
680 Circulating Tumor Cells Others Humans Upregulated with increasing PSA Prognostic progression Vs No Progression p=0.002 Plasma 21723797
681 Lactate Dehydrogenase (LDH) Metabolites Humans Upregulated with increasing PSA Prognostic progression Vs No Progression p= 0.014 Plasma 21723797
682 thrombospondin 1 (THBS1) + C-Reactive Prostien (CRP) + poliovirus receptor-related 1 (PVRL1) + memembrane metallo endopeptidase (MME) +ephrin- A5 (EFNA5) Protein Humans NA Prognostic Overall Survival Vs No Survival (12 months) NA Serum 21741162
683 thrombospondin 1 (THBS1) + C-Reactive Prostien (CRP) + poliovirus receptor-related 1 (PVRL1) + memembrane metallo endopeptidase (MME) +ephrin- A5 (EFNA5) Protein Humans NA Prognostic Overall Survival Vs No Survival (24 months) NA Serum 21741162
684 PVRL1 (poliovirus receptor-related 1); PRG4 (proteoglycan 4); AP (alkaline phosphatase); FSTL1 (follistatin-like 1); Albumin; CEACAM1 (carcinoembryonic antigen related cell adhesion molecule 1); ANPEP (alanyl (membrane) aminopeptidase); CRP (C-reactive protein); Hb (hemoglobin); CADM1a (cell adhesion molecule 1a); POSTN (periostin, osteoblast specific factor); CADM1b (cell adhesion molecule 1b); CP (ceruloplasmin); AZGP1 (alpha-2-glycoprotein 1, zinc-binding). Protein Humans NA Prognostic Overall Survival Vs No Survival PVRL1 (poliovirus receptor-related 1) p= 0.002; CD10 p= 0.004; PRG4 (proteoglycan 4) p = 0.006; AP (alkaline phosphatase) p= 0.007; FSTL1 (follistatin-like 1) p= 0.01; Albumin p= 0.016; CEACAM1 (carcinoembryonic antigen related cell adhesion molecule 1) p = 0.018; ANPEP (alanyl (membrane) aminopeptidase) p=0.02; CRP (C-reactive protein) p= 0.02; Hb (hemoglobin) p=0.022; CADM1a (cell adhesion molecule 1a) p =0.03; POSTN (periostin, osteoblast specific factor) p=0.034; CADM1b (cell adhesion molecule 1b) p=0.035; CP (ceruloplasmin) p =0.046; AZGP1 (alpha-2-glycoprotein 1, zinc-binding) p =0.046. Serum 21741162
685 miR-96; miR-182; miR-32; miR-221; miR-25; miR-93; miR-182*; miR-106b; miR-183; miR-153; miR-602; miR-455-5p; miR-205 miR-183*; miR-425; miR-375; miR-193b; miR-30e*; miR-95; miR-378; miR-455-3p; miR-133a; miR-873; miR-222; miR-21; miR-142-3p; miR-575 ;miR-130b; miR-339-3p; miR-149; miR-338-3p; miR-19a; miR-148a; miR-146b-5p; miR-125a-5p; miR-27b; miR-10b*; miR-141; miR-7; miR-505; miR-30c-1*; miR-145*; miR-145; miR-125b; miR-99a; miR-378*; miR-583; miR-221*; miR-20a; miR-124; miR-103; miR-542-5p; miR-193b*; miR-940 miRNA Humans Differentially Expressed (Fold Change): [miR-96 (2.12 fold); miR-182 (2.02 fold); miR-32 (2.01 fold); miR-221 (2.27 fold); miR-25 (1.53 fold); miR-93 (1.61 fold); miR-182* (2.25 fold); miR-106b (1.56 fold); miR-183 (2.18 fold); miR-153 (2.74 fold); miR-602 (1.57 fold); miR-455-5p (2.01 fold); miR-205 (6.29 fold); miR-183* (1.8 fold); miR-425 (1.66 fold); miR-375 (1.72 fold); miR-193b (1.58 fold); miR-30e* (1.32 fold); miR-95 (378 fold); miR-378 (1.65 fold); miR-455-3p (2.12 fold); miR-133a (2.19 fold); miR-873 (2.3 fold); miR-222 (2.17 fold); miR-21 (1.71 fold); miR-142 -3p (1.65 fold); miR-575 (1.7 fold) ;miR-130b (1.62 fold); miR-339-3p (1.19 fold); miR-149 (1.82 fold); miR-338-3p (1.96 fold); miR-19a (1.4 fold); miR-148a (1.63 fold); miR-146b-5p (1.68 fold); miR-125a-5p (1.41 fold); miR-27b (1.27 fold); miR-10b* (1.94 fold); miR-141 (1.42 fold); miR-7 (1.76 fold); miR-505 (1.33 fold); miR-30c-1* (1.41 fold); miR-145* (2.01 fold); miR-145 (2.01 fold); miR-125b (1.37 fold); miR-99a (1.34 fold); miR-378* (1.97 fold); miR-583 (1.82 fold); miR-221* (2.1 fold); miR-20a (1.4 fold); miR-124 (1.67 fold); miR-103 (1.21 fold); miR-542-5p (1.77 fold); miR-193b* (1.68 fold); miR-941 (1.52 fold)] Diagnostic Prostate Cancer (PCa)Vs Normal Adjacent Prostate (NAP) p= 0.0046 Tissue 21765474
686 miR-96; miR-182; miR-32; miR-221; miR-25; miR-93; miR-182*; miR-106b; miR-183; miR-153; miR-602; miR-455-5p; miR-205 miR-183*; miR-425; miR-375; miR-193b; miR-30e*; miR-95; miR-378; miR-455-3p; miR-133a; miR-873; miR-222; miR-21; miR-142-3p; miR-575 ;miR-130b; miR-339-3p; miR-149; miR-338-3p; miR-19a; miR-148a; miR-146b-5p; miR-125a-5p; miR-27b; miR-10b*; miR-141; miR-7; miR-505; miR-30c-1*; miR-145*; miR-145; miR-125b; miR-99a; miR-378*; miR-583; miR-221*; miR-20a; miR-124; miR-103; miR-542-5p; miR-193b*; miR-941 miRNA Humans Differentially Expressed (Fold Change): [miR-96 (2.12 fold); miR-182 (2.02 fold); miR-32 (2.01 fold); miR-221 (2.27 fold); miR-25 (1.53 fold); miR-93 (1.61 fold); miR-182* (2.25 fold); miR-106b (1.56 fold); miR-183 (2.18 fold); miR-153 (2.74 fold); miR-602 (1.57 fold); miR-455-5p (2.01 fold); miR-205 (6.29 fold); miR-183* (1.8 fold); miR-425 (1.66 fold); miR-375 (1.72 fold); miR-193b (1.58 fold); miR-30e* (1.32 fold); miR-95 (378 fold); miR-378 (1.65 fold); miR-455-3p (2.12 fold); miR-133a (2.19 fold); miR-873 (2.3 fold); miR-222 (2.17 fold); miR-21 (1.71 fold); miR-142 -3p (1.65 fold); miR-575 (1.7 fold) ;miR-130b (1.62 fold); miR-339-3p (1.19 fold); miR-149 (1.82 fold); miR-338-3p (1.96 fold); miR-19a (1.4 fold); miR-148a (1.63 fold); miR-146b-5p (1.68 fold); miR-125a-5p (1.41 fold); miR-27b (1.27 fold); miR-10b* (1.94 fold); miR-141 (1.42 fold); miR-7 (1.76 fold); miR-505 (1.33 fold); miR-30c-1* (1.41 fold); miR-145* (2.01 fold); miR-145 (2.01 fold); miR-125b (1.37 fold); miR-99a (1.34 fold); miR-378* (1.97 fold); miR-583 (1.82 fold); miR-221* (2.1 fold); miR-20a (1.4 fold); miR-124 (1.67 fold); miR-103 (1.21 fold); miR-542-5p (1.77 fold); miR-193b* (1.68 fold); miR-941 (1.52 fold)] Diagnostic Prostate Cancer (PCa)Vs Normal Adjacent Prostate (NAP) p= 0.0046 Tissue 21765474
687 miR-139-5p; miR-1; miR-133b; miR-133a; miR-143*; miR-145*; miR-143; miR-145; miR-27b, miR-221; miR-222; miR-378; miR-204; miR-141*; miR-32; let-7b; miR-183*, miR-301b; miR-106b; miR-93; miR-25; miR-183; miR-96; miR-425; miR-663 miRNA Humans NA Prognostic group I (good prognosis) from group II (poor prognosis) p=0.0005 Tissue 21765474
688 PCA3 mRNA Humans Upregulated in Prostate Cancer Diagnostic Prostate Cancer Vs Non- Prostate Cancer p<0.001 Urine 21788966
689 PCA3 mRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs Non- Prostate Cancer p=0.04 Urine 21788966
690 AMACR mRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs Non- Prostate Cancer p=0.04 Urine 21788966
691 Multiplex Model (PCA3+ AMACR+ SPINK1+ EZH2+ GOLM1+ TRPM8 + MSMB + Serum PSA) mRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs Non- Prostate Cancer p<0.001 Urine 21788966
692 Quadriplex Model (TRPM8 + MSMB+ PCA3+ AMACR) mRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs Non- Prostate Cancer p<0.001 Urine 21788966
693 Triplex Model (TRPM8 + MSMB+AMACR) mRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs Non- Prostate Cancer p<0.001 Urine 21788966
694 Duplex Model (TRPM8 + MSMB) mRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs Non- Prostate Cancer p=0.01 Urine 21788966
695 AMACR mRNA Humans Upregulated in locally advanced cancers Prognostic localized Vs locally advanced cancers p= 0.044 Urine 21788966
696 EZH2 mRNA Humans Upregulated in locally advanced cancers Prognostic localized Vs locally advanced cancers p= 0.022 Urine 21788966
697 EZH2 mRNA Humans Upregulated in Intermediate and further upregulated in High Risk Group Prognostic Low Vs Intermediate Vs High Risk Group High vs low-risk group patients (P = 0.002), intermediate vs low risk group patients (P = 0.044) Urine 21788966
698 PCAT-1 ncRNA Humans Upregulated in a subset of metastatic and high-grade localized (Gleason score ≥7) cancers Prognostic High grade tumor vs. low grade tumor/non-tumor NA Tissue 21804560
699 KBP4; CRKL; PDHB, PRDX3; HYPK; MYL6;KHSRP; ENO1; ANXA5 ; RPLP0; OSTF1; CFL1; TXNDC12 ; PFDN5 ; HRNR; COPS8 ; Protein Humans Upregulated (Atleast 2 fold): [KHSRP; ENO1; ANXA5 ; RPLP0; OSTF1; CFL1; TXNDC12 ; PFDN5 ; HRNR; COPS8;]Downregulated (Atleast 0.5 fold): [KBP4; CRKL; PDHB, PRDX3; HYPK; MYL6;] Prognostic CD44+ Vs CD44- Cells p<0.05 Cell Lines 21820414
700 Cofilin Protein Humans Upregulated in CD44++ Cells Prognostic CD44+ Vs CD44- Cells p<0.01 Cell Lines 21820414
701 Annexin A5 Protein Humans Upregulated in CD44++ Cells Prognostic CD44+ Vs CD44- Cells p<0.05 Cell Lines 21820414
705 PCA3 mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Controls NA Blood 21832279
720 Katanin p60 Protein Humans Upregulated in PCa Prognostic bone metastasis (Met) Vs No bone metastasis (controls) p<0.05 Bone Marrow (Tissue) 21681775
752 CEP55 Protein Humans Upregulated in Patients with Recurrence Prognostic PSA Reccurence Vs No Recurrence p<0.0001 Tissue 21917134
753 NUF2 Protein Humans Upregulated in Patients with Recurrence Prognostic PSA Reccurence Vs No Recurrence p<0.0001 Tissue 21917134
754 PAGE4 Protein Humans Downregulated in Patients with Recurrence Prognostic PSA Reccurence Vs No Recurrence p=0.0045 Tissue 21917134
755 CEP55 Protein Humans Upregulated with high Gleason Score Prognostic Gleason Score (≤6, (3+4), (4+3), 8-10) For Hazrard Ratio: (p = 0.003) Tissue 21917134
756 NUF2 Protein Humans Upregulated with high Gleason Score Prognostic Gleason Score (≤6, (3+4), (4+3), 8-10) For Hazrard Ratio: (p = 0.002) Tissue 21917134
757 PBK Protein Humans Upregulated with high Gleason Score Prognostic Gleason Score (≤6, (3+4), (4+3), 8-10) For Hazrard Ratio: (p = 0.001) Tissue 21917134
758 TTK Protein Humans Upregulated with high Gleason Score Prognostic f For Hazrard Ratio: (p = 0.002) Tissue 21917134
759 PAGE4 Protein Humans Downregulated with high Gleason Score Prognostic Gleason Score (≤6, (3+4), (4+3), 8-10) For Hazrard Ratio: (p = 0.002) Tissue 21917134
760 OPNa (osteopontin -a ) mRNA Humans Upregulated in Cancerous Conditions (PCA: Median: 62.43; BPH: Median: 0.20) Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.05 Tissue 21963599
761 OPNb (osteopontin -b ) mRNA Humans Upregulated in Cancerous Conditions (PCA: Median: 43.47; BPH: Median: 0.50) Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.05 Tissue 21963599
762 OPNc (osteopontin -c ) mRNA Humans Upregulated in Cancerous Conditions (PCA: Median: 200.36; BPH: Median: 0.0) Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.05 Tissue 21963599
764 OPNa+OPNb+OPNc mRNA Humans Upregulated in Cancerous Conditions Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.05 Tissue 21963599
765 OPNa+OPNb+OPNc+PSA mRNA Humans Upregulated in Cancerous Conditions Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.05 Tissue 21963599
766 OPNc+PSA mRNA Humans Upregulated in Cancerous Conditions Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.05 Tissue 21963599
767 OPNa (osteopontin -a ) mRNA Humans Upregulated with high Gleason Score (Median for GS< 7: 0.35, Median for GS ≥ 7: 84.54) Prognostic Gleason Score <7 Vs Gleason Score ≥ 7 p= 0.006 Tissue 21963599
768 OPNb (osteopontin -b ) mRNA Humans Upregulated with high Gleason Score (Median for GS< 7: 3.54, Median for GS ≥ 7: 61.19) Prognostic Gleason Score <7 Vs Gleason Score ≥ 7 p = 0.003 Tissue 21963599
769 OPNa (osteopontin -a ) mRNA Humans Upregulated with high Gleason Score (Median for GS< 7: 112.06, Median for GS ≥ 7: 526.39) Prognostic Gleason Score <7 Vs Gleason Score ≥ 7 p= 0.001 Tissue 21963599
770 miR-7; miR-126; miR-144; miR-144*; miR-335*; miR-374a;miR-374a*; miR-28-3p; miR-542-3p miRNA Humans Upregulated: [miR-7: (3.22 fold); miR-126: (14.45 fold); miR-144 (6.78 fold);miR-144* (12.98 fold); miR-335* (1.39 fold) ; miR-374a (2.43 fold) ; miR-374a (1.16 fold) ; miR-28-3p (1.69 fold); miR-542-3p (3.72 fold)] Prognostic Metastatic Vs Non Metastatic p<0.001 Tissue 21980368
771 miR-7-1*; miR-126*; miR-335; miR-28-5p; miR-339-3p; miR-339-5p; miR-542-5p miRNA Humans Downregulated: [miR-7-1* (8.88 fold); miR-126* (3.46b fold); miR-335 (2,42 fold); miR-28-5p (6.84 fold); miR-339-3p (-1.57 fold); miR-339-5p (5.26 fold); miR-542-5p (13.31 fold)] Prognostic Metastatic Vs Non Metastatic p<0.001 Tissue 21980368
786 AMACR+CSTA+HPN+MYO6+LAMB3+ABCC4 mRNA Humans Upregulated: [ABCC4, AMACR, HPN and MYO6]; Downregulated: [CSTA and LAMB3] Diagnostic Tumor Vs Normal Tissues p<0.001 Tissue 22009027
787 Auto-antibody profile (TTLL12+VAT1L+GGA1+RPIA+NHSL1+NOVA2+MAP2+PRPF38B+SRP14+ HSPH1+ZNF154+ADD1+RASSF7+RBM15+394 other genes) Protein (Auto-antibodies) Humans Upregulated in PCa Diagnostic prostate cancer Vs benign disease p<0.001 Serum 22012634
788 TTLL12+VAT1L+GGA1+RPIA+NHSL1+NOVA2+MAP2+PRPF38B+SRP14+ HSPH1+ZNF154+ADD1+RASSF7+RBM15+394 other genes Protein (Auto-antibodies) Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Healthy Men p<0.001 Serum 22012634
795 mmu-mir-24; mmu-mir-141; mmu-mir-182; mmu-mir-184; mmu-mir-215; mmu-mir-298; mmu-mir-320; mmu-mir-346; mmu-mir-375; mmu-mir-887 miRNA Mice Upregulated: [mmu-mir-24; mmu-mir-141; mmu-mir-182; mmu-mir-184; mmu-mir-298; mmu-mir-320; mmu-mir-346; mmu-mir-375; mmu-mir-887]; Downregulated: [mmu-mir-215] Diagnostic TRAMP and wild-type (WT) littermate control mice p≤ 0.05 Serum 22052531
796 hsa-mir-141; hsa-mir-298; hsa-mir-375 miRNA Humans Upregulated in PCa [hsa-mir-141; hsa-mir-298; hsa-mir-375] Diagnostic Normal Vs Primary Tumor p≤ 0.05 Serum 22052531
797 hsa-mir-141; hsa-mir-298; hsa-mir-346; hsa-mir-375 miRNA Humans Upregulated in PCa [hsa-mir-141; hsa-mir-298; hsa-mir-346 ; hsa-mir-375] Diagnostic Normal Vs Metastatic Tumor p≤ 0.05 Serum 22052531
798 hsa-mir-375 miRNA Humans High expression associated with an increased risk of BCR Prognostic Biochemical Recurrenece p = 0.002 Serum 22052531
799 hsa-mir-375 miRNA Humans High expression with reduced chances of relapse free survival Prognostic Biochemical Recurrenece Univariate: p=0.0001; Multivariate: p=0.0260 Serum 22052531
800 PRKAR1A; LRRN3; PCDH17; TTN; LAIR2; RNASE3; CEACAM6; AZU1; HIST1H4C; PGLYRP1; CEACAM8; LCN2; MPO; CAMP; DEFA1;DEFA1; DEFA1; DEFA3; DEFA1; DEFA1; CTSG; DEFA4; ELA2; mRNA Humans Downregulated (0.6-0.82 fold): [PRKAR1A; LRRN3; PCDH17; TTN;] ; Upregulated (0.6 - 1.36 fold): [LAIR2; RNASE3; CEACAM6; AZU1; HIST1H4C; PGLYRP1; CEACAM8; LCN2; MPO; CAMP; DEFA1e;DEFA1e; DEFA1e; DEFA3; DEFA1e; DEFA1e; CTSG; DEFA4; ELA2;] Prognostic Long-term survivors (survived for >900 days) Vs Short-Term survivors (died within 300 days) - prevaccination p< 0.008 Blood 22071976
801 LTB; OLR1; CEACAM1; ARG1; MYL4; ALAS2; SLPI; SELENBP1; SNCA; AZU1; HMGXB4; RNASE3; HBQ1; MMP9; GYPE; SNCA; EPB42; HP; IFIT1L; BPI; CEACAM6; MPO; OLFM4; HBM; ALAS2; CEACAM8; CA1; HBD; LCN2; CTSG; DEFA1; CAMP; ELA2; DEFA4; DEFA3; DEFA1; DEFA1; DEFA1; DEFA1; mRNA Humans Downregulated: [LTB (1.03 fold)] ; Upregulated (1.04- 2.87 fold): [OLR1; CEACAM1; ARG1; MYL4; ALAS2; SLPI; SELENBP1; SNCAe; AZU1; HMGXB4; RNASE3; HBQ1; MMP9; GYPE; SNCAe; EPB42; HP; IFIT1L; BPI; CEACAM6; MPO; OLFM4; HBM; ALAS2; CEACAM8; CA1; HBD; LCN2; CTSG; DEFA1e; CAMP; ELA2; DEFA4; DEFA3; DEFA1e; DEFA1e; DEFA1e; DEFA1e;] Prognostic Long-term survivors (survived for >900 days) Vs Short-Term survivors (died within 300 days) - Postvaccination p< 0.008 Blood 22071976
802 RNASE2; SLC4A1; HEMGN; CEACAM1; S100P; ALS2; ARG1; SLPI; OLR1; RETN; HBQ1; ALAS2; MMP9; RNASE3; HMGXB4; SELENBP1; GYPE; BPI; TCN1; ORM1; CEACAM6; SNCA; MPO; SNCA; HP; CD24; IFIT1L; EPB42; CTSG; ELA2; PGLYRP1; DEFA1; CEACAM8; HBM; DEFA4; ALAS2; CAMP; LCN2; OLFM4; DEFA3; DEFA1; DEFA1; DEFA1; ERAF; CA1; HBD; DEFA1; mRNA Humans Upregulated Postvaccine treatment: [RNASE2; SLC4A1; HEMGN; CEACAM1; S100P; ALS2; ARG1; SLPI; OLR1; RETN; HBQ1; ALAS2; MMP9; RNASE3; HMGXB4; SELENBP1; GYPE; BPI; TCN1; ORM1; CEACAM6; SNCA; MPO; HP; CD24; IFIT1L; EPB42; CTSG; ELA2; PGLYRP1; DEFA1; CEACAM8; HBM; DEFA4; CAMP; LCN2; OLFM4; DEFA3; DEFA1;ERAF; CA1; HBD;] Predictive Short Term Survival Pre Vs Post Vaccination p< 0.008 Blood 22071976
803 LRRN3+PCDH17+HIST1H4C+PGLYRP1 mRNA Humans Downregulated: [LRRN3; PCDH17;] ; Upregulated: [HIST1H4C; PGLYRP1;] Prognostic Long-term survivors (survived for >900 days) Vs Short-Term survivors (died within 300 days) - prevaccination p< 0.008 Blood 22071976
813 TGFβ1 (transforming growth factor beta 1) mRNA Humans Associated with Prostate cancer specific Survival Prognostic disease specific survival Vs no survival p=0.0 Tissue 22113713
814 (IL-7) Interleukin-7 mRNA Humans Associated with Prostate cancer specific Survival Prognostic disease specific survival Vs no survival p=0.03 Tissue 22113713
815 miRNA - 221 and miRNA-222 miRNA Humans Upregulated in aggressive Prostate Cancer (Aggressive: 20.1 ± 2.4; Non Aggressive: 3.4 ± 0.2) Prognostic Agressive Vs Non - Agressive Prostate Cancer p=0.001 Tissue 22117988
816 ARHI mRNA Humans Downregulated in aggressive Prostate Cancer (Aggressive:9.6 ± 1.2; Non Agressive: 8.3 ± 2.3 ) Prognostic Agressive Vs Non - Agressive Prostate Cancer p=0.001 Tissue 22117988
817 Interleukin-18 (IL-18) Protein Humans Upregulated in BPH and Prostate cancer: [ Controls: 143.97 ± 2.29; BPH: 145.88 ± 1.93; TNM Stage 2: 229.54 ± 3.30; TNM Stage 3: 245.66 ± 4.05; TNM Stage 4: 251.64 ± 4.12] Prognostic Controls Vs BPH Vs TNM T2 stage Vs TNM T3 stage Vs TNM T4 stage p<0.05 (Controls Vs TNM Stage 2,3 and 4 ; BPH Vs TNM Stage 2,3 and 4; TNM Stage 2 Vs TNM Stage 3,4] Serum 22126577
818 Interleukin-10 (IL-10) Protein Humans Upregulated in BPH and Prostate cancer: [ Controls: 2.08 ± 0.27; BPH: 2.15 ± 0.18; TNM Stage 2: 8.03 ± 0.49; TNM Stage 3: 13.06 ± 0.45; TNM Stage 4: 6.32 ± 0.29] Prognostic Controls Vs BPH Vs TNM T2 stage Vs TNM T3 stage Vs TNM T4 stage p<0.05 (Controls Vs TNM Stage 2,3 and 4 ; BPH Vs TNM Stage 2,3 and 4; TNM Stage 2 Vs TNM Stage 3,4] Serum 22126577
819 Interleukin-18 (IL-18) Protein Humans Increased expression in patients with poor survival Prognostic Survival Vs No Survival p<0.001 Serum 22126577
820 Interleukin-10 (IL-10) Protein Humans Increased expression in patients with poor survival Prognostic Survival Vs No Survival p<0.001 Serum 22126577
822 TDRD1 mRNA Humans Upregulated in Prostate cancer Diagnostic Benign Vs Tumor p<0.05 Tissue 22142399
823 TDRD1 mRNA Humans Upregulated in TMPRSS2-ERG gene fusion (36 fold) compared to benign samples and TMPRSS2-ERG gene fusion compared to non fusion (23 fold). Prognostic Benign Vs TMPRSS2-ERG gene fusion Vs non-fusion TMPRSS2-ERG positive tumors compared to normal (p = 1.77*10^-9) and fusion-negative samples (p = 1.51*10^-9) Tissue 22142399
824 CRISP3 mRNA Humans Upregulated in Prostate cancer Diagnostic Benign Vs Tumor p<0.05 Tissue 22142399
825 CRISP3 mRNA Humans Upregulated in TMPRSS2-ERG gene fusion (37 fold) compared to benign samples, normal and fusion-negative tumor samples (FC = 1.2) Diagnostic Benign Vs TMPRSS2-ERG gene fusion Vs non-fusion TMPRSS2-ERG positive tumors compared to normal tissue (p = 2.2*10-12), normal and fusion-negative tumor samples (p = 0.03) Tissue 22142399
826 CRISP3, AMACR , OR51E2, SPRR2F , TDRD1, F5, ACSM1, C20orf74, GOLM1 , MYC, CACNA1D, SFRP4, TRIB1, GDF15, LRRN1, FOLH1 , PRR16, LUZP2, RRM2, ERG, COL1A1, DNAH5, ZNF417 , SPON2, RICS, HIPK2 , ACACA , TUG1, COQ6 , LARP1, NETO2, FLJ20184, FASN, NEDD4L, LOC286161, MAOA, XPO6, ABCC4, RAB3B, TMEM45B, IMPDH2, DAPK1, LOC100131821 , C19orf48, KIAA1244 , GPI , HIVEP1, NAALADL2, C11orf92, THBS4, MYO6, BAMBI, ZNF462, SPOCK1, REPS2, SGEF, TBC1D16, TRIM36, LBH, AGPAT3, CAMKK2, GCNT1, F2R, BAT2L , LRIG1, GLYATL1 , DDX21, PLA1A, TMEFF2, SLC7A1, KIAA0368, PCDHB13 , UGT2B10 , EEF2 , C10orf137 , MICAL2, BGN, BICC1 , EIF4A1 , STX19, CHD6, ASPN, PTPN13, RAB3IP, ZNF146, BCOR, SH3RF1, TMTC4, ZDHHC9, MS4A8B, UTRN, DIP2B, UAP1, C4A , HDLBP, KIF5C, PMEPA1, GRPR , ZNF217, HUWE1, ZNF417 , AAK1 , CCDC6, BRD2, CRKRS, TP53INP1, ABCA1 , H2BFS , LIG3, PHF12, FAM117B, MED13L, TMEM2, PLA2G7, DICER1, SRRM2, BAGE2 , USP54, MYH10, SLC36A1, SLC7A11, LOC651907 , CREB3L1, ATP13A5 , ATP2B1, ANKRD34B, BAZ2A, C10orf12, POSTN, CALR3 , ZNF828, CS, ERGIC1, BXDC1, EIF4G1, PRKCSH, ABHD2, SIM2, NUFIP2, SPP1, RPL9P11 , HSN2 , JAG1, TPX2, MOSC1, TMEM161B , C4orf18 , BAT2L, DDAH1, NOLC1, ANKRD17, LOC100130958 , CMTM4, APOF, GALNT7, SETD5, HIST1H3B, TSPAN13, EPCAM, MLL, ADAR, EGR1, DNAJC10, MLEC, SEL1L, HYOU1, COL1A2, PSD3, MYO10 , ENC1 , BAT2D1, DDI2 , KDM2A , ENO1, C20orf191 , EP300, ALDH1A3, FAM119A , SLC27A2, C9orf91, TKT, NCL , ABHD2, STK33, ACTG2, IGJ, SLC26A4, SLC39A2, ZNF701 , COCH , BZW1 , CCDC68, PTPLA, VSNL1, GCNT2 , RND3, SCN7A, CYP27A1, CYP3A5 , GJA1, GSTM3, CFL2, C2 , HBB, SPATA6, KRT23, GPR87, MPPED2, HIST1H4C, OGN, LRCH2, C12orf75, NTN4, LOC100188947 , NEFH, SRD5A2, ADAM32, DPT, AZGP1, ACSS3, SLC15A2, PROM1, CACNA2D1, CXCL13, MME, ZNF483, L3MBTL4, APLF , CHRDL1, HIST1H1A, LEPREL1, ARMCX1, ANGPT1, MT1M , DSC3, B3GALT2, SLC22A3, ANO5, MT1G, PCP4, ANXA1 , PLN, EAF2 , ANPEP, TCEAL2 , LTF, PRDM5, LOC100134430 , ATRNL1, KRT15, SPOCK3, PI15, CD177, GDEP, CD38, FLRT3, SLC18A2, AOX1, MSMB, TGM4, OLFM4, SLC14A1, AMY1A mRNA Humans Differentially expressed (Log fold change) [CRISP3 ( 2.93 fold); , AMACR ( 2.85 fold); , OR51E2 ( 2.46 fold); , SPRR2F ( 2.36 fold); , TDRD1 ( 2.31 fold); , F5 ( 2.23 fold); , ACSM1 ( 2.23 fold); , C20orf74 ( 2.05 fold); , GOLM1 ( 2.01 fold); , MYC ( 1.83 fold); , CACNA1D ( 1.73 fold); , SFRP4 ( 1.68 fold); , TRIB1 ( 1.68 fold); , GDF15 ( 1.67 fold); , LRRN1 ( 1.67 fold); , FOLH1 ( 1.66 fold); , PRR16 ( 1.59 fold); , LUZP2 ( 1.58 fold); , RRM2 ( 1.57 fold); , ERG ( 1.57 fold); , COL1A1 ( 1.57 fold); , DNAH5 ( 1.57 fold); , ZNF417 ( 1.56 fold); , SPON2 ( 1.56 fold); , RICS ( 1.55 fold); , HIPK2 ( 1.54 fold); , ACACA ( 1.54 fold); , TUG1 ( 1.51 fold); , COQ6 ( 1.5 fold); , LARP1 ( 1.49 fold); , NETO2 ( 1.49 fold); , FLJ20184 ( 1.48 fold); , FASN ( 1.48 fold); , NEDD4L ( 1.47 fold); , LOC286161 ( 1.46 fold); , MAOA ( 1.45 fold); , XPO6 ( 1.43 fold); , ABCC4 ( 1.43 fold); , RAB3B ( 1.42 fold); , TMEM45B ( 1.42 fold); , IMPDH2 ( 1.39 fold); , DAPK1 ( 1.38 fold); , LOC100131821 ( 1.38 fold); , C19orf48 ( 1.37 fold); , KIAA1244 ( 1.36 fold); , GPI ( 1.35 fold); , HIVEP1 ( 1.34 fold); , NAALADL2 ( 1.34 fold); , C11orf92 ( 1.34 fold); , THBS4 ( 1.33 fold); , MYO6 ( 1.31 fold); , BAMBI ( 1.31 fold); , ZNF462 ( 1.3 fold); , SPOCK1 ( 1.3 fold); , REPS2 ( 1.28 fold); , SGEF ( 1.28 fold); , TBC1D16 ( 1.27 fold); , TRIM36 ( 1.27 fold); , LBH ( 1.26 fold); , AGPAT3 ( 1.26 fold); , CAMKK2 ( 1.25 fold); , GCNT1 ( 1.24 fold); , F2R ( 1.24 fold); , BAT2L ( 1.24 fold); , LRIG1 ( 1.23 fold); , GLYATL1 ( 1.23 fold); , DDX21 ( 1.23 fold); , PLA1A ( 1.22 fold); , TMEFF2 ( 1.22 fold); , SLC7A1 ( 1.22 fold); , KIAA0368 ( 1.22 fold); , PCDHB13 ( 1.21 fold); , UGT2B10 ( 1.21 fold); , EEF2 ( 1.2 fold); , C10orf137 ( 1.2 fold); , MICAL2 ( 1.2 fold); , BGN ( 1.19 fold); , BICC1 ( 1.19 fold); , EIF4A1 ( 1.19 fold); , STX19 ( 1.18 fold); , CHD6 ( 1.18 fold); , ASPN ( 1.18 fold); , PTPN13 ( 1.18 fold); , RAB3IP ( 1.18 fold); , ZNF146 ( 1.18 fold); , BCOR ( 1.17 fold); , SH3RF1 ( 1.17 fold); , TMTC4 ( 1.16 fold); , ZDHHC9 ( 1.16 fold); , MS4A8B ( 1.16 fold); , UTRN ( 1.16 fold); , DIP2B ( 1.15 fold); , UAP1 ( 1.15 fold); , C4A ( 1.15 fold); , HDLBP ( 1.15 fold); , KIF5C ( 1.14 fold); , PMEPA1 ( 1.14 fold); , GRPR ( 1.14 fold); , ZNF217 ( 1.13 fold); , HUWE1 ( 1.13 fold); , ZNF417 ( 1.13 fold); , AAK1 ( 1.13 fold); , CCDC6 ( 1.12 fold); , BRD2 ( 1.12 fold); , CRKRS ( 1.12 fold); , TP53INP1 ( 1.12 fold); , ABCA1 ( 1.12 fold); , H2BFS ( 1.12 fold); , LIG3 ( 1.11 fold); , PHF12 ( 1.11 fold); , FAM117B ( 1.11 fold); , MED13L ( 1.11 fold); , TMEM2 ( 1.11 fold); , PLA2G7 ( 1.11 fold); , DICER1 ( 1.11 fold); , SRRM2 ( 1.1 fold); , BAGE2 ( 1.1 fold); , USP54 ( 1.1 fold); , MYH10 ( 1.1 fold); , SLC36A1 ( 1.1 fold); , SLC7A11 ( 1.1 fold); , LOC651907 ( 1.1 fold); , CREB3L1 ( 1.1 fold); , ATP13A5 ( 1.09 fold); , ATP2B1 ( 1.09 fold); , ANKRD34B ( 1.09 fold); , BAZ2A ( 1.08 fold); , C10orf12 ( 1.08 fold); , POSTN ( 1.08 fold); , CALR3 ( 1.07 fold); , ZNF828 ( 1.07 fold); , CS ( 1.07 fold); , ERGIC1 ( 1.07 fold); , BXDC1 ( 1.07 fold); , EIF4G1 ( 1.06 fold); , PRKCSH ( 1.06 fold); , ABHD2 ( 1.06 fold); , SIM2 ( 1.06 fold); , NUFIP2 ( 1.06 fold); , SPP1 ( 1.06 fold); , RPL9P11 ( 1.06 fold); , HSN2 ( 1.05 fold); , JAG1 ( 1.05 fold); , TPX2 ( 1.05 fold); , MOSC1 ( 1.04 fold); , TMEM161B ( 1.04 fold); , C4orf18 ( 1.04 fold); , BAT2L ( 1.04 fold); , DDAH1 ( 1.04 fold); , NOLC1 ( 1.03 fold); , ANKRD17 ( 1.03 fold); , LOC100130958 ( 1.03 fold); , CMTM4 ( 1.03 fold); , APOF ( 1.03 fold); , GALNT7 ( 1.02 fold); , SETD5 ( 1.02 fold); , HIST1H3B ( 1.02 fold); , TSPAN13 ( 1.02 fold); , EPCAM ( 1.02 fold); , MLL ( 1.02 fold); , ADAR ( 1.02 fold); , EGR1 ( 1.02 fold); , DNAJC10 ( 1.02 fold); , MLEC ( 1.02 fold); , SEL1L ( 1.01 fold); , HYOU1 ( 1.01 fold); , COL1A2 ( 1.01 fold); , PSD3 ( 1.01 fold); , MYO10 ( 1.01 fold); , ENC1 ( 1.01 fold); , BAT2D1 ( 1.01 fold); , DDI2 ( 1.01 fold); , KDM2A ( 1.01 fold); , ENO1 ( 1.01 fold); , C20orf191 ( 1.01 fold); , EP300 ( 1.01 fold); , ALDH1A3 ( 1.01 fold); , FAM119A ( 1.01 fold); , SLC27A2 ( 1.0 fold); , C9orf91 ( 1.0 fold); , TKT ( 1.0 fold); , NCL ( 1.0 fold); , ABHD2 ( 1.0 fold); , STK33 ( -1.0 fold); , ACTG2 ( -1.01 fold); , IGJ ( -1.01 fold); , SLC26A4 ( -1.01 fold); , SLC39A2 ( -1.01 fold); , ZNF701 ( -1.01 fold); , COCH ( -1.02 fold); , BZW1 ( -1.03 fold); , CCDC68 ( -1.03 fold); , PTPLA ( -1.04 fold); , VSNL1 ( -1.04 fold); , GCNT2 ( -1.05 fold); , RND3 ( -1.05 fold); , SCN7A ( -1.05 fold); , CYP27A1 ( -1.05 fold); , CYP3A5 ( -1.05 fold); , GJA1 ( -1.06 fold); , GSTM3 ( -1.07 fold); , CFL2 ( -1.09 fold); , C2 ( -1.09 fold); , HBB ( -1.1 fold); , SPATA6 ( -1.1 fold); , KRT23 ( -1.11 fold); , GPR87 ( -1.11 fold); , MPPED2 ( -1.11 fold); , HIST1H4C ( -1.11 fold); , OGN ( -1.12 fold); , LRCH2 ( -1.12 fold); , C12orf75 ( -1.12 fold); , NTN4 ( -1.12 fold); , LOC100188947 ( -1.12 fold); , NEFH ( -1.13 fold); , SRD5A2 ( -1.15 fold); , ADAM32 ( -1.16 fold); , DPT ( -1.16 fold); , AZGP1 ( -1.16 fold); , ACSS3 ( -1.17 fold); , SLC15A2 ( -1.17 fold); , PROM1 ( -1.18 fold); , CACNA2D1 ( -1.18 fold); , CXCL13 ( -1.18 fold); , MME ( -1.18 fold); , ZNF483 ( -1.19 fold); , L3MBTL4 ( -1.19 fold); , APLF ( -1.21 fold); , CHRDL1 ( -1.21 fold); , HIST1H1A ( -1.23 fold); , LEPREL1 ( -1.25 fold); , ARMCX1 ( -1.25 fold); , ANGPT1 ( -1.26 fold); , MT1M ( -1.27 fold); , DSC3 ( -1.29 fold); , B3GALT2 ( -1.29 fold); , SLC22A3 ( -1.3 fold); , ANO5 ( -1.31 fold); , MT1G ( -1.31 fold); , PCP4 ( -1.32 fold); , ANXA1 ( -1.32 fold); , PLN ( -1.32 fold); , EAF2 ( -1.33 fold); , ANPEP ( -1.35 fold); , TCEAL2 ( -1.39 fold); , LTF ( -1.4 fold); , PRDM5 ( -1.42 fold); , LOC100134430 ( -1.42 fold); , ATRNL1 ( -1.42 fold); , KRT15 ( -1.43 fold); , SPOCK3 ( -1.44 fold); , PI15 ( -1.44 fold); , CD177 ( -1.46 fold); , GDEP ( -1.47 fold); , CD38 ( -1.53 fold); , FLRT3 ( -1.58 fold); , SLC18A2 ( -1.69 fold); , AOX1 ( -1.72 fold); , MSMB ( -1.74 fold); , TGM4 ( -1.76 fold); , OLFM4 ( -1.85 fold); , SLC14A1 ( -1.95 fold); , AMY1A ( -2.11 fold)] Diagnostic Benign Vs Tumor p<0.006857824 Tissue 22142399
827 Auto-antibody signature (TARDBP, TLN1, PARK7, LEDGF/ PSIP1, and CALD1) Protein Humans Differentially Expressed Diagnostic prostate cancer Vs benign prostatic hyperplasia p< 0.05 Serum 22146597
828 TARDBP; TLN1; ;PARK7; LEDGF/PSIP1; CALD1; p73; PTEN; PXN; PEX10; KLK3; DBN1; NFAT1; B Tubulin; SOS1; HSF4; TOP1; HSPA1A/B; Protein Humans Differentially Expressed Diagnostic prostate cancer Vs benign prostatic hyperplasia p< 0.05 Serum 22146597
829 Secreted frizzled-related protein (SFRP)-2 Protein Humans Downregulated in Prostate cancer (PCa: 2.28 ± 0.33 Vs Controls: 1.11 ± 0.09) Diagnostic Benign Vs malignant prostate glands p<0.0001 Tissue 22175903
830 Secreted frizzled-related protein (SFRP)-2 Protein Humans Upregulated in Gleason Grade 5 (PCa: 3.16 ± 0.99; Control: 0.77±0.15) Prognostic Gleason Grade 3,4 Vs Gleason Grade 5 p<0.0001 Tissue 22175903
833 APOD; C1QTNF3; CD27; CFB; CFH; CLU; CRABP1; DDAH2; FTL; IGSF8; ITIH4l; LGALS3; LYZ; MGAT5; PECAM1; RBP4; RECK; SELENBP1; SLIT2; mRNA Humans (1.358 fold) Upregulated in PCa [APOD (2.803 fold) ; C1QTNF3 (1.100 fold); CD27 (1.183 fold); CFB (3.231 fold); CFH (1.381 fold); CLU (1.638 fold); CRABP1 (1.477 fold) ; DDAH2 (1.152 fold) ; FTL (1.718 fold); IGSF8 (1.358 fold) ; ITIH4l (1.215 fold) ; LGALS3 (4.121 fold) ; LYZ (2.093 fold) ; MGAT5 (1.112 fold); PECAM1 (2.404 fold) ; RBP4 (1.872 fold); RECK (2.569 fold) ; SELENBP1 (1.327 fold) ; SLIT2 (1.848 fold)] Diagnostic Prostate Cancer Vs Normal controls p<0.001 Urine 22194848
837 mir-107; mir-130b; mir-141; mir-181a-2*; mir-2110; mir-301a; mir-326; mir-331-3p; mir-432; mir-574-3p; mir-625; miRNA Humans Upregulated in PCa: [mir-107; mir-130b; mir-141; mir-2110; mir-301a; mir-326; mir-331-3p; mir-432; mir-574-3p; mir-625;] Downregulated in PCa: [miR-181a-2* (2.69 fold)] Diagnostic Normal Vs prostate cancer p<0.001 Plasma 22240788
838 mir-107; mir-141; mir-181a-2*; mir-2110; mir-301a; mir-326; mir-432; mir-574-3p; mir-625; miRNA Humans Upregulated in localised PCa: [mir-107; mir-141; mir-2110; mir-301a; mir-326; mir-432; mir-574-3p; mir-625;] Downregulated in localised PCa: [miR-181a-2* (2.69 fold)] Diagnostic Normal Vs localised prostate cancer p<0.001 Plasma 22240788
839 mir-582-3p; mir-20a*; mir-375; mir-200b; mir-379; mir-572; mir-513a-5p; mir-577; mir-23a*; mir-1236; mir-609; mir-17*; mir-619; mir-624*; mir-198; mir-130b miRNA Humans Upregulated in metastatic PCa: [mir-582-3p; mir-20a*; mir-375; mir-200b; mir-379; mir-513a-5p; mir-577; mir-23a*; mir-1236; mir-609; mir-17*; mir-619; mir-624*; mir-198; mir-130b] Downregulated in metastatic PCa: [miR-572 (7.39 fold)] Diagnostic metastatic prostate cancer Vs localised prostate cancer p<0.001 Plasma 22240788
840 miRNA - 107 miRNA Humans Upregulated in Pca Diagnostic Benign Vs Prostate Cancer p=0.001 Urine 22240788
841 miRNA - 574-3p miRNA Humans Upregulated in PCa Diagnostic Benign Vs Prostate Cancer p=0.012 Urine 22240788
842 breast cancer antiestrogen resistance 1 (BCAR1) Protein Humans Significantly associated with Biochemical Relapse Prognostic Biochemical Recurrence p=0.02 Tissue 22241677
843 let-7c + let-7e+miR30c+ miR-622+ miR1285 miRNA Humans Differentially expressed Diagnostic prostate cancer Vs benign prostatic hyperplasia p<0.001 Plasma 22298030
844 let-7c + let-7e+miR30c+ miR-622+ miR1285 miRNA Humans Differentially expressed Diagnostic Prostate Cancer Vs Healthy Men p<0.001 Plasma 22298030
845 let-7c miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Healthy Men Testing: p<0.001 Plasma 22298030
846 let-7e miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Healthy Men Testing: p<0.001 Plasma 22298030
847 miR-30c miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Healthy Men Testing: p<0.001 Plasma 22298030
848 miR-622 miRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Healthy Men Testing: p<0.001 Plasma 22298030
849 miR-1285 miRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Healthy Men Testing: p=0.0047 Plasma 22298030
850 let-7c miRNA Humans Downregulated in PCa Diagnostic prostate cancer Vs benign prostatic hyperplasia Training & Testing: p<0.0001 Plasma 22298030
851 let-7e miRNA Humans Downregulated in PCa Diagnostic prostate cancer Vs benign prostatic hyperplasia Training: p=0.0029; Testing = p<0.0001 Plasma 22298030
852 miR-25 miRNA Humans Downregulated in PCa Diagnostic prostate cancer Vs benign prostatic hyperplasia Training: p<0.0001; Not significant in validation set Plasma 22298030
853 miR-30c miRNA Humans Downregulated in PCa Diagnostic prostate cancer Vs benign prostatic hyperplasia Training: p<0.0001 Plasma 22298030
854 miR-346 miRNA Humans Upregulated in PCa Diagnostic prostate cancer Vs benign prostatic hyperplasia Training: p<0.0001; Not significant in validation set Plasma 22298030
855 miR-622 miRNA Humans Upregulated in PCa Diagnostic prostate cancer Vs benign prostatic hyperplasia Training: p<0.0001 Plasma 22298030
856 miR-940 miRNA Humans Upregulated in PCa Diagnostic prostate cancer Vs benign prostatic hyperplasia Training: p= 0.0062 Plasma 22298030
857 miR-1285 miRNA Humans Upregulated in PCa Diagnostic prostate cancer Vs benign prostatic hyperplasia Training: p<0.0001 Plasma 22298030
858 basic fibroblast growth factor (bFGF) Protein Humans Upregulated in Treatment Group: [Treatment: 32 (25–71) Vs Control : 11 (8–14)] Predictive ADT Treatment Vs No Treatment p=0.0006 Plasma 22302227
859 Interleukin 1 (IL-1β) Protein Humans Upregulated in Treatment Group [Treatment:0.56 (0.45–0.90) Vs Control : 0.34 (0.25–0.52)] Predictive ADT Treatment Vs No Treatment p=0.026 Plasma 22302227
860 Interleukin 8 (IL-8) Protein Humans Upregulated in Treatment Group (Treatment: 5.7 (3.8–7.7) Vs Control : 2.2 (1.6–2.8) ) Predictive ADT Treatment Vs No Treatment p=0.0001 Plasma 22302227
861 stromal cell–derived factor 1α (SDF-1α) Protein Humans Upregulated in Treatment Group (Treatment: 2,294 (1,775–2,671) Vs Control : 1,736 (1,577–1,842) ) Predictive ADT Treatment Vs No Treatment p=0.023 Plasma 22302227
868 Alpha2- macroglobin (α2m); Elongation Factor 1A (EFA1) ; Lumican ; Complement Factor 1 Light Chain; Heparin Cofactor 2; Inter-alpha-trypsin inhbitor heavy chain H2; Serum amyloid P-component; Histidine Rich gylcoprotien; Transthyretin Protein Humans Upregulated: [Alpha2- macroglobin (α2m) (1.4 fold); Elongation Factor 1A (EFA1) (1.2 fold); Lumican (1.1 fold); Downregulated: [Complement Factor 1 Light Chain (1.1 fold); Heparin Cofactor 2 (1.1 fold) ; Inter-alpha-trypsin inhbitor heavy chain H2 (1.1 fold) ; Serum amyloid P-component (1.1 fold); Histidine Rich gylcoprotien (1.3 fold) ; Transthyretin (1.4 fold)] Diagnostic BPH Vs Non Progressing Prostate Cancer p ≤0.01 Serum 22355332
869 Beta-2-gylcoprotien 1 + Somatomedin- B Protein Humans Upregulated: [Beta-2-gylcoprotien 1 (1.2 fold)+ Somatomedin- B (1.1 fold)] Diagnostic BPH Vs Non Progressing Prostate Cancer p ≤0.01 Serum 22355332
870 Antithrombin III + Inter-alpha-trypsin inhibitor heavy chain H3 Protein Humans Downregulated: [Antithrombin III (1.4 fold)+ Inter-alpha-trypsin inhibitor heavy chain H3 (1.7 fold)] Diagnostic BPH Vs Non Progressing Prostate Cancer p ≤0.01 Serum 22355332
871 Afamin + Fibronectin 1 + Alpha-2-HS-glycoprotien chain B Protein Humans Upregulated : [Afamin (1.4 fold) + Fibronectin 1 (1.4 fold) + Alpha-2-HS-glycoprotien chain B (1.1 fold)] Diagnostic BPH Vs Non Progressing Prostate Cancer p ≤0.01 Serum 22355332
872 cDNA FLJ55673 + cDNA FLJ58564 + Ceruplasmin + Complement C5 + Alpha-1-antichymotrypsin + Complement component C9b + cDNA FLJ54228 Protein Humans Downregulated : [cDNA FLJ55673 (1.1 fold)+ cDNA FLJ58564 (1.1 fold)+ Ceruplasmin (1.1 fold) + Complement C5 (1.1 fold) + Alpha-1-antichymotrypsin (1.2 fold) + Complement component C9b (1.2 fold) + cDNA FLJ54228 (1.5 fold) Diagnostic BPH Vs Non Progressing Prostate Cancer p ≤0.01 Serum 22355332
873 cDNA FLJ51403 ; Elongation Factor 1A (EF-A1) ; Alpha 1B - glycoprotien; Complement component C7; Inter-alpha (Globulin) inhibitor H4; Kininogen 1; Plasma retinol-binding protien; cDNA FLJ77744; Complement C1r subcomponent-like Protein; Ficolin-3 Protein Humans Upregulated: [cDNA FLJ51403 (1.9 fold); Elongation Factor 1A (EF-A1) (1.8 fold); Alpha 1B - glycoprotien (1.1 fold) ; Complement component C7 (1.1 fold) ; Inter-alpha (Globulin) inhibitor H4;(1.1 fold)]; Downregulated: [Kininogen 1 (1.1 fold); Plasma retinol-binding protien (1.2 fold); cDNA FLJ77744 (1.4 fold); Complement C1r subcomponent-like Protein (1.4 fold); Ficolin-3 (1.4 fold)] Prognostic Non Progressing Vs Progressing Prostate Cancer p ≤0.01 Serum 22355332
874 Inter-alpha-trypsin inhibitor heavy chain H3 + Antithrombin III Protein Humans Upregulated [Inter-alpha-trypsin inhibitor heavy chain H3 (2.0 fold) + Antithrombin III (1.2 fold)] Prognostic Non Progressing Vs Progressing Prostate Cancer p ≤0.01 Serum 22355332
875 Apliopoprotien A-IV + Complement Component 4B Protein Humans Downregulated [Apliopoprotien A-IV (1.1 fold)+ Complement Component 4B (1.3 fold)] Prognostic Non Progressing Vs Progressing Prostate Cancer p ≤0.01 Serum 22355332
876 Beta 2-Glycoprotein 1 + Somatomedin- B Protein Humans Downregulated [Beta 2-Glycoprotien 1 (1.1 fold) + Somatomedin- B (1.2 fold)] Prognostic Non Progressing Vs Progressing Prostate Cancer p ≤0.01 Serum 22355332
877 Alpha-2 HS-glycoprotien chain B + Afamin + Fibronectin 1 Protein Humans Downregulated [Alpha-2 HS-glycoprotien chain B (1.2 fold) + Afamin (1.5 fold)+ Fibronectin 1 (1.6 fold)] Prognostic Non Progressing Vs Progressing Prostate Cancer p ≤0.01 Serum 22355332
878 Elongation Factor 1A (EFA1) ; Zinc-alpha-2-glycoprotien ; Complement Compnent C6; Hemopexin ; Vitamin D-binding protien; cDNA FLJ53698; Histidine-rich glycoprotien; Inter-alpha-trypsin inhibitor heavy chain H1; Inter-alpha-trypsin inhibitor heavy chain H2; N-acetlymuramoyl-L-alanine amidase; Thyroxine-binding globulin Protein Humans Upregulated [Elongation Factor 1A (EFA1) (1.4 fold) ; Zinc-alpha-2-glycoprotien (1.3 fold) ; Complement Compnent C6 (1.2 fold); Hemopexin (1.2 fold); Vitamin D-binding protien (1.1 fold)];Downregulated [cDNA FLJ53698 (1.3 fold); Histidine-rich glycoprotien (1.3 fold); Inter-alpha-trypsin inhibitor heavy chain H1 (1.3 fold); Inter-alpha-trypsin inhibitor heavy chain H2 (1.4 fold); N-acetlymuramoyl-L-alanine amidase (1.4 fold); Thyroxine-binding globulin (1.5 fold)] Prognostic Progressing Vs Metastatic Prostate Cancer p ≤0.01 Serum 22355332
879 Apliopoprotien A-IV + Complement Component 4B Protein Humans Upregulated [Apliopoprotien A-IV (1.3 fold) + Complement Component 4B (1.4 fold)] Prognostic Progressing Vs Metastatic Prostate Cancer p ≤0.01 Serum 22355332
880 Alpha-2 HS-glycoprotien chain B + Afamin + Fibronectin 1 Protein Humans Downregulated [Alpha-2 HS-glycoprotien chain B (1.9 fold) + Afamin (1.9 fold)+ Fibronectin 1 (2.1 fold)] Prognostic Progressing Vs Metastatic Prostate Cancer p ≤0.01 Serum 22355332
881 cDNA FLJ54228 + Alpha-1-antichymotrypsin+ Complement component C9b+ cDNA FLJ58564 + Complement C5+Ceruloplasmin+cDNA FLJ55673 Protein Humans Upregulated [cDNA FLJ54228 (2.2 fold)+ Alpha-1-antichymotrypsin (1.8 fold)+ Complement component C9b (1.4 fold)+ cDNA FLJ58564 (1.3 fold) + Complement C5 (1.3 fold) +Ceruloplasmin (1.2 fold) +cDNA FLJ55673 (1.1 fold)] Prognostic Progressing Vs Metastatic Prostate Cancer p ≤0.01 Serum 22355332
882 ANRIL; H19; PCA3; MALAT1; PCGEM1; PTENP1 LncRNA Humans Differentially expressed (Median Fold Change): [ANRIL (MFD: −1.17 fold); H19 (MFD: 1.32 fold); PCA3 (MFD: 14.3 fold); MALAT1 (MFD: −1.64 fold); PCGEM1 (MFD: 1.75 fold); PTENP1 (MFD: −1.34 fold);] Diagnostic Primary Vs Normal p<0.01 Tissue 22371711
883 ANRIL; H19; PCA3; MALAT1 LncRNA Humans Differentially expressed (Median Fold Change): [ANRIL (MFD: 1.49 fold); H19 (MFD: 1.43 fold); PCA3 (MFD: 4.46 fold); MALAT1 (MFD: -3.33 fold)] Diagnostic Metastatic Vs Normal p<0.01 Tissue 22371711
884 ANRIL; H19; PCA3; MALAT1; PCGEM1; PTENP1 LncRNA Humans Differentially expressed (Median Fold Change): [ANRIL (MFD: 1.33 fold); H19 (MFD: -1.12 fold); PCA3 (MFD: -3.44 fold); MALAT1 (MFD: -2.63 fold); PCGEM1 (MFD: -4 fold); PTENP1 (MFD: 1.50 fold);] Diagnostic Metastatic Vs Primary p<0.04 Tissue 22371711
885 miR145; miR221; miRNA Humans Differentially expressed (Median Fold Change): [miR145 (MFD: -7.98 fold); miR221 (MFD: -2.11 fold);] Diagnostic Metastatic Vs Normal p<0.01 Tissue 22371711
886 miR143; miR145; miR221; miRNA Humans Differentially expressed (Median Fold Change): [miR143 (MFD: -1.78 fold); miR145 (MFD: -4.77 fold); miR221 (MFD: -1.52 fold);] Diagnostic Metastatic Vs Primary p<0.04 Tissue 22371711
887 kallikrein-related peptide 4 (KLK4) mRNA Humans Downregulated in genistein treated patients compared to placebo treated Predictive Treated with Placebo Vs Treated with Genistein (30mg capsule) p=0.033 Tissue 22397815
888 NK3 homeobox 1 (NKX3-1) Protein Humans Downregulated in Gleason Grade 3 Diagnostic Normal Prostate Vs Gleason Grade 3 p=0.012 Tissue 22397815
896 Ring finger protein 19A (RNF19A) mRNA Humans Upregulated in PCa (>2 fold) Diagnostic Prostate Cancer vs healthy controls p = 0.0066 Blood 22493721
897 Macroglobulin α2 ; HP protein; CLU precursor; Fibronectin; Human Fcari bound To Iga1-Fc; α2-HS glycoprotein; Transthyretin precursor; Apolipoprotein E precursor; Igκ chain C region; Protein Humans Upregulated [>1.5 fold]: (Macroglobulin α2 ; HP protein; CLU precursor; ) Downregulated: [1.5 fold] (Fibronectin; Human Fcari bound To Iga1-Fc; α2-HS glycoprotein; Transthyretin precursor; Apolipoprotein E precursor; Igκ chain C region;) Predictive Before and after androgen ablation therapy (AAT) p<0.01 Serum 22496929
898 Transthyretin (TTR) Protein Humans Downregulated (1.58 fold ) in Post AAT patients Predictive Before and after androgen ablation therapy (AAT) p<0.01 Serum 22496929
899 Clusterin (CLU) Protein Humans Upregulated (1.51 fold ) in Post AAT patients Predictive Before and after androgen ablation therapy (AAT) p<0.01 Serum 22496929
900 Transthyretin (TTR) Protein Humans Upregulated in Prostate Cancer Diagnostic Normal Tissue Vs BPH Vs PCa p<0.01 Tissue 22496929
901 Clusterin (CLU) Protein Humans Upregulated in Prostate Cancer Diagnostic Normal Tissue Vs BPH Vs PCa p<0.01 Tissue 22496929
902 (Table 1) Protein Humans Upregulated in PCa [1.12-2.25] Diagnostic Patients Vs Controls p<0.05 Serum 22499197
903 ERG mRNA Humans Upregulated in TMPRSS2-ERG positive fusion cases Prognostic TMPRSS2-ERG positive fusion compared to TMPRSS2-ERG negative fusion in Prostate cancer p<0.0001 Tissue 22505341
904 SPINK1 mRNA Humans Upregulated in TMPRSS2-ERG negative fusion cases Prognostic TMPRSS2-ERG positive fusion compared to TMPRSS2-ERG negative fusion in Prostate cancer p=0.03 Tissue 22505341
905 ERG mRNA Humans Upregulated in TERT positive cases Prognostic TERT positive compared to TERT negative in Prostate cancer p=0.016 Tissue 22505341
906 Fusion status of TMPRSS2-ERG and TERT expression mRNA Humans TMPRSS2–ERG and TERT-negative tumors had significantly lower rate of recurrence Prognostic Biochemical Recurrence Free Survival p=0.025 Urine 22505341
910 PCA3 Protein Humans Upreregulated in PCa Diagnostic PCa VS No PCa group p< 0.001 Urine 22542564
911 Minichromosome Maintenance Complex Protein 2 (MCM2) product scores Protein Humans Upregulated in Prostate Cancer Diagnostic Prostate Cancer Vs No Tumor p<0.001 Tissue 22554381
912 Minichromosome Maintenance Complex Protein 2 (MCM2) product scores Protein Humans Upregulated with Increasing Gleason Score Prognostic Gleason Score ≤6 Vs 7 Vs ≥8 p=0.002 Tissue 22554381
913 Ki-67 Protein Humans Upregulated in Prostate Cancer Diagnostic Prostate Cancer Vs No Tumor p<0.001 Tissue 22554381
914 Ki-67 Protein Humans Upregulated with Increasing Gleason Score Prognostic Gleason Score ≤ 6 Vs 7 Vs ≥ 8 p=0.008 Tissue 22554381
915 Minichromosome Maintenance Complex Protein 2 (MCM2) product scores Protein Humans High in Patients with BCR Prognostic Biochemical Recurrence (Group 1) p=0.001 Tissue 22554381
916 Minichromosome Maintenance Complex Protein 2 (MCM2) product score OR ki-67 Product Score Protein Humans High in Patients with BCR Prognostic Biochemical Recurrence (Group 1) p=0.02 Tissue 22554381
917 Minichromosome Maintenance Complex Protein 2 (MCM2) product score AND ki-67 Product Score Protein Humans High in Patients with BCR Prognostic Biochemical Recurrence (Group 1) p=0.002 Tissue 22554381
918 PCA3 mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs No Cancer (@ first negative biopsy) [Group A] NA Urine 22564540
919 PCA3 mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs No Cancer (@ first negative biopsy) [Group B] NA Urine 22564540
920 Deoxycarnitine; Acetylcarnitine; Hexanoylcarnitine; Octanoylcarnitine; Decanoylcarnitine; Laurylcarnitine; Palmitoylcarnitine; Stearoylcarnitine; Oleoylcarnitine; 3-hydroxybutyrate (BHBA); Acetoacetate; Dodecanedioate; Octadecanedioate; Metabolites Humans Differentially expressed [ Deoxycarnitine (0.89 fold); Acetylcarnitine (0.80 fold); Hexanoylcarnitine (0.80 fold_; Octanoylcarnitine (0.72 fold); Decanoylcarnitine (0.71 fold); Laurylcarnitine (0.65 fold); Palmitoylcarnitine (0.82 fold0; Stearoylcarnitine (0.77 fold); Oleoylcarnitine (0.88 fold); 3-hydroxybutyrate (BHBA) (0.36 fold); Acetoacetate (0.52 fold); Dodecanedioate (0.80 fold); Octadecanedioate (0.73 fold);] Predictive Effect of Androgen deprivation therapy (ADT) baseline to 3 months <0.05 Plasma 22589396
929 Spondin-2 (SPON2) Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Healthy Men p=0.001 Serum 22615945
930 Triosephosphate isomerase 1 (TPI1); Spondin-2 (SPON-2); Thrombospondin 1, N-Terminal Domain (THBS1); Phosphoglycerate mutase 1 (PGAM1); Syndecan binding protein 1 (ST1); Peroxiredoxin 1 (PRDX1); Nucleophosmin- isoform CRA_c (NPM1) Protein Cell Lines Differentially Expressed in PCA Diagnostic BPH-1, LNCaP Vs C4-2 p<0.05 Serum 22615945
931 Spondin-2 (SPON2) Protein Humans Upregulated with Gleason Score >=7 and 8 Diagnostic Gleason Score (2-6), (7-8) and (9-10) p=0.001 Tissue 22615945
934 NACA + CCNB1 mRNA Humans CCNB1 upregulated in Prostate cancer; NACA Downregulated in Prostate Cancer Diagnostic BPC VS BP p<0.05 Tissue 22640805
935 GPR37; SOX4; CCNB1; TOP2A; DLG5; NACA; NR2C2; PDCD5; IDSP1 mRNA Humans Upregulated: [GPR37; SOX4; CCNB1; TOP2A;] Downregulated: [DLG5; NACA; NR2C2; PDCD5; IDSP1] Diagnostic BPC (benign prostates containing PCa) VS BP GPR37 (training: 0.018, testing: 0.003); SOX4 (training: 0.03, testing: 0.03); CCNB1 (training: 0.002, testing: 0.007); TOP2A (training: 0.018); DLG5 (training: p< 0.001, testing: 0.004); NACA (p<0.001, testing: 0.003) ; NR2C2 (training: p<0.001, testing: 0.02); PDCD5 (training: p<0.001); IDSP1 (training: p<0.001) Tissue 22640805
936 PCA3 mRNA Humans Upregulated (RQ = NP: 7.4 Vs LG = 202) Diagnostic Normal adjacent to Prostate (NP) Vs Low Grade PCa <0.005 Tissue 22674214
938 PCA3 + TMPRSS2:ERG gene fusion mRNA Humans Upregulated in PCa Diagnostic Normal adjacent to Prostate (NP) Vs Low Grade PCa NA Tissue 22674214
939 TMPRSS2:ERG gene fusion (given that PCA3 test is negative) mRNA Humans Upregulated in PCa Diagnostic Normal adjacent to Prostate (NP) Vs Low Grade PCa NA Tissue 22674214
940 Apolipoprotein A-II (APOA2); Complement C3 (C3f); Inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4f); Alpha-1 antitrypsin (AAT); High molecular weight kininogen (KNG); Transthyretin (TTR) Protein Humans Downregulated in PCa [Apolipoprotein A-II (APOA2); Complement C3 (C3f); Inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4f); ] Upregulated in PCa [Alpha-1 antitrypsin (AAT); High molecular weight kininogen (KNG); Transthyretin (TTR)] Diagnostic Benign Prostatic Hyperplasia (BPH) Vs Prostate Cancer (PCa) p<0.01 Serum 22740474
961 Prostate health index (phi) Protein Humans Upregulated in PCa [No PCa: 36.84 (28.82–46.14) Vs PCa 49.97 (37.75–69.65)] Diagnostic PCa Vs No-PCa <0.001 Serum 22821756
962 Prostate Cancer Antigen 3 (PCA3) mRNA Humans Upregulated in PCa [No PCa: 32 (13.5–68) Vs PCa 50 (34–83)] Diagnostic PCa Vs No-PCa p=0.001 Urine 22821756
963 PCA3 + phi mRNA Humans Upregulated in PCa Diagnostic PCa Vs No-PCa p=0.001 Urine + Serum 22821756
966 Osteopontin Protein Humans Upregulated in PCa Diagnostic PCa Vs Controls (Healthy Donors + BPH) p<0.05 Serum 22870138
967 Osteopontin Protein Humans Upregulated in PCa Diagnostic PCa Vs BPH VS Healthy Donors p<0.05 Plasma 22870138
968 GADD45B; CDKN1A; NLRP1; ERBB3; FMO5; SERINC2; AMFR; DPP4; PGC; YWHAE; EHF; TF; TNFSF10; EIF5A; TGM4; mRNA Humans Upregulated in Relapse: [GADD45B (4.86 fold); CDKN1A (2.65 fold); NLRP1 (1.57 fold)]; Downregulated in Relapse: [ERBB3 (0.55 fold); FMO5 (0.55 fold); SERINC2 (0.43 fold); AMFR (0.41 fold); DPP4 (0.40 fold); PGC (0.38 fold); YWHAE (0.34 fold); EHF(0.33 fold); TF (0.33 fold); TNFSF10 (0.31 fold); EIF5A (0.15 fold); TGM4 (0.03 fold);] Prognostic Relpase Vs No Relapse p<0.05 Tissue 22870216
969 hsa-miR-375; hsa-miR-96; hsa-miR-892b; hsa-miR-378; hsa-miR-302b; hsa-miR-548c-3p; hsa-miR-124; hsa-miR-141; hsa-miR-875-5p; hsa-miR-409-3p; hsa-miR-548a-3p; hsa-miR-623; hsa-miR-520d-5p; hsa-miR-489 miRNA Humans Upregulated in PCa: [hsa-miR-375 (8 fold); hsa-miR-96 (45.3 fold); hsa-miR-892b (9.9 fold); hsa-miR-378 (9.2 fold); hsa-miR-302b (45.3 fold); hsa-miR-548c-3p (2.8 fold); hsa-miR-124 (4.6 fold); hsa-miR-141 (6.5 fold); hsa-miR-875-5p (4.6 fold) ;hsa-miR-548a-3p (2.8 fold); hsa-miR-520d-5p (2.6 fold); hsa-miR-489 (7.5 fold)]; Downregulated in PCa: [ hsa-miR-409-3p (7 fold); hsa-miR-623 (2.6 fold); ] Prognostic LowRisk(LR) Vs Metastatic CRPC p<0.0001 Serum 22887127
970 miR-375; miR-141; miR-378*; miRNA Humans Upregulated in Primary Tumors: [miR-375 and miR-141]; Downregulated in Primary Tumors: [miR-378*] Prognostic Normal Vs Primary Tumor p<0.0001 Tissue 22887127
971 miR-375; miR-141; miR-378*; miR-409-3p miRNA Humans Upregulated in Low Risk PCa: [miR-375 ; miR-141]; Downregulated in Low Risk PCa: [miR-378*, miR-409-3p] Prognostic Normal Vs Low Risk Prostate Cancer miR-375; miR-141; miR-378*[p<0.0001]; miR-409-3p [p=0.004] Tissue 22887127
976 RhoC score Protein Humans 10-point increase in the RhoC score reduced the subsequent risk of PSA failure by about 6% Prognostic Time to PSA Failure p=0.009 Tissue 22935975
977 RhoC score Protein Humans Decreased in Cases Prognostic Time to PSA Failure p=0.009 Tissue 22935975
978 ACOT11-001; AOX1-001; C19orf46-002; C8orf84-001; COCH-202; CTA-55I10.1;001; DMD-024; FGF10-002 ;FGFR2-008; FGFR2-016; GABRE-006; GNAL-001; GNAO1-002; HEATR8-006; ISL1-002; NR2F2-202; PCP4-004; PDE5A-005; PDZRN4-202; RSRC2-017; TGM4-001; TSPAN2-001; ABCC4-004; ALK-001; ATP1A1-002; NAMPT-006; NAMPT-007; RP11-627G23.1-004; genes or ncRNA Humans Upregulated: AOX1-001, RSRC2-017, ABCC4-004, ALK-001, ATP1A1-002, NAMPT-006, RP11-627G23.1-004 get upregulated with fold change >1.2; Downregualted: Others get downregulated with Fold Change < 1.0 Diagnostic Primary Vs Normal p<0.05 Tissue 22956952
979 ACOT11-001; AOX1-001; C19orf46-002; C8orf84-001; COCH-202; CTA-55I10.1;001; DMD-024; FGF10-002 ;FGFR2-008; FGFR2-016; GABRE-006; GNAL-001; GNAO1-002; HEATR8-006; ISL1-002; NR2F2-202; PCP4-004; PDE5A-005; PDZRN4-202; RSRC2-017; TGM4-001; TSPAN2-001; ABCC4-004; ALK-001; ATP1A1-002; NAMPT-006; NAMPT-007; RP11-627G23.1-004; genes or ncRNA Humans Upregulated: C19orf46-002, RSRC2-017 get upregulated with fold change >1.2; Downregualted: Others get downregulated with Fold Change < 1.1 Prognostic Metastatic Vs Primary p<0.05 Tissue 22956952
980 ACOT11-001; AOX1-001; C19orf46-002; C8orf84-001; COCH-202; CTA-55I10.1;001; DMD-024; FGF10-002 ;FGFR2-008; FGFR2-016; GABRE-006; GNAL-001; GNAO1-002; HEATR8-006; ISL1-002; NR2F2-202; PCP4-004; PDE5A-005; PDZRN4-202; RSRC2-017; TGM4-001; TSPAN2-001; genes or ncRNA Humans Upregulated: C19orf46-002, RSRC2-017 get upregulated with fold change >1.2; Downregualted: Others get downregulated with Fold Change < 1.1 Diagnostic Metastatic Vs Normal p<0.05 Tissue 22956952
981 ACOT11-001; AOX1-001; C19orf46-002; C8orf84-001; COCH-202; CTA-55I10.1;001; DMD-024; FGF10-002 ;FGFR2-008; FGFR2-016; GABRE-006; GNAL-001; GNAO1-002; HEATR8-006; ISL1-002; NR2F2-202; PCP4-004; PDE5A-005; PDZRN4-202; RSRC2-017; TGM4-001; TSPAN2-001; ABCC4-004; ALK-001; ATP1A1-002; NAMPT-006; NAMPT-007; RP11-627G23.1-004; genes or ncRNA Humans NA Prognostic Biochemical Recurrence p<0.005 Tissue 22956952
982 EGFR Protein Humans Overexpressed for Progression Free Survival Prognostic Progression Free Survival p= 0.01 Tissue 22977195
983 EGFR mRNA Humans Overexpressed for Progression Free Survival Prognostic Progression Free Survival p= 0.005 Tissue 22977195
984 PTEN Protein Humans Overexpressed for Progression Free Survival Prognostic Progression Free Survival p= 0.02 Tissue 22977195
985 PTEN mRNA Humans Overexpressed for Progression Free Survival Prognostic Progression Free Survival p= 0.0003 Tissue 22977195
986 PTEN mRNA Humans Overexpressed for Progression Free Survival Prognostic Overall Survival p= 0.02 Tissue 22977195
987 EGFR + PTEN mRNA Humans Overexpressed for Progression Free Survival Prognostic Progression Free Survival NA Tissue 22977195
988 Zinc α2-glycoprotein (ZAG) Protein Humans Upregulated in PCa Diagnostic PCA VS No PCA group p=0.05 Urine 23020913
989 Zinc α2-glycoprotein (ZAG) + PSA Protein Humans Upregulated in PCa Diagnostic PCA VS No PCA group p=0.05 Urine + Serum 23020913
990 FLIP Protein Humans NA Prognostic PSA Failure Vs Non Failure p<0.05 Tissue 23028678
991 Sp1 Protein Humans NA Prognostic PSA Failure Vs Non Failure p<0.05 Tissue 23028678
992 Sp3 Protein Humans NA Prognostic PSA Failure Vs Non Failure p<0.05 Tissue 23028678
993 FLIP + Sp1 + Sp3 + Gleason Score Protein Humans NA Prognostic PSA Failure Vs Non Failure p<0.05 Tissue 23028678
994 Ras-related GTP binding D (RRAGD) + polyglutamine binding protein 1 (PQBP1) +histone cluster 1, H2bg (HIST1H2BC)+ aldehyde dehydrogenase 1 family, member A2 (ALDH1A2) +tripartite motif-containing 22 (TRIM22) + RNA binding protein with multiple splicing (RBPMS) + heat shock 22 kDa protein 8 (HSPB8) mRNA Humans Upregulated: [histone cluster 1, H2bg (HIST1H2BC) (1.88 fold); polyglutamine binding protein 1 (PQBP1) (2.08 fold)]; Downregulated: [Ras-related GTP binding D (RRAGD) (0.45 fold); aldehyde dehydrogenase 1 family, member A2 (ALDH1A2) (0.49 fold) ; tripartite motif-containing 22 (TRIM22) (0.54 fold) ; RNA binding protein with multiple splicing (RBPMS) (0.49 fold) + heat shock 22 kDa protein 8 (HSPB8) (0.44 fold)] Prognostic Biochemical relapse Vs No biochemical Relpase p<0.002 Tissue 23028830
995 Ras-related GTP binding D (RRAGD) + polyglutamine binding protein 1 (PQBP1) +histone cluster 1, H2bg (HIST1H2BC)+ aldehyde dehydrogenase 1 family, member A2 (ALDH1A2) +tripartite motif-containing 22 (TRIM22) + RNA binding protein with multiple splicing (RBPMS) + heat shock 22 kDa protein 8 (HSPB8) + Cell Type Hetrogenity + Gleason Score mRNA Humans Upregulated: [histone cluster 1, H2bg (HIST1H2BC) (1.88 fold); polyglutamine binding protein 1 (PQBP1) (2.08 fold)]; Downregulated: [Ras-related GTP binding D (RRAGD) (0.45 fold); aldehyde dehydrogenase 1 family, member A2 (ALDH1A2) (0.49 fold) ; tripartite motif-containing 22 (TRIM22) (0.54 fold) ; RNA binding protein with multiple splicing (RBPMS) (0.49 fold) + heat shock 22 kDa protein 8 (HSPB8) (0.44 fold)] Prognostic Biochemical relapse Vs No biochemical Relpase p<0.002 Tissue 23028830
996 GPX1 mRNA Humans Upregulated in Metatstasis Prognostic Relpase Vs No Relapse p<0.001 Blood 23046102
997 SOD2 mRNA Humans Upregulated in Metatstasis Prognostic Relpase Vs No Relapse p=0.01 Blood 23046102
998 AR mRNA Humans Differentially Expressed Prognostic Relpase Vs No Relapse p=0.001 Blood 23046102
999 Cyclin B mRNA Humans Differentially Expressed Prognostic Relpase Vs No Relapse p=0.007 Blood 23046102
1000 bFGF mRNA Humans Differentially Expressed Prognostic Relpase Vs No Relapse p=0.004 Blood 23046102
1001 2 or more out of (GPX1; SOD2; AR; Cyclin B; bFGF) mRNA Humans Differentially Expressed Prognostic Relpase Vs No Relapse p<0.001 Blood 23046102
1002 ABL2+SEMA4D+ITGAL+C1QA+TIMP1+CDKN1A mRNA Humans NA Prognostic low-risk group Vs high-risk group p<0.05 Blood 23059047
1003 CRTAM (cytotoxic and regulatory T cell molecule) + SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1) mRNA Humans Downregulated (1.58 fold) Diagnostic Controls Vs High Grade Prostate Cancer (GS 8 and above) p = 0.0000346 Blood 23071848
1004 CXCR3 [chemokine (C-X-C motif) receptor 3] + SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1) mRNA Humans Downregulated (1.59 fold) Diagnostic Controls Vs High Grade Prostate Cancer (GS 8 and above) p=0.0000338 Blood 23071848
1005 FCRL3 (Fc receptor-like 3)+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1) mRNA Humans Downregulated (1.61 fold) Diagnostic Controls Vs High Grade Prostate Cancer (GS 8 and above) p = 0.00000285 Blood 23071848
1006 KIAA1143+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1) mRNA Humans Downregulated (1.44 fold) Diagnostic Controls Vs High Grade Prostate Cancer (GS 8 and above) p = 0.000000182 Blood 23071848
1007 KLF12 (Kruppel-like factor 12)+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1) mRNA Humans Downregulated (1.66 fold) Diagnostic Controls Vs High Grade Prostate Cancer (GS 8 and above) p=0.000000816 Blood 23071848
1008 TMEM204 (transmembrane protein 204)+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1) mRNA Humans Downregulated (1.52 fold) Diagnostic Controls Vs High Grade Prostate Cancer (GS 8 and above) p = 0.000084 Blood 23071848
1009 Combination of 6 genes duplexes [CRTAM (cytotoxic and regulatory T cell molecule) + SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)] + [CXCR3 [chemokine (C-X-C motif) receptor 3] + SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)] + [FCRL3 (Fc receptor-like 3)+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)] + [KIAA1143+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)] + [KLF12 (Kruppel-like factor 12)+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)] + [TMEM204 (transmembrane protein 204)+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1)] mRNA Humans Downregulated (1.52 fold) Diagnostic Controls Vs High Grade Prostate Cancer (GS 8 and above) p = 0.000084 Blood 23071848
1010 PSA +CRTAM (cytotoxic and regulatory T cell molecule)+ CXCR3 [chemokine (C-X-C motif) receptor 3]+ FCRL3 (Fc receptor-like 3) + KIAA1143+ KLF12 (Kruppel-like factor 12)+ TMEM204 (transmembrane protein 204)+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1) mRNA Humans Downregulated (1.52 fold) Diagnostic Controls Vs High Grade Prostate Cancer (GS 8 and above) p = 0.000084 Blood 23071848
1011 PSA +CRTAM (cytotoxic and regulatory T cell molecule)+ CXCR3 [chemokine (C-X-C motif) receptor 3]+ FCRL3 (Fc receptor-like 3)+ KIAA1143+ KLF12 (Kruppel-like factor 12)+ TMEM204 (transmembrane protein 204)+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1) mRNA Humans Downregulated (1.52 fold) Diagnostic Controls Vs High Grade Prostate Cancer (GS 8 and above) p = 0.000084 Blood 23071848
1014 Chromatin Assembly Factor 1 (CAF-1 p60) Protein Humans Upregulated in Prostate Cancer Diagnostic Normal Vs prostate cancer NA Tissue 23109837
1020 PCA3 score >= 25 mRNA Humans PCA3 Score upregulated in PCa (No PCa: 24; Pca: 60) Diagnostic PCa Vs No PCA group p<0.001 Urine 23201468
1021 TMPRSS2-ERG (v-ets erythroblastosis virus E26 oncogene homolog) >= 10 mRNA Humans TMPRSS2-ERG fusion upregulated in PCa (No PCa: 15; Pca: 46) Diagnostic PCa Vs No PCA group p<0.001 Urine 23201468
1022 TMPRSS2-ERG (v-ets erythroblastosis virus E26 oncogene homolog) >= 10 mRNA Humans NA Prognostic Gleason Score <7 Vs Gleason score ≥ 7 p<0.001 Urine 23201468
1023 TMPRSS2-ERG mRNA Humans NA Prognostic Tumor Stage (T3-T4) p = 0.023 Urine 23201468
1024 Serum PSA Protein Humans NA Prognostic PCa Vs No PCA group p<0.001 Serum 23201468
1025 Serum PSA Protein Humans NA Prognostic Gleason Score <7 Vs Gleason score ≥ 7 p = 0.003 Serum 23201468
1026 Serum PSA Protein Humans NA Prognostic Tumor Stage (T3-T4) p = 0.002 Serum 23201468
1029 miR-30d miRNA Humans Upregulated in PCa Cell Lines (> 2 fold) Diagnostic Normal Vs Cancerous Prostate Cell Lines p<0.05 Cell Lines 23231923
1030 miR-30d miRNA Humans Upregulated in PCa [Normal (6.23 ± 6.06) Vs Cancer (7.95 ± 7.03)] Diagnostic Cancerous Vs Cancer Adjacent from Same patient p = 0.03 Tissue 23231923
1031 miR-30d miRNA Humans Shorter Survival Time in High miRNA-30d group Prognostic Biochemical Recurrence p = 0.026 (BCR); p =0.04 (Univariate); 0.003 (multivariate) Tissue 23231923
1037 Aminopeptidase N (APN) Protein Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Non Malignant Tissue p=0.034 Tissue 23322201
1040 Aminopeptidase N (APN) Protein Humans NA Prognostic Recurrence Free Survival Univariate: p=0.002; Mutlivariate: p=0.017 Tissue 23322201
1041 Aminopeptidase N (APN) Protein Humans NA Prognostic Cancer Specific Survival Univariate: p=0.017; Mutlivariate: p=0.049 Tissue 23322201
1042 Early Growth Response 3 (Egr3) mRNA Humans Upregulated in PCa (5.35 fold) Diagnostic Prostate Cancer Vs Normal Prostate p = 2 x 10^-15 Tissue 23342084
1043 Early Growth Response 3 (Egr3) Protein Humans Upregulated in PCa (NSR (number of strong positive pixels ratio):normal prostate: 0.039 ; NSR: prostate cancer: 0.13) Diagnostic Prostate Cancer Vs Normal Prostate p = 0.00047 Tissue 23342084
1044 Prostate Specific Membrane Antigen (PSMA) Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Normal Prostate p = 0.001 Tissue 23342084
1045 Early Growth Response 1 (Egr1) mRNA Humans Downregulated in Relapse (0.784 fold) Prognostic Relpase Vs No Relapse p = 0.017 Tissue 23342084
1064 miR-141 miRNA Humans Upregulated in Bone Metastasis Prognostic Patients with Bone Metastasis Vs No Bone Metastasis p<0.001 Serum 23377530
1065 PCA3 mRNA Humans Upregulated in Cancerous Conditions (Cancerous: 7.69 Vs Non Cancerous: 7.00) Diagnostic Cancerous Vs Non Cancerous p<0.0005 Tissue 23391636
1066 PCA3 mRNA Humans Upregulated in Stage pT3/4 (1.9 Median fold difference) Diagnostic Stage pT2 Vs Stage pT3/4 p=0.015 Tissue 23391636
1067 KLK15 mRNA Humans Upregulated in Stage pT3/4 (2.71 Median fold difference) Diagnostic Stage pT2 Vs Stage pT3/4 p=0.032 Tissue 23391636
1068 AMBP precursor (AMBPf1) Protein Humans Upregulated in Prostate Cancer Diagnostic Prostate Cancer Vs Controls p=0.005 Urine 23417432
1069 AMBP precursor (AMBPf2) Protein Humans Upregulated in Prostate Cancer Diagnostic Prostate Cancer Vs Controls p=0.004 Urine 23417432
1070 Saposin Protein Humans Upregulated in Prostate Cancer Diagnostic Prostate Cancer Vs Controls p=0.002 Urine 23417432
1071 AMBP precursor (AMBPf2) Protein Humans Upregulated in Prostate Cancer Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p=0.004 Urine 23417432
1072 Inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4) Protein Humans Upregulated in Prostate Cancer Diagnostic Prostate Cancer Vs Controls p=0.006 Urine 23417432
1076 3-hydroxy-3-methylglutaryl coenzyme A synthase ( HMGCS2 ); aldehyde dehydrogenase 1 family, member A3 ( ALDH1A3 ); chromosome 6 open reading frame 115 ( C6orf115 ); hydroxysteroid (11-beta) dehydrogenase 2 ( HSD11B2 ); anterior gradient homolog 2 (Xenopus laevis) ( AGR2 ); S100 calcium binding protein P ( S100P ); dehydrogenase/reductase (SDR family) member 2 ( DHRS2 ); monoamine oxidase B ( MAOB ); thymidine phosphorylase ( TYMP ); monoamine oxidase A ( MAOA ); sequestosome 1 ( SQSTM1 ); tropomyosin 1 (alpha) ( TPM1 ); cathepsin D ( CTSD ); growth differentiation factor 15 ( GDF15 ); arginase, type II ( ARG2 ); glutaminase ( GLS ); arylacetamide deacetylase-like 1 ( AADACL1 ); aldehyde dehydrogenase 4 family, member A1 ( ALDH4A1 ); solute carrier family 12 (potassium/chloride transporters), member 7 ( SLC12A7 ); spermatogenesis associated, serine-rich 2-like ( SPATS2L ); N-acylsphingosine amidohydrolase (acid ceramidase) 1 ( ASAH1 ); calpain 2, (m/II) large subunit ( CAPN2 ); acyl-CoA thioesterase 9 ( ACOT9 ); keratin 18 ( KRT18 ); epoxide hydrolase 1, microsomal (xenobiotic) ( EPHX1 ); glutathione S-transferase kappa ( GSTK1 ); aldo-keto reductase family 1, member C2 ( AKR1C2 ); acyl-CoA synthetase long-chain family member 3 ( ACSL3 ); mannosidase, beta A, lysosomal ( MANBA ); vesicle-associated membrane protein 8 (endobrevin) ( VAMP8 ); retinol saturase (all-trans-retinol 13,14-reductase) ( RETSAT ); occludin ( OCLN ); sulfide dehydrogenase like ( SQRDL ); acyl-CoA dehydrogenase, C-2 to C-3 short chain ( ACADS ); microtubule associated monoxygenase, calponin and LIM domain containing 1 ( MICAL1 ); 3-hydroxyisobutyryl-CoA hydrolase ( HIBCH ); abhydrolase domain containing 11 ( ABHD11 ); acyl-CoA synthetase long-chain family member 4 ( ACSL4 ); superoxide dismutase 2, mitochondrial ( SOD2 ); fucosidase, alpha-L- 1, tissue ( FUCA1 ); sideroflexin 3 ( SFXN3 ); carnitine palmitoyltransferase 2 ( CPT2 ); Protein Humans Upregulated in LNCAP-SF [3-hydroxy-3-methylglutaryl coenzyme A synthase ( HMGCS2 ); ( 9.2394 fold) aldehyde dehydrogenase 1 family, member A3 ( ALDH1A3 ); ( 8.1484 fold) chromosome 6 open reading frame 115 ( C6orf115 ); ( 6.6899 fold) hydroxysteroid (11-beta) dehydrogenase 2 ( HSD11B2 ); ( 5.4227 fold) anterior gradient homolog 2 (Xenopus laevis) ( AGR2 ); ( 5.0377 fold) S100 calcium binding protein P ( S100P ); ( 4.92 fold) dehydrogenase/reductase (SDR family) member 2 ( DHRS2 ); ( 4.5974 fold) monoamine oxidase B ( MAOB ); ( 4.3792 fold) thymidine phosphorylase ( TYMP ); ( 3.8776 fold) monoamine oxidase A ( MAOA ); ( 3.8563 fold) sequestosome 1 ( SQSTM1 ); ( 3.8075 fold) tropomyosin 1 (alpha) ( TPM1 ); ( 3.5117 fold) cathepsin D ( CTSD ); ( 3.3074 fold) growth differentiation factor 15 ( GDF15 ); ( 3.2564 fold) arginase, type II ( ARG2 ); ( 3.2251 fold) glutaminase ( GLS ); ( 3.2099 fold) arylacetamide deacetylase-like 1 ( AADACL1 ); ( 3.1698 fold) aldehyde dehydrogenase 4 family, member A1 ( ALDH4A1 ); ( 3.0362 fold) solute carrier family 12 (potassium/chloride transporters), member 7 ( SLC12A7 ); ( 3.0201 fold) spermatogenesis associated, serine-rich 2-like ( SPATS2L ); ( 2.9743 fold) N-acylsphingosine amidohydrolase (acid ceramidase) 1 ( ASAH1 ); ( 2.9654 fold) calpain 2, (m/II) large subunit ( CAPN2 ); ( 2.9387 fold) acyl-CoA thioesterase 9 ( ACOT9 ); ( 2.9016 fold) keratin 18 ( KRT18 ); ( 2.8839 fold) epoxide hydrolase 1, microsomal (xenobiotic) ( EPHX1 ); ( 2.8828 fold) glutathione S-transferase kappa ( GSTK1 ); ( 2.8356 fold) aldo-keto reductase family 1, member C2 ( AKR1C2 ); ( 2.8239 fold) acyl-CoA synthetase long-chain family member 3 ( ACSL3 ); ( 2.8157 fold) mannosidase, beta A, lysosomal ( MANBA ); ( 2.813 fold) vesicle-associated membrane protein 8 (endobrevin) ( VAMP8 ); ( 2.7515 fold) retinol saturase (all-trans-retinol 13,14-reductase) ( RETSAT ); ( 2.7151 fold) occludin ( OCLN ); ( 2.7082 fold) sulfide dehydrogenase like ( SQRDL ); ( 2.7062 fold) acyl-CoA dehydrogenase, C-2 to C-3 short chain ( ACADS ); ( 2.6711 fold) microtubule associated monoxygenase, calponin and LIM domain containing 1 ( MICAL1 ); ( 2.6382 fold) 3-hydroxyisobutyryl-CoA hydrolase ( HIBCH ); ( 2.5805 fold) abhydrolase domain containing 11 ( ABHD11 ); ( 2.5752 fold) acyl-CoA synthetase long-chain family member 4 ( ACSL4 ); ( 2.5729 fold) superoxide dismutase 2, mitochondrial ( SOD2 ); ( 2.536 fold) fucosidase, alpha-L- 1, tissue ( FUCA1 ); ( 2.5286 fold) sideroflexin 3 ( SFXN3 ); ( 2.5136 fold) carnitine palmitoyltransferase 2 ( CPT2 ); ( 2.5117 fold) Prognostic LNCAP Cell Lines Vs LNCaP-SF (androgen independent) NA Cell Lines 23443136
1077 semenogelin I ( SEMG1 ); Cyclin-dependent kinase 1 ( CDC2 ); thymidine kinase 1, soluble ( TK1 ); semenogelin II ( SEMG2 ); barrier to autointegration factor 1 ( BANF1 ); cDNA FLJ16186 ( cDNA FLJ16186 ); polo-like kinase 1 ( PLK1 ); cyclin-dependent kinase 2 ( CDK2 ); insulin-like growth factor binding protein 2, 36kDa ( IGFBP2 ); stathmin 1 ( STMN1 ); ribonucleotide reductase M2 ( RRM2 ); S100 calcium binding protein A13 ( S100A13 ); GINS complex subunit 3 (Psf3 homolog) ( GINS3 ); neural cell adhesion molecule 2 ( NCAM2 ); thyroid hormone receptor interactor 13 ( TRIP13 ); ribonucleotide reductase M1 ( RRM1 ); nucleolar pre-rRNA processing protein ( ESF1 ); stathmin-like 2 ( STMN2 ); H3 histone, family 3A ( H3F3A ); GINS complex subunit 4 (Sld5 homolog) ( GINS4 ); H2A histone family, member Z ( H2AFZ ); DNA (cytosine-5-)-methyltransferase 1 ( DNMT1 ); ATPase family, AAA domain containing 2 ( ATAD2 ); SCD6 homolog B (S. cerevisiae) ( LSM14B ); chromosome 13 open reading frame 33 ( C13orf33 ); karyopherin alpha 2 (RAG cohort 1, importin alpha 1) ( KPNA2 ); Nuclear autoantigenic sperm protein (histone-binding) ( NASP ); acireductone dioxygenase 1 ( ADI1 ); histone cluster 1, H4a ( HIST1H4A ); lamin B1 ( LMNB1 ); 3-hydroxybutyrate dehydrogenase, type 2 ( BDH2 ); phosphorylase, glycogen, liver ( PYGL ); PDZ binding kinase ( PBK ); histone cluster 1, H1b ( HIST1H1B ); histone acetyltransferase 1 ( HAT1 ); Ras association (RalGDS/AF-6) domain family member 3 ( RASSF3 ); nitrogen fixation 1 homolog (S. cerevisiae) ( NFS1 ); programmed cell death 4 (neoplastic transformation inhibitor) ( PDCD4 ); H2A histone family, member Y ( H2AFY ); ligase I, DNA, ATP-dependent ( LIG1 ); structural maintenance of chromosomes 4 ( SMC4 ); topoisomerase (DNA) II beta 180kDa ( TOP2B ); nucleus accumbens associated 1, BEN and BTB (POZ) domain containing ( NACC1 ); structural maintenance of chromosomes 2 ( SMC2 ); DEAH (Asp-Glu-Ala-His) box polypeptide 36 ( DHX36 ); Metastasis-associated protein 1 ( MTA1 ); Protein Humans Downregulated in LNCAP-SF [semenogelin I ( SEMG1 ); ( 0.076735 fold) Cyclin-dependent kinase 1 ( CDC2 ); ( 0.081925 fold) thymidine kinase 1, soluble ( TK1 ); ( 0.083392 fold) semenogelin II ( SEMG2 ); ( 0.10883 fold) barrier to autointegration factor 1 ( BANF1 ); ( 0.17609 fold) cDNA FLJ16186 ( cDNA FLJ16186 ); ( 0.19531 fold) polo-like kinase 1 ( PLK1 ); ( 0.20362 fold) cyclin-dependent kinase 2 ( CDK2 ); ( 0.22407 fold) insulin-like growth factor binding protein 2, 36kDa ( IGFBP2 ); ( 0.22637 fold) stathmin 1 ( STMN1 ); ( 0.24713 fold) ribonucleotide reductase M2 ( RRM2 ); ( 0.25054 fold) S100 calcium binding protein A13 ( S100A13 ); ( 0.2628 fold) GINS complex subunit 3 (Psf3 homolog) ( GINS3 ); ( 0.26922 fold) neural cell adhesion molecule 2 ( NCAM2 ); ( 0.26951 fold) thyroid hormone receptor interactor 13 ( TRIP13 ); ( 0.27195 fold) ribonucleotide reductase M1 ( RRM1 ); ( 0.27289 fold) nucleolar pre-rRNA processing protein ( ESF1 ); ( 0.27757 fold) stathmin-like 2 ( STMN2 ); ( 0.28292 fold) H3 histone, family 3A ( H3F3A ); ( 0.28744 fold) GINS complex subunit 4 (Sld5 homolog) ( GINS4 ); ( 0.28965 fold) H2A histone family, member Z ( H2AFZ ); ( 0.2989 fold) DNA (cytosine-5-)-methyltransferase 1 ( DNMT1 ); ( 0.3037 fold) ATPase family, AAA domain containing 2 ( ATAD2 ); ( 0.30571 fold) SCD6 homolog B (S. cerevisiae) ( LSM14B ); ( 0.30649 fold) chromosome 13 open reading frame 33 ( C13orf33 ); ( 0.3127 fold) karyopherin alpha 2 (RAG cohort 1, importin alpha 1) ( KPNA2 ); ( 0.31541 fold) Nuclear autoantigenic sperm protein (histone-binding) ( NASP ); ( 0.32372 fold) acireductone dioxygenase 1 ( ADI1 ); ( 0.33027 fold) histone cluster 1, H4a ( HIST1H4A ); ( 0.33313 fold) lamin B1 ( LMNB1 ); ( 0.33412 fold) 3-hydroxybutyrate dehydrogenase, type 2 ( BDH2 ); ( 0.33637 fold) phosphorylase, glycogen, liver ( PYGL ); ( 0.33849 fold) PDZ binding kinase ( PBK ); ( 0.34986 fold) histone cluster 1, H1b ( HIST1H1B ); ( 0.35951 fold) histone acetyltransferase 1 ( HAT1 ); ( 0.36643 fold) Ras association (RalGDS/AF-6) domain family member 3 ( RASSF3 ); ( 0.37213 fold) nitrogen fixation 1 homolog (S. cerevisiae) ( NFS1 ); ( 0.37728 fold) programmed cell death 4 (neoplastic transformation inhibitor) ( PDCD4 ); ( 0.37993 fold) H2A histone family, member Y ( H2AFY ); ( 0.38303 fold) ligase I, DNA, ATP-dependent ( LIG1 ); ( 0.38796 fold) structural maintenance of chromosomes 4 ( SMC4 ); ( 0.38871 fold) topoisomerase (DNA) II beta 180kDa ( TOP2B ); ( 0.38889 fold) nucleus accumbens associated 1, BEN and BTB (POZ) domain containing ( NACC1 ); ( 0.39627 fold) structural maintenance of chromosomes 2 ( SMC2 ); ( 0.3968 fold) DEAH (Asp-Glu-Ala-His) box polypeptide 36 ( DHX36 ); ( 0.39825 fold) Metastasis-associated protein 1 ( MTA1 ); ( 0.39986 fold) ] Prognostic LNCAP Cell Lines Vs LNCaP-SF (androgen independent) NA Cell Lines 23443136
1078 ACAT1 Protein Humans Upregulated in LNCAP-SF [3-hydroxy-3-methylglutaryl coenzyme A synthase ( HMGCS2 ); ( 9.2394 fold) aldehyde dehydrogenase 1 family, member A3 ( ALDH1A3 ); ( 8.1484 fold) chromosome 6 open reading frame 115 ( C6orf115 ); ( 6.6899 fold) hydroxysteroid (11-beta) dehydrogenase 2 ( HSD11B2 ); ( 5.4227 fold) anterior gradient homolog 2 (Xenopus laevis) ( AGR2 ); ( 5.0377 fold) S100 calcium binding protein P ( S100P ); ( 4.92 fold) dehydrogenase/reductase (SDR family) member 2 ( DHRS2 ); ( 4.5974 fold) monoamine oxidase B ( MAOB ); ( 4.3792 fold) thymidine phosphorylase ( TYMP ); ( 3.8776 fold) monoamine oxidase A ( MAOA ); ( 3.8563 fold) sequestosome 1 ( SQSTM1 ); ( 3.8075 fold) tropomyosin 1 (alpha) ( TPM1 ); ( 3.5117 fold) cathepsin D ( CTSD ); ( 3.3074 fold) growth differentiation factor 15 ( GDF15 ); ( 3.2564 fold) arginase, type II ( ARG2 ); ( 3.2251 fold) glutaminase ( GLS ); ( 3.2099 fold) arylacetamide deacetylase-like 1 ( AADACL1 ); ( 3.1698 fold) aldehyde dehydrogenase 4 family, member A1 ( ALDH4A1 ); ( 3.0362 fold) solute carrier family 12 (potassium/chloride transporters), member 7 ( SLC12A7 ); ( 3.0201 fold) spermatogenesis associated, serine-rich 2-like ( SPATS2L ); ( 2.9743 fold) N-acylsphingosine amidohydrolase (acid ceramidase) 1 ( ASAH1 ); ( 2.9654 fold) calpain 2, (m/II) large subunit ( CAPN2 ); ( 2.9387 fold) acyl-CoA thioesterase 9 ( ACOT9 ); ( 2.9016 fold) keratin 18 ( KRT18 ); ( 2.8839 fold) epoxide hydrolase 1, microsomal (xenobiotic) ( EPHX1 ); ( 2.8828 fold) glutathione S-transferase kappa ( GSTK1 ); ( 2.8356 fold) aldo-keto reductase family 1, member C2 ( AKR1C2 ); ( 2.8239 fold) acyl-CoA synthetase long-chain family member 3 ( ACSL3 ); ( 2.8157 fold) mannosidase, beta A, lysosomal ( MANBA ); ( 2.813 fold) vesicle-associated membrane protein 8 (endobrevin) ( VAMP8 ); ( 2.7515 fold) retinol saturase (all-trans-retinol 13,14-reductase) ( RETSAT ); ( 2.7151 fold) occludin ( OCLN ); ( 2.7082 fold) sulfide dehydrogenase like ( SQRDL ); ( 2.7062 fold) acyl-CoA dehydrogenase, C-2 to C-3 short chain ( ACADS ); ( 2.6711 fold) microtubule associated monoxygenase, calponin and LIM domain containing 1 ( MICAL1 ); ( 2.6382 fold) 3-hydroxyisobutyryl-CoA hydrolase ( HIBCH ); ( 2.5805 fold) abhydrolase domain containing 11 ( ABHD11 ); ( 2.5752 fold) acyl-CoA synthetase long-chain family member 4 ( ACSL4 ); ( 2.5729 fold) superoxide dismutase 2, mitochondrial ( SOD2 ); ( 2.536 fold) fucosidase, alpha-L- 1, tissue ( FUCA1 ); ( 2.5286 fold) sideroflexin 3 ( SFXN3 ); ( 2.5136 fold) carnitine palmitoyltransferase 2 ( CPT2 ); ( 2.5117 fold) Diagnostic Normal Prostate Vs Bone Metastatis p = 0.0001 Tissue 23443136
1079 PCA3 mRNA Humans Upregulated with High Gleason Score Prognostic Low Gleason Score Vs high Gleason Score (≥7) p=0.02 Urine 23515404
1080 TMPRSS2:ERG mRNA Humans Upregulated with High Gleason Score Prognostic Low Gleason Score Vs high Gleason Score (≥7) p=0.02 Urine 23515404
1081 PCA3 + TMPRSS2:ERG mRNA Humans Upregulated with High Gleason Score Prognostic Low Gleason Score Vs high Gleason Score (≥7) NA Urine 23515404
1082 PCA3 mRNA Humans Upregulated in Positive Biopsy Diagnostic Positive Vs Negative Biopsy P =0.01 Urine 23515404
1083 TMPRSS2:ERG mRNA Humans Upregulated in Positive Biopsy Diagnostic Positive Vs Negative Biopsy P =0.001 Urine 23515404
1084 PCA3 + TMPRSS2:ERG + PSA mRNA Humans Upregulated with High Gleason Score Prognostic Low Gleason Score Vs high Gleason Score (≥7) NA Urine 23515404
1085 miR-183 miRNA Humans Upregulated in PC Cells Diagnostic Prostate Cancer Cell Lines Vs Normal Prostate Cell Lines p<0.05 Cell Lines 23538390
1086 miR-183 miRNA Humans Upregulated in Prostate Cancer Diagnostic prostate tumour Vs adjacent normal tissues p<0.05 Tissue 23538390
1087 miR-183 miRNA Humans Upregulated in Prostate Cancer Prognostic Tumor Stage pT2 Vs pT3 p<0.05 Tissue 23538390
1088 miR-183 miRNA Humans Upregulated in Prostate Cancer Prognostic Overall Survival p<0.05 Tissue 23538390
1091 miR-141 miRNA Humans Upregulated in metastatic castration-resistant PCa (mCRPC) Prognostic localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC) p < 0.001 Plasma 23574937
1092 miR-375 miRNA Humans Upregulated in metastatic castration-resistant PCa (mCRPC) Prognostic localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC) p < 0.001 Plasma 23574937
1093 miR-151-3p miRNA Humans Upregulated in metastatic castration-resistant PCa (mCRPC) Prognostic localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC) p < 0.001 Plasma 23574937
1094 miR-126 miRNA Humans Upregulated in metastatic castration-resistant PCa (mCRPC) Prognostic localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC) p < 0.001 Plasma 23574937
1095 miR-16 miRNA Humans Downregulated in metastatic castration-resistant PCa (mCRPC) Prognostic localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC) p < 0.001 Plasma 23574937
1096 miR-205 miRNA Humans Downregulated in metastatic castration-resistant PCa (mCRPC) Prognostic localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC) p < 0.001 Plasma 23574937
1097 PSA + miR141 + mir-151-3p + mir-16 miRNA Humans Upregulated in metastatic castration-resistant PCa (mCRPC) Prognostic localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC) p < 0.001 Plasma 23574937
1098 miR-423-3p miRNA Humans Upregulated with High Gleason Score Prognostic Gleason Score < 7 Vs Gleason Score ≥ 8 p = 0.002 Plasma 23574937
1099 miR-205 miRNA Humans Downregulated with High Gleason Score Prognostic Gleason Score < 7 Vs Gleason Score ≥ 8 p = 0.004 Plasma 23574937
1100 miR-205 miRNA Humans Upregulated in Biochemical Recurrence Prognostic Biochemical recurrence p = 0.006 Plasma 23574937
1101 miR-423-3p miRNA Humans Downregulated in Biochemical Recurrence Prognostic Biochemical recurrence p<0.001 Plasma 23574937
1102 miR-151-3p miRNA Humans Downregulated in Biochemical Recurrence Prognostic Biochemical recurrence p<0.001 Plasma 23574937
1123 miR-24 miRNA Mice Upregulated in TRAMP Mice Diagnostic TRansgenic Adenocarcinoma of Mouse Prostate (TRAMP) VS Wild Type (WT) mice p < 0.01 Serum 23719956
1126 PCA3; GAS5; PVT1; DANCR; PCAT1; MEG3; PRINS; HOTTIP; EGOT; LncRNA Humans Upregulated in PCa: [PCA3; GAS5; PVT1; DANCR; PCAT1;]lDownregulated in PCa: [MEG3; PRINS; HOTTIP; EGOT;] Diagnostic Tumor Vs Normal Tissues p< 0.05 Tissue 23728290
1140 hsa-miR-10b; hsa-miR-15a; hsa-miR-15b; hsa-miR-16; hsa-miR-18a; hsa-miR-18b; hsa-miR-25; hsa-miR-30c; hsa-miR-32; hsa-miR-34a; hsa-miR-34c-5p; hsa-miR-92a; hsa-miR-181a; hsa-miR-181b; hsa-miR-181c; hsa-miR-184; hsa-miR-122; hsa-miR-124; hsa-miR-125a-5p; hsa-miR-125b; hsa-miR-128a; hsa-miR-133b; hsa-miR-134; hsa-miR-135b; hsa-miR-146b-5p; hsa-miR-148b; hsa-miR-193a-5p; hsa-miR-193b hsa-miR-206; hsa-miR-20b; hsa-miR-214; hsa-miR-215; hsa-miR-301a; hsa-miR-372 miRNA Humans Upregulated with fold change > 2 Diagnostic prostate tumor Vs normal epithelium p<0.05 Tissue 23781281
1141 let-7a; let-7b; let-7c, miR-515-3p; miR515-5p; miR-181b; miR-146b; miR-361 miRNA Humans Upregulated: [let-7a - 1.7 fold; let-7b 3.7 fold; let-7c 3.0 fold, miR-515-3p 3.2 fold; miR515-5p 3.2 fold;] Downregulated: [miR-181b 1.8 fold; miR-146b 1.7 fold; miR-361 1.7 fold] Prognostic Clinical progression free survival (CPFS) Vs. clinical failure (CF) p<0.05 Tissue 23798998
1142 let-7a; let-7b; let-7c miRNA Humans Downregulated in PCa: [let-7a; let-7b; let-7c] Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.01 Tissue 23798998
1144 HPN; CLDN3; AMACR; GOLPH2; TRIB1; LOC729677; GDF15; TARP; MYC; LOC731404; ZFP36; SIM2; CTGF; GJB1; CENPN; EGR2; FBP1; KLF4; LUZP2; C8orf4; PDLIM3; CREB3L1; GCNT1; CTPS; PTP4A3 mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.001 Tissue 23813660
1145 SLC14A1; LOC642587; TRIM29; CYP3A5; TP73L; SNAI2; PIK3R1; KRT5; NPAL3; FGFR2; CSTA; CAPG; ITGA2; FER1L3; MEIS2; LGALS3BP; GPRC5B; NEFH; GSTM2; S100A16; MME; EVA1; KRT23; ADD3; GSTP1; mRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.001 Tissue 23813660
1155 LASP1 + IQGAP3+ NFIB+ S1PR4+ THBS2+ANO7+ PCDH7 + MYBPC1+ EPPK1+ TSBP+ PBX1+ NUSAP1+ ZWILCH+ UBE2C+ CAMK2N1+ RABGAP1+ PCAT-32 + GLYATL1P4/PCAT-80 + TNFRSF19 mRNA Humans Differentially Expressed Prognostic Metastasis Vs No Metastasis p<0.01 Tissue 23826159
1160 Crystallin, alpha B (CRYAB) mRNA Humans Downregulated in PCa Diagnostic Cancerous Vs non cancerous conditions p<0.01 Tissue 23840433
1161 Distal-less homeobox 1 (DLX1) mRNA Humans Upregulated in PCa Diagnostic Cancerous Vs non cancerous conditions p<0.01 Tissue 23840433
1162 Serum deprivation response (SDPR) mRNA Humans Downregulated in PCa Diagnostic Cancerous Vs non cancerous conditions p<0.01 Tissue 23840433
1163 Potassium large conductance calcium-activated channel, subfamily M, alpha member 1 (KCNMA1) mRNA Humans Downregulated in PCa Diagnostic Cancerous Vs non cancerous conditions p<0.01 Tissue 23840433
1164 Prostate Cancer Antigen 3 (PCA3) mRNA Humans Upregulated in PCa Diagnostic Cancerous Vs non cancerous conditions p<0.01 Tissue 23840433
1165 Aldo-keto reductase family 1, member C1/2 (AKR1C1/2) mRNA Humans Downregulated in PCa Diagnostic Cancerous Vs non cancerous conditions p<0.01 Tissue 23840433
1166 Cyclin-dependent kinase 5, regulatory subunit 1 (CDK5R1) mRNA Humans Downregulated in PCa Diagnostic Cancerous Vs non cancerous conditions p<0.01 Tissue 23840433
1167 Claudin 7 (CLDN7) mRNA Humans Upregulated in PCa Diagnostic Cancerous Vs non cancerous conditions p<0.01 Tissue 23840433
1168 Activated leukocyte cell adhesion molecule (ALCAM) mRNA Humans Upregulated in PCa Diagnostic Cancerous Vs non cancerous conditions p<0.01 Tissue 23840433
1169 RAS, dexamethasone-induced 1 (RASD1) mRNA Humans Upregulated in PCa Diagnostic Cancerous Vs non cancerous conditions p<0.01 Tissue 23840433
1170 miR-141 miRNA Humans Upregulated in patients with Biochemical Recurrence Prognostic Biochemical recurrence Vs No Biochemical Recurrence p = 0.007 Serum 23846169
1171 miR-146b-3p miRNA Humans Upregulated in patients with Biochemical Recurrence Prognostic Biochemical recurrence Vs No Biochemical Recurrence p = 0.008 Serum 23846169
1172 miR-194 miRNA Humans Upregulated in patients with Biochemical Recurrence Prognostic Biochemical recurrence Vs No Biochemical Recurrence p = 0.044 Serum 23846169
1173 miR-146b-3p miRNA Humans Upregulated in patients with Biochemical Recurrence Prognostic Biochemical recurrence Vs No Biochemical Recurrence p = 0.02 Serum 23846169
1174 miR-194 miRNA Humans Upregulated in patients with Biochemical Recurrence Prognostic Biochemical recurrence Vs No Biochemical Recurrence p = 0.029 Serum 23846169
1175 PCA3 mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs No evidence of Maligancy p <0.001 Urine 23861782
1199 miR-210 miRNA Humans Upregulated in PCa [Cohort 1: 6.9 fold; Cohort 2: 3.1 fold] Diagnostic Controls Vs Metastatic Castration Resistant Prostate Cancer (mCRPC) p=0.022 Serum 23935962
1200 miR-141 miRNA Humans Upregulated in PCa [Cohort 1: 27.9 fold; Cohort 2: 5.1 fold] Diagnostic Controls Vs Metastatic Castration Resistant Prostate Cancer (mCRPC) Training: p<0.0001; Testing: p<0.001 Serum 23935962
1201 miR-200a miRNA Humans Upregulated in PCa [Cohort 1: 6.1 fold; Cohort 2: 1.76 fold] Diagnostic Controls Vs Metastatic Castration Resistant Prostate Cancer (mCRPC) Training: p=0.007; Testing: p=NS Serum 23935962
1202 miR-200c miRNA Humans Upregulated in PCa [Cohort 1: 22.4 fold; Cohort 2: 2.56 fold] Diagnostic Controls Vs Metastatic Castration Resistant Prostate Cancer (mCRPC) Training: p=0.017; Testing: p=NS Serum 23935962
1203 miR-375 miRNA Humans Upregulated in PCa [Cohort 1: 4.6 fold; Cohort 2: 11.27 fold] Diagnostic Controls Vs Metastatic Castration Resistant Prostate Cancer (mCRPC) Training: p=0.009; Testing: p=0.021 Serum 23935962
1204 hsa-mir-31; hsa-mir-145; hsa-mir-455; hsa-mir-221; hsa-mir-222; hsa-mir-143; hsa-mir-221; hsa-mir-133b; hsa-mir-376c; hsa-mir-187; hsa-mir-139; hsa-mir-455; hsa-mir-224; hsa-mir-204; hsa-mir-505; hsa-mir-149; hsa-mir-222; hsa-mir-34a; hsa-mir-152; hsa-mir-30e; hsa-mir-377; hsa-mir-181c; miRNA Humans Upregulated in PCa (log Fold Change): [] Diagnostic Cancer Vs Benign p < 0.0401 Tissue 23984644
1205 hsa-mir-33a; hsa-mir-25; hsa-mir-18b; hsa-mir-130b; hsa-mir-769; hsa-mir-182; hsa-mir-148a; hsa-mir-96; miRNA Humans Downregulated in PCa (log Fold Change): [] Diagnostic Cancer Vs Benign p < 0.0401 Tissue 23984644
1211 PSMA/PSA Protein Humans Upregulated in PCa (PCa: 4.95 ± 0.83; BPH: 0.47 ± 0.02) Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.0001 Tissue 24063616
1212 PSMA/PSA Protein Humans Upregulated in PCa (PCa: 4.95 ± 0.83; NP: 1.22 ± 0.15) Diagnostic Prostate Cancer Vs Normal Prostate p= 0.0001 Tissue 24063616
1214 PCA3 mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Normal Prostate NA Urine 24080222
1215 PCA3 + Multiparametric MRI Others Humans PCA3 Upregulated in PCa Diagnostic Prostate Cancer Vs Normal Prostate NA Urine + Technique 24080222
1216 Cytochrome P450 family 24 subfamily A member 1 (CYP24A1) mRNA Humans Upregulated in PCa (4 fold) Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p = 0.03 Tissue 24081904
1220 Semaphorin 4F (SF4) mRNA Humans Upregulated (high levels) had increased risk of biochemical recurrence Prognostic Biochemical recurrence Vs No Biochemical Recurrence p = 0.0002 Tissue 24097862
1221 β-Microseminoprotein Protein Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Other Prostatic Conditions p = 0.01 Urine 24115268
1222 β-Microseminoprotein + PSA Protein Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Other Prostatic Conditions β-Microseminoprotein: [p = 0.01] Urine 24115268
1223 Prostate Specific Membrane Antigen (PSMA) Protein Humans Upregulted in Lethal PCa Prognostic Lethal Vs Non Lethal Prostate Cancer p< 0.01 Tissue 24130224
1224 hsa-miR-367; hsa-miR-758; hsa-miR-190 hsa-miR-221; hsa-miR-205; hsa-miR-212; hsa-miR-99b; hsa-miR-214; hsa-miR-203; hsa-miR-127-3p; hsa-miR-130a; hsa-miR-335; hsa-miR-376; hsa-miR-10a; hsa-miR-589; hsa-miR-422a; hsa-miR-10b; hsa-miR-25; hsa-miR-210; hsa-miR-99a; hsa-miR-429; hsa-miR-92a; hsa-miR-100; hsa-miR-222; hsa-miR-484; hsa-miR-125b; hsa-miR-574-3p; hsa-miR-328; hsa-miR-483-5p; hsa-miR-331-3p; hsa-let-7c; hsa-miR-135a; miRNA Humans miR-367, miR-758 and miR-190 were found to be upregulated in PCa; while, rest were Downregulated in PCa Diagnostic Prostate Cancer Vs Adjacent Normal p ≤ 0.046 Tissue 24167554
1225 miR-205 miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Adjacent Normal p<0.0001 Tissue 24167554
1226 miR-214 miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Adjacent Normal p<0.0001 Tissue 24167554
1227 miR-221 miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Adjacent Normal p<0.001 Tissue 24167554
1228 miR-99b miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Adjacent Normal p<0.0001 Tissue 24167554
1229 miR-205 miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Healthy Controls p<0.001 Urine 24167554
1230 miR-214 miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Healthy Controls p<0.001 Urine 24167554
1231 miR-205+ miR-214 miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Healthy Controls p<0.001 Urine 24167554
1233 Prostate Stem Cell Antigen (PSCA) Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.05 Tissue 24183365
1234 Prostate Stem Cell Antigen (PSCA) Protein Humans Upregulated in PCa Diagnostic Prostate Cancer VS HGPIN p<0.05 Tissue 24183365
1235 Prostate Stem Cell Antigen (PSCA) Protein Humans Upregulated in PCa Diagnostic Gleason Score 6 Vs Gleason Score 8 p<0.05 Tissue 24183365
1236 Prostate Stem Cell Antigen (PSCA) Protein Humans Upregulated in PCa Diagnostic Gleason Score 7 Vs Gleason Score 8 p<0.05 Tissue 24183365
1237 Peroxisome proliferator activated receptors (PPAR) [PPARβ/δ] Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.001 Tissue 24189640
1238 cutaneous fatty acid-binding protein (C-FABP) Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.001 Tissue 24189640
1239 cutaneous fatty acid-binding protein (C-FABP) Protein Humans Upregulated in PCa Prognostic Low Vs Moderate Vs High Gleason Score p<0.05 Tissue 24189640
1240 Prostate cancer antigen 3 [PCA3] mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs No Prostate Cancer NA Urine 24211598
1241 PCA3 /PSA ratio (PCa antigen 3 [PCA3]) mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs No Prostate Cancer NA Urine 24211598
1243 N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 (NAALADL2 ) Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign Tissue p<0.0001 Tissue 24240687
1244 N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 (NAALADL2 ) Protein Humans Upregulated with High Tumor Stage Prognostic Tumor Stage pT2 Vs pT3 Vs pT4 p= 0.004 Tissue 24240687
1245 N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 (NAALADL2 ) Protein Humans Upregulated with High Gleason Score Prognostic Gleason Score 3 Vs 4 Vs 5 p=0.028 Tissue 24240687
1246 N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 (NAALADL2 ) Protein Humans Increased in Biochemical Recurrence Prognostic Biochemical recurrence Vs No Biochemical Recurrence Univariate: p = 0.0038; Multivariate: p =0.036 Tissue 24240687
1254 Forkhead Box A1 [FOXA1] mRNA Humans Increased in shorter time to Biochemical Recurrence Prognostic Biochemical recurrence Vs No Biochemical Recurrence p = 0.028 Tissue 24292680
1255 ACACA; CDCA3; CEP55; CCNB1; CKS2; DLGAP5; SLC7A1;HMMR; HIG2; LOX; MMP10; MCOLN2; NLN; PDLIM5; PSD3; C20orf74; FAM80A; SDK1; STC2; SOX4; TMEM200A; TFF3; UBE2C; UBE2E3; mRNA Humans Upregulated in PCa (log 2 PCa/Normal): [] Diagnostic Prostate Cancer Vs Normal Prostate NA Tissue 24349376
1256 Discs Large Homolog 7 [DLG7] mRNA Humans Upregulated in PCa (log 2 PCa/Normal): [] Prognostic Progression Vs No Progression NA Tissue 24349376
1257 Occludin mRNA Humans Downregulated in: [CAHPV-10 (19.08 fold); DU145 (3.2 fold); PC-3 (4.3 fold)]; Upregulated in LNCaP: (2.2 fold) Diagnostic CAHPV-10, DU145, PC-3, LNCaP Vs PNT2 CAHPV-10 (p= 0.001); DU145 (p=0.003); PC-3 (0.003); LNCaP: (p = 0.001) Cell Lines 24358122
1258 Claudin 1 mRNA Humans Downregulated in: [CAHPV-10 (10 fold); LNCaP: (100 fold); DU145 (2.1 fold); PC-3 (3.8 fold)]; Diagnostic CAHPV-10, DU145, PC-3, LNCaP Vs PNT2 p = 0.001 Cell Lines 24358122
1259 Claudin 7 mRNA Humans Downregulated in: [DU145 (5.3 fold); PC-3 (24.8 fold)];Upregulated in LNCaP: (4.63 fold) Diagnostic CAHPV-10, DU145, PC-3, LNCaP Vs PNT2 DU145 (p=0.004); PC-3 (p= 0.01); LNCaP (p = 0.001) Cell Lines 24358122
1260 Claudin 7 mRNA Humans Downregulated in DU145 and PC-3 Prognostic DU145, PC-3 Vs CAHPV-10 DU145 (p=0.02); PC-3 (p<0.001) Cell Lines 24358122
1261 α-catenin mRNA Humans Downregulated in: [DU145 (2.2 fold); PC-3 (33 fold)]; Diagnostic CAHPV-10, DU145, PC-3, LNCaP Vs PNT2 p<0.001 Cell Lines 24358122
1262 α-catenin mRNA Humans Downregulated in DU145 and PC-3 Prognostic DU145, PC-3 Vs CAHPV-10 p<0.001 Cell Lines 24358122
1263 β-catenin mRNA Humans Downregulated in: [CAHPV-10 (3 fold)] ;Upregulated in [LNCaP: (3.8 fold) DU145 (2.2 fold); PC-3 (2.1 fold)] Diagnostic CAHPV-10, DU145, PC-3, LNCaP Vs PNT2 CAHPV-10 (p= 0.015); DU145 (p=0.001); PC-3 (p=0.001) LNCap: (p<0.001) Cell Lines 24358122
1264 β-catenin mRNA Humans Upregulated in DU145 and PC-3 Prognostic DU145, PC-3 Vs CAHPV-10 DU145 (p=0.006); PC-3 (p=0.001) Cell Lines 24358122
1265 E-Cadherin mRNA Humans Downregulated in: [CAHPV-10 (2.3 fold) ; DU145 (5.6 fold); PC-3 (7.25 fold)] Diagnostic CAHPV-10, DU145, PC-3, LNCaP Vs PNT2 CAHPV-10 (p= 0.004); DU145 (p<0.001); PC-3 (p<0.001); Cell Lines 24358122
1266 Claudin 1 Protein Humans Downregulated in LNCaP (9.3 fold) Diagnostic CAHPV-10, DU145, PC-3, LNCaP Vs PNT2 p = 0.04 Cell Lines 24358122
1267 Claudin 7 Protein Humans Downregulated in LNCaP (1.1 fold); DU145 (1.1 fold); PC-3 (1.5 fold) Diagnostic CAHPV-10, DU145, PC-3, LNCaP Vs PNT2 p < 0.01 Cell Lines 24358122
1268 Claudin 7 Protein Humans Downregulated in CAHPV-10 Prognostic CAHPV-10 Vs PC-3 p < 0.01 Cell Lines 24358122
1269 α-catenin Protein Humans Downregulated in LNCaP (4.4 fold); DU145 (2 fold); Diagnostic CAHPV-10, DU145, PC-3, LNCaP Vs PNT2 LNCaP: p = 0.03; DU145: p=0.04 Cell Lines 24358122
1270 E-cadherin Protein Humans Downregulated in CAHPV-10 (1.7 fold); DU145 (1.5 fold); Upregulated in LNCaP: (2.7 fold) Diagnostic CAHPV-10, DU145, PC-3, LNCaP Vs PNT2 p < 0.01 Cell Lines 24358122
1271 ITGA3; ITGB1; TLN1; VCL; ITGA1; FLNC; Protein Humans Differentially Expressed Prognostic LNCaP Cell Lines Vs PC-3 Cell Lines p<0.05 Cell Lines 24371517
1272 Integrin α3 [ITGA3] Protein Humans Upregulated in Metastatic Prostate Cancer Diagnostic Metastasis Vs Prostate Cancer and BPH p<0.005 Urine 24371517
1273 Integrin β1 [ITGB1] Protein Humans Upregulated in Metastatic Prostate Cancer Diagnostic Metastasis Vs Prostate Cancer and BPH p<0.01 Urine 24371517
1274 BTF3 Protein Humans Upregulated in PCa (2.5 fold) Diagnostic Benign Vs Malignant p<0.0001 Tissue 24386364
1275 HINT1 Protein Humans Upregulated in PCa (2.3 fold) Diagnostic Benign Vs Malignant p<0.0001 Tissue 24386364
1276 NDRG1 Protein Humans Upregulated in PCa (2.6 fold) Diagnostic Benign Vs Malignant p<0.0001 Tissue 24386364
1277 ODC1 Protein Humans Upregulated in PCa (1.8 fold) Diagnostic Benign Vs Malignant p<0.0001 Tissue 24386364
1278 BTF3 + HINT1 Protein Humans Upregulated in PCa [BTF3: 2.5 fold; HINT1: 2.3 fold] Diagnostic Benign Vs Malignant p<0.0001 Tissue 24386364
1279 BTF3 + NDRG1 Protein Humans Upregulated in PCa [BTF3: 2.5 fold; NDRG1: 2.6 fold] Diagnostic Benign Vs Malignant p<0.0001 Tissue 24386364
1280 BTF3 + ODC1 Protein Humans Upregulated in PCa [BTF3: 2.5 fold; ODC1: 1.8 fold] Diagnostic Benign Vs Malignant p<0.0001 Tissue 24386364
1281 HINT1 + NDRG1 Protein Humans Upregulated in PCa [NDRG1: 2.6 fold; HINT1: 2.3 fold] Diagnostic Benign Vs Malignant p<0.0001 Tissue 24386364
1282 HINT1 + ODC1 Protein Humans Upregulated in PCa [ODC1: 1.8 fold; HINT1: 2.3 fold] Diagnostic Benign Vs Malignant p<0.0001 Tissue 24386364
1283 NDRG1 + ODC1 Protein Humans Upregulated in PCa [ODC1: 1.8 fold; NDRG1: 2.6 fold] Diagnostic Benign Vs Malignant p<0.0001 Tissue 24386364
1284 PDCD6IP; EEF1A2; FASN; VPS28; PABPC1;YWHAB; ANXA2; ATP1A1; ATP1B1; ATP1B3; BSG; CLIC1; ITGA6; F11R; ACTA2; ATP12A; CTNNB1; ENO1; HSPA5; KPNB1; PKM2; TPI1; YWHAE; SLC3A2; ARF1; CXADR; EHD4; HSP90AB2P; HSP90AB3P; IQGAP1; KRT9; KRT2; MFGE8; PARK7; PGK1; PRDX1; RAB10; RAB1A;RAP1A; AHCY; TUBA1A; CCT5; UGDH; Protein Humans Upregulated in PC346C cell lines (log2 fold):Downregulated in PC346C cell lines (log2 fold): [] Diagnostic PC346C vs PNT2C2 p<0.05 Cell Lines 24391718
1285 PDCD6IP; EEF1A2; FASN; UBA52; VPS28; ACTR3B; CD9; YWHAB; ANXA2; ATP1A1; ATP1B1; ATP1B3; BSG; CLIC1; ITGA6 ;F11R; ATP12A; CTNNB1; ENO1;KPNB1; PKM2; TPI1; YWHAE; SLC3A2; EHD4; PTGFRN; HSP90AB2P; HBB; KRT9; KRT2; MFGE8; PARK7; RAB1A; RAC1; AHCY; CCT5; Protein Humans Upregulated in PC346C cell lines (log2 fold):Downregulated in PC346C cell lines (log2 fold): [] Diagnostic PC346C vs RWPE p<0.05 Cell Lines 24391718
1286 PDCD6IP; UBA52; BCAM; PABPC1; YWHAB; ANXA2; ATP1A1; ATP1B1; ATP1B3; BSG; CLIC1; ITGA6; F11R; ACTA2; ATP12A; CTNNB1; ENO1; HSPA5; KPNB1; PKM2; TPI1; ARF1; CD151; CXADR; HSP90AB3P; IQGAP1; PGK1; PRDX1; RAB10; RAP1A; TUBA1A; UGDH; Protein Humans Upregulated in VCaP cell lines (log2 fold): Downregulated in VCaP cell lines (log2 fold): [] Diagnostic VCaP vs PNT2C2 p<0.05 Cell Lines 24391718
1287 PDCD6IP; EEF1A2; FASN; UBA52; VPS28; ACTR3B; BCAM; CD9;YWHAB; ANXA2; ATP1A1; ATP1B1; ATP1B3; BSG; CLIC1; ITGA6; F11R; ACTA2; HSPA5; YWHAQ; CD151; PTGFRN; HBB; RAC1; Protein Humans Upregulated in VCaP cell lines (log2 fold): Downregulated in VCaP cell lines (log2 fold): [] Diagnostic VCaP vs RWPE p<0.05 Cell Lines 24391718
1288 F3 mRNA Humans NA Prognostic Overall Survival Vs No Survival p=0.001 Tissue 24394557
1289 WNT5B mRNA Humans NA Prognostic Overall Survival Vs No Survival p=0.004 Tissue 24394557
1290 VGLL3 mRNA Humans NA Prognostic Overall Survival Vs No Survival p<0.0001 Tissue 24394557
1291 c-MAF-a mRNA Humans NA Prognostic Overall Survival Vs No Survival p=0.008 Tissue 24394557
1292 CTGF mRNA Humans NA Prognostic Overall Survival Vs No Survival p=0.008 Tissue 24394557
1293 AMACR mRNA Humans NA Prognostic Overall Survival Vs No Survival p=0.009 Tissue 24394557
1294 MUC1 mRNA Humans NA Prognostic Overall Survival Vs No Survival p=0.025 Tissue 24394557
1295 F3 mRNA Humans NA Prognostic PCa Specific Survival Vs No PCa Specific Survival p<0.0001 Tissue 24394557
1296 WNT5B mRNA Humans NA Prognostic PCa Specific Survival Vs No PCa Specific Survival p<0.0001 Tissue 24394557
1297 VGLL3 mRNA Humans NA Prognostic PCa Specific Survival Vs No PCa Specific Survival p=0.014 Tissue 24394557
1298 c-MAF-a mRNA Humans NA Prognostic PCa Specific Survival Vs No PCa Specific Survival p=0.036 Tissue 24394557
1299 CTGF mRNA Humans NA Prognostic PCa Specific Survival Vs No PCa Specific Survival p=0.023 Tissue 24394557
1300 IGFBP3 mRNA Humans NA Prognostic PCa Specific Survival Vs No PCa Specific Survival p=0.013 Tissue 24394557
1301 c-MAF-b mRNA Humans NA Prognostic PCa Specific Survival Vs No PCa Specific Survival p=0.019 Tissue 24394557
1302 EZH2 mRNA Humans NA Prognostic PCa Specific Survival Vs No PCa Specific Survival p=0.018 Tissue 24394557
1303 AMACR mRNA Humans NA Prognostic PCa Specific Survival Vs No PCa Specific Survival p=0.049 Tissue 24394557
1304 VGLL3 + IGFBP3 + F3 mRNA Humans NA Prognostic Overall Survival Vs No Survival Univariate: [p<0.0001;] Multivariate:[Group2: p=0.013 Group 1: p<0.0001] Tissue 24394557
1305 Clinical Parameters + VGLL3 + IGFBP3 + F3 mRNA Humans NA Prognostic Overall Survival Vs No Survival NA Tissue 24394557
1306 VGLL3 + IGFBP3 + F3 mRNA Humans NA Prognostic PCa Specific Survival Vs No PCa Specific Survival Group2: [Univariate: p= 0.002; Multivariate: 0.030]; Group 1: p<0.0001 Tissue 24394557
1307 Clinical Parameters + VGLL3 + IGFBP3 + F3 mRNA Humans NA Prognostic PCa Specific Survival Vs No PCa Specific Survival NA Tissue 24394557
1321 miR-25; miR-101;miR-628-5p miRNA Humans Differentially Expressed Diagnostic African Americans Vs Caucasian Americans with PCa p<0.05 Serum 24477576
1322 miR-25 miRNA Humans Downregulated in PCa Diagnostic African Americans Vs Caucasian Americans with PCa p= 0.0109 Serum 24477576
1323 miR-101 miRNA Humans Downregulated in PCa Diagnostic African Americans Vs Caucasian Americans with PCa p= 0.0006 Serum 24477576
1324 miR-628-5p miRNA Humans Downregulated in PCa Diagnostic African Americans Vs Caucasian Americans with PCa p<0.0001 Serum 24477576
1325 Monoclonal Antibody MIB-1 [Ki-67] Protein Humans Increased with increased risk of death Prognostic PCa Specific Mortality Vs No Mortality p<0.001 Tissue 24486077
1326 Monoclonal Antibody MIB-1 [Ki-67] Protein Humans Increased with increased risk of death Prognostic Progression Vs No Progression p<0.001 Tissue 24486077
1327 Human Serum Albumin Complexed with Myristate and Aspirin; Apolipoprotein-D; Prostaglandin H2 D-isomerase; Ig A1 Bur; G-protein coupled receptor 115; Cadherin-1; α-N-acetylglucosaminidase; Pro-epidermal growth factor; Apolipoprotein-J precursor; Human Beta-Defensin-1; Matrilin-4; CD14 antigen; Chemo- kine-like factor superfamily-5 isoform a; Fibronectin precursor; Immunoglobulin-kappa light chain varia- ble region; SLURP1. Protein Humans Differentially Expressed Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia NA Urine 24494028
1328 Cadherin -1 Protein Humans Differentially Expressed Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia NA Urine 24494028
1329 Fibronectin Protein Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia NA Urine 24494028
1330 TP53INP2 Protein Humans Differentially Expressed Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia NA Urine 24494028
1331 UAP1+ PDLIM5+ IMPDH2+ HSPD1+ PCA3+ TMPRSS2+ ERG+ GAPDH+ B2M+age+sPSA level mRNA Humans NA Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia NA Urine + Plasma 24512523
1332 UAP1+ PDLIM5+ IMPDH2+ HSPD1+ PCA3+ TMPRSS2+ ERG+ GAPDH+ B2M+age+sPSA level mRNA Humans NA Prognostic Gleason Score <7 Vs Gleason Score ≥ 7 NA Urine + Plasma 24512523
1333 U78_x; SNORD78; U78_s; miR-182; U17b; miR-22; miR-34a*; miR-221*; miR-187; miR-221; miR-34c-3p; miRNA Humans Upregulated in PCa: U78_x (3.8 fold); SNORD78 (3.6-fold); U78_s (3.7-fold); miR-182 (4.7-fold); U17b (2.7- fold)Downregulated in PCa: miR-224 (4.05-fold); miR-34a* (3-fold); miR-221* (3.3-fold); miR-187 (12-fold); miR-221 (2.2-fold); miR-34c-3p (1.7-fold) Diagnostic Prostate Cancer Vs Normal Prostate p<0.05 Tissue 24518785
1334 miR-182 miRNA Humans Upregulated in PCa (4.7 fold) Diagnostic Prostate Cancer Vs Normal Prostate 0.717 Tissue 24518785
1335 miR-187 miRNA Humans Downregulated in PCa (12 fold) Diagnostic Prostate Cancer Vs Normal Prostate 0.052 Tissue 24518785
1336 PSA+PCA3+miR-187 miRNA Humans Downregulated in PCa (12 fold) Diagnostic Prostate Cancer Vs Normal Prostate p<0.05 Tissue 24518785
1337 PCAT18 LncRNA Humans Upregulated in PCa (8.8-11.1 fold) Diagnostic Prostate Cancer Vs Normal Prostate p<0.001 Tissue 24519926
1338 PCAT18 LncRNA Humans Upregulated in metastatic Prostatic Cancer Prognostic Localised Vs Metastatic Prostate Cancer p<0.001 Tissue 24519926
1339 miR-1826; miR-1234; miR-1238; miR-191*; miR-484; miR-191; miR-451; miR-486-5p; miR-1913; miR-625*; miR-1825; miR-92a; miR-92b; miR-483-5p; miR-486-3p; miR-563; miR-940; miRNA Humans Downregulated in PCa: miR-1826; miR-1234; miR-1238; miR-191*; miR-484; miR-191; miR-451; miR-486-5p; miR-1913; miR-625*; miR-1825; miR-92a; miR-92b; miR-486-3p; miR-563; miR-940; Upregulated in PCa: miR-483-5p Diagnostic Prostate Cancer Vs Healthy Controls p<0.01 Urine 24563673
1340 miR-1825 miRNA Humans Downregulated in PCa vs BPH vs Healthy Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.01 Urine 24563673
1341 miR-484 miRNA Humans Downregulated in PCa vs BPH vs Healthy Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.01 Urine 24563673
1342 miR-1825 + miR-484 miRNA Humans NA Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.01 Urine 24563673
1343 miR-1825 + miR-484 + PSA miRNA Humans NA Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.01 Urine 24563673
1351 miR-221 miRNA Humans Downregulation in high-risk prostate cancer Prognostic Cancer Related Death Vs No Cancer Related Death p<0.0001 Tissue 24607843
1352 ERG Protein Humans NA Prognostic Histopathological Progression For ERG Positive Vs ERG Negative samples p<0.0001 Tissue 24630684
1353 ERG Protein Humans NA Prognostic Active Survillence (AS) Progression For ERG Positive Vs ERG Negative samples p<0.0001 Tissue 24630684
1369 Hyaluronan-Mediated Motility Receptor (HMMR) Metabolites Humans NA Prognostic Biochemical Failure Vs No Biochemical Faliure Univariate: p=0.028; Multivariate: p=0.04 Tissue 24668563
1370 hsa-miR-337-3p; hsa-miR-330-3p; hsa-miR-339-3p; hsa-miR-124; hsa-miR-218; hsa-miR-128; hsa-miR-10a; hsa-miR-199b-5p; hsa-miR-200b; hsa-miR-15b; miRNA Humans NA Prognostic High Vs Intermediate Vs Low risk p<0.05 Blood 24661838
1371 CCND1 Protein Humans NA Prognostic Biochemical Failure Vs No Biochemical Faliure p=0.042 Tissue 24708576
1372 HMMR Protein Humans NA Prognostic Biochemical Failure Vs No Biochemical Faliure Univariate: p=0.005 Multivariate; p=0.008 Tissue 24708576
1373 HOXC6 Protein Humans NA Prognostic Biochemical Failure Vs No Biochemical Faliure p=0.05 Tissue 24708576
1374 IGF1 Protein Humans NA Prognostic Biochemical Failure Vs No Biochemical Faliure Univariate: p=0.039 Multivariate; p=0.015 Tissue 24708576
1375 MAP4K4 Protein Humans NA Prognostic Biochemical Failure Vs No Biochemical Faliure p=0.024 Tissue 24708576
1376 MKI67 Protein Humans NA Prognostic Biochemical Failure Vs No Biochemical Faliure p=0.026 Tissue 24708576
1377 SIAH2 Protein Humans NA Prognostic Biochemical Failure Vs No Biochemical Faliure p=0.016 Tissue 24708576
1378 SMAD4 Protein Humans NA Prognostic Biochemical Failure Vs No Biochemical Faliure Univariate: p=0.01 Multivariate; p=0.016 Tissue 24708576
1379 HMMR+ SIAH2+ SMAD4 Protein Humans NA Prognostic Biochemical Failure Vs No Biochemical Faliure (3 years) p=0.052 Tissue 24708576
1380 HMMR+ SIAH2+ SMAD4 Protein Humans NA Prognostic Biochemical Failure Vs No Biochemical Faliure (5 years) p=0.024 Tissue 24708576
1381 BTG2; CDC37L1; COL15A1; COL3A1; EIF2D; FDPS; HIST1H1C; HIST1H2BG; IFT57; IGFBP3; ITPR1; LBH; LOC284801; MARCH5; MED4; MEMO1; MXI1; PTN; RPL23AP53; SACM1L; SIRT1; SNORA20; SRSF3; SYNM; mRNA Humans Poor score with decreased BCR Survival Prognostic Biochemical recurrence Vs No Biochemical Recurrence p = 1.45E-21; Validation: p=2.85e-3 Tissue 24713434
1382 miR-598; miR-105; miR-767-5p; miR-24; miR-342-3p; miR-125a-5p; miR-27a; miR-194; miR-454; miR-26b; miR-146a miR-99b; miR-455-3p; miR-301a; miR-9; miR-200a; miR-1267 miR-205 miR-95 miR-200a-5p; miR-200b; miR-203; miR-34a; miR-375; miR-191; miR-100; miR-135b; miR-429 miRNA Humans Upregulated in docetaxel-resistant cell lines: [miR-598; miR-105; miR-767-5p; miR-24; miR-342-3p; miR-125a-5p; miR-27a; miR-194; miR-454; miR-26b; miR-146a miR-99b; miR-455-3p; miR-301a];Downreegulated in docetaxel-resistant cell lines: [miR-9; miR-200a; miR-1267 miR-205 miR-95 miR-200a-5p; miR-200b; miR-203; miR-34a; miR-375; miR-191; miR-100; miR-135b; miR-429] Prognostic PC3 Cell Line Vs PC3Rx Cell Line (docetaxel-resistant sublines) p≤0.001 Cell Lines 24714754
1383 miR-30e-3p; miR-191-3p; miR-30a-5p; miR-152; miR-34b; miR-301b; miR-100; miR-301a; miR-99a; miR-151-3p; miR-30a-3p; miR-146b-5p; miR-210; miR-15a-3p; miR-135b; miR-200b; miR-590-3p; miR-429; miR-590-5p; miR-20b; miR-200c; miR-200a; miR-25; miR-146a; miR-196b; miR-489; miR-96; miR-486-5p; miRNA Humans Upregulated in docetaxel-resistant cell lines: [miR-30e-3p; miR-191-3p; miR-30a-5p; miR-152; miR-34b; miR-301b; miR-100; miR-301a; miR-99a; miR-151-3p; miR-30a-3p; miR-146b-5p; miR-210; miR-15a-3p;]Downregulated in docetaxel-resistant cell lines: [miR-135b; miR-200b; miR-590-3p; miR-429; miR-590-5p; miR-20b; miR-200c; miR-200a; miR-25; miR-146a; miR-196b; miR-489; miR-96; miR-486-5p;] Prognostic DU145 Cell Line Vs DU145Rx Cell Line(docetaxel-resistant sublines) p≤0.001 Cell Lines 24714754
1384 mir-200c miRNA Humans Upregulated in Non Responders (Median NR/median R): 1.6 fold Predictive PSA responder Vs Non Responder (Pre Docetaxel levels) p=0.02 Blood 24714754
1385 mir-200b miRNA Humans Upregulated in Non Responders (Median NR/median R): 2.7 fold Predictive PSA responder Vs Non Responder (Pre Docetaxel levels) p=0.02 Blood 24714754
1386 mir-146a miRNA Humans Downregulated in Non Responders (Median NR/median R): 1.4 fold Predictive PSA responder Vs Non Responder (Pre Docetaxel levels) p=0.05 Blood 24714754
1387 mir-222 miRNA Humans Upregulated after Docetaxel treatment in Responders (1.4 fold) and Downregulated after Docetaxel treatment in Non Responders (1.1 fold) Predictive PSA responder Vs Non Responder -Post Docetaxel Change p=0.01 Blood 24714754
1388 mir-301b miRNA Humans Upregulated after Docetaxel treatment in Responders (1.1 fold) and in Non Responders (1.6 fold) Predictive PSA responder Vs Non Responder -Post Docetaxel Change p=0.04 Blood 24714754
1389 mir-20a miRNA Humans Upregulated after Docetaxel treatment in Responders (1.6 fold) and in Non Responders (1.1 fold) Predictive PSA responder Vs Non Responder -Post Docetaxel Change p=0.04 Blood 24714754
1390 mir-200c + mir-200b + mir-146a miRNA Humans NA Predictive PSA responder Vs Non Responder (Pre Docetaxel levels) p=0.001 Blood 24714754
1391 mir-222 + mir-301b + mir-20a miRNA Humans NA Predictive PSA responder Vs Non Responder -Post Docetaxel Change p = 0.02 Blood 24714754
1392 mir-200c + mir-200b + mir-146a+ mir-222 + mir-301b + mir-20a miRNA Humans NA Predictive PSA responder Vs Non Responder (Pre Docetaxel levels and Post Docetaxel Changes) p=0.001 Blood 24714754
1395 GABRE mRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Non Malignant p=0.001 Tissue 24737792
1396 miR-224 miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Non Malignant p=0.000628 Tissue 24737792
1397 miR-452 miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Non Malignant p=0.000494 Tissue 24737792
1414 POSTN; ASPN; LAMB2; SERPH; CSPG2; ENTP1; SE1L1; ITAV; FOLH1; STIM1; PTK7; ICOSL; SPP2A; CD276; KLK3; ZA2G; FBN1; CD38; CNTP2; AMPN; FAM3B; RNT2; NAAA; PPAP; GSLG1; TSN1; DPP4; ST14; Protein Humans Upregulated in Agressive PCa; Downregulated in Agressive PCa: [] Prognostic Agressive Vs Non Agressive PCa NA Tissue 24741114
1415 TIMP1; CLUS; MFAP4; AOC3; CADM1; HYOU1; FSTL1; KLK11; NBL1; GOLM1; VTNC; CERU; A1AG2; LYVE1; A1AG1; Protein Humans Upregulated in Metastatic PCa;Downregulated in Non Metastatic PCa: [] Prognostic Metastatic Vs Non Metastatic Prostate Cancer NA Tissue 24741114
1416 ATRN; CATD; BTD; MTA1; NCAM1; PECA1; Protein Humans Upregulated in PCa: [];Downregulated in PCa: [] Diagnostic Prostate Cancer Vs Normal Prostate NA Tissue 24741114
1417 NAAA Protein Humans Downregulated in GS >7 Prognostic Gleason Score ≤ 7 and Gleason Score >7 p <0.05 Tissue 24741114
1418 PTK7 Protein Humans Upregulated in GS >7 Prognostic Gleason Score ≤ 7 and Gleason Score >7 p <0.01 Tissue 24741114
1419 NAAA+ PTK7 Protein Humans NAAA: Downregulated in GS >7; PTK7: Upregulated in GS >7 Prognostic Gleason Score ≤ 7 and Gleason Score >7 p <0.05 Tissue 24741114
1424 miR-7; miR-221; miR-222 miRNA Humans Upregulated in PC-3 Cell Lines: [ miR-7(11.3 fold); miR-222 (8.6 fold); miR-221 (8.6 fold)] Prognostic LNCaP Cell Lines Vs PC-3 Cell Lines p<0.05 Cell Lines 24760272
1425 miR-7; miR-221; miRNA Humans Upregulated in Early Castration Resistant Acquisition Prognostic Early Vs Late Castration-resistant acquisition (≤20 months and ≥60 months) miR-7: p=0.034; miR-221: p=0.036; Blood 24760272
1426 PCA3 mRNA Humans Upregulated in PCa Diagnostic Negative Vs Positive Biopsy for PCa p<0.0001 Urine 24803095
1427 PCA3 mRNA Humans Upregulated in PCa Diagnostic Controls Vs Positive Biopsy for PCa p <0.0001 Urine 24803095
1428 DAB2IP Protein Humans Reduced in lower FFBF (Freedom From Biochemical Faliure) Prognostic Freedom From Biochemical Failure Vs Biochemical Failure p=0.04 Tissue 24867541
1429 miR-19a miRNA Humans Upregulated in Cases Prognostic Gleason Score ≥7 or Gleason Score =6 p<0.05 Tissue 24893170
1430 miR-19b miRNA Humans NA Prognostic Gleason Score ≥7 or Gleason Score =6 p<0.05 Tissue 24893170
1431 miR-345 miRNA Humans Downregulated in Cases Prognostic Gleason Score ≥7 or Gleason Score =6 p<0.05 Tissue 24893170
1432 miR-519c-5p miRNA Humans Downregulated in Cases Prognostic Gleason Score ≥7 or Gleason Score =6 p<0.05 Tissue 24893170
1433 miR-19a miRNA Humans Upregulated in Cases Prognostic Gleason Score ≥7 or Gleason Score =6 p<0.05 Tissue 24893170
1434 miR-19b miRNA Humans Upregulated in Cases Prognostic Gleason Score ≥7 or Gleason Score =6 p<0.05 Tissue 24893170
1435 miR-345 miRNA Humans NA Prognostic Gleason Score ≥7 or Gleason Score =6 p<0.05 Tissue 24893170
1436 miR-519c-5p miRNA Humans NA Prognostic Gleason Score ≥7 or Gleason Score =6 p<0.05 Tissue 24893170
1437 miR_19a+ miR_345+ miR_519c_5p miRNA Humans NA Prognostic Gleason Score ≥7 or Gleason Score =6 p<0.05 Tissue 24893170
1438 miR_19b+miR_345+ miR_519c_5p miRNA Humans NA Prognostic Gleason Score ≥7 or Gleason Score =6 p<0.05 Tissue 24893170
1439 miR_19a + miR_19b + miR_345 + miR_519c_5p miRNA Humans NA Prognostic Gleason Score ≥7 or Gleason Score =6 p<0.05 Tissue 24893170
1440 MUC1 Protein Humans Increased with Increased mortality Prognostic PCa Specific Mortality Vs No Mortality p=0.02 Tissue 24909936
1441 p53 Protein Humans Increased with Increased mortality Prognostic PCa Specific Mortality Vs No Mortality p=0.005 Tissue 24909936
1442 AZGP1 Protein Humans Increased with Decreased mortality Prognostic PCa Specific Mortality Vs No Mortality p=0.04 Tissue 24909936
1443 MUC1 + p53+ AZGP1 Protein Humans Increased with Increased mortality Prognostic PCa Specific Mortality Vs No Mortality NA Tissue 24909936
1445 miR-1 miRNA Humans Downregulated in Recurrent PCa Prognostic Recurrence Vs No Recurrence p = 0.036 Tissue 24967583
1446 miR-133b miRNA Humans Downregulated in Recurrent PCa Prognostic Recurrence Vs No Recurrence p = 0.012 Tissue 24967583
1447 miR-1 + miR-133b miRNA Humans Downregulated in Recurrent PCa Prognostic Recurrence Vs No Recurrence p = 0.012 Tissue 24967583
1448 miR-361-3p miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p=0.004 Prostate Secretion Samples 24976077
1449 mir-221 miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p=0.03 Prostate Secretion Samples 24976077
1450 mir-203 miRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p= 0.0002 Prostate Secretion Samples 24976077
1451 mir-133b miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p < 0.01 Prostate Secretion Samples 24976077
1452 miR-361-3p + miR-361-3p+ mir-221+ mir-203 + mir-133b miRNA Humans Downregulated in PCa [miR-361-3p; miR-361-3p; mir-221; mir-133b]; Upregulated in PCa: [mir-203] Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia NA Prostate Secretion Samples 24976077
1457 Brachyury Protein Humans Increases with increasing Gleason Score Prognostic Gleason Score GS <7 Vs GS = 7 Vs GS >7 p = 0.027 Tissue 25009296
1460 Receptor for advanced glycation end products (RAGE) Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p=0.002 Tissue 25057439
1461 High Mobility Group Box 1 (HMGB1) Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p=0.001 Tissue 25057439
1462 Receptor for advanced glycation end products (RAGE) Protein Humans Upregulated in Stage T3-T4 Prognostic stage T1-T2 Vs Stage T3-T4 p=0.004 Tissue 25057439
1463 High Mobility Group Box 1 (HMGB1) Protein Humans Upregulated in Stage T3-T5 Prognostic stage T1-T2 Vs Stage T3-T4 p=0.009 Tissue 25057439
1464 High Mobility Group Box 1 (HMGB1) + Receptor for advanced glycation end products (RAGE) Protein Humans Upregulated in Stage T3-T6 Prognostic stage T1-T2 Vs Stage T3-T4 p=0.007 Tissue 25057439
1465 Receptor for advanced glycation end products (RAGE) Protein Humans Upregulated in Distant Metastases Prognostic Distant Metastases Vs No Distant Metastases p=0.013 Tissue 25057439
1466 High Mobility Group Box 1 (HMGB1) Protein Humans Upregulated in Distant Metastases Prognostic Distant Metastases Vs No Distant Metastases p=0.019 Tissue 25057439
1467 High Mobility Group Box 1 (HMGB1) + Receptor for advanced glycation end products (RAGE) Protein Humans Upregulated in Distant Metastases Prognostic Distant Metastases Vs No Distant Metastases p=0.026 Tissue 25057439
1468 High Mobility Group Box 1 (HMGB1) + Receptor for advanced glycation end products (RAGE) Protein Humans Increased Coexpression in patients with Decreased overall Survival Prognostic Overall Suvival Vs No Survival p=0.047 Tissue 25057439
1469 miR-135a miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer And Adjacent Normal p<0.0001 Tissue 25065599
1470 miR-135a miRNA Humans Downregulated in GS ≥ 8 Prognostic Glesaon Score ≥ 8 and Gleason Score <8 p<0.01 Tissue 25065599
1471 miR-135a miRNA Humans Downregulated in Stage pT3a Prognostic Stage pT3a Vs Stage pT2c p<0.05 Tissue 25065599
1472 PTEN Protein Humans NA Prognostic Lethal Outcome Vs No Lethal Outcome p=0.0011 Tissue 25075204
1473 CCND1 Protein Humans NA Prognostic Lethal Outcome Vs No Lethal Outcome p=0.036 Tissue 25075204
1474 SMAD4 Protein Humans NA Prognostic Lethal Outcome Vs No Lethal Outcome p=0.0035 Tissue 25075204
1475 PTEN + CCND1 +SMAD4 + SSP1 Protein Humans NA Prognostic Lethal Outcome Vs No Lethal Outcome p = 0.00000456 Tissue 25075204
1476 pS6 Protein Humans NA Prognostic Lethal Outcome Vs No Lethal Outcome p=0.021 Tissue 25075204
1477 pPRAS40 Protein Humans NA Prognostic Lethal Outcome Vs No Lethal Outcome p=0.019 Tissue 25075204
1478 CCND1 +SMAD4 + SSP1 + pS6 + pPRAS40 Protein Humans NA Prognostic Lethal Outcome Vs No Lethal Outcome p = 0.000013 Tissue 25075204
1479 miR-30c miRNA Humans Downregulated in Malignant Samples (Benign: 0.621 ± 0.06; malignant: 0.438 ± 0.022) Diagnostic Benign Vs Malignant p=0.014 Tissue 25075250
1480 miR-219 miRNA Humans Downregulated in Malignant Samples (Benign: 0.773 ± 0.082; malignant: 0.467 ± 0.019) Diagnostic Benign Vs Malignant p=0.004 Tissue 25075250
1481 miR-21 miRNA Humans Downregulated in GS ≥ 8 (Benign: 0.636 ± 0.048; malignant: 0.521 ± 0.027) Prognostic Gleason Score ≥ 8 Vs Gleason Score < 8 p=0.004 Tissue 25075250
1482 miR-21 miRNA Humans Downregulated in Metastatis (No Metastasis: 0.667 ± 0.037; Metastatis: 0.463 ± 0.027) Prognostic Metastatic Vs Non Metastatic Prostate Cancer p<0.0001 Tissue 25075250
1483 miR-30c miRNA Humans Downregulated in Metastatis (No Metastasis: 0.514 ± 0.029; Metastatis: 0.354 ± 0.032) Prognostic Metastatic Vs Non Metastatic Prostate Cancer p= 0.0003 Tissue 25075250
1484 miR-219 miRNA Humans Downregulated in Metastatis (No Metastasis: 0.532 ± 0.028; Metastatis: 0.448 ± 0.029) Prognostic Metastatic Vs Non Metastatic Prostate Cancer p= 0.039 Tissue 25075250
1485 miR-21 miRNA Humans Downregulated in Patients who suvived (Survival : 0.636 ± 0.039; No Survival: 0.507 ± 0.03) Prognostic Survival Vs No Survival p= 0.009 Tissue 25075250
1486 miR-30c miRNA Humans Downregulated in Patients who suvived (Survival : 0.500 ± 0.031; No Survival: 0.406 ± 0.028) Prognostic Survival Vs No Survival p= 0.024 Tissue 25075250
1487 miR-30c miRNA Humans Downregulated in Patients With Recurrence (No Recurrence : 0.609 ± 0.036; recurrence: 0.415 ± 0.051) Prognostic PSA Recurrence Vs No Recurrence p= 0.003 Tissue 25075250
1488 let-7c miRNA Humans Downregulated in Patients With Recurrence (No Recurrence : 0.703 ± 0.098; recurrence: 0.963 ± 0.06) Prognostic PSA Recurrence Vs No Recurrence p=0.0266 Tissue 25075250
1489 Interleukin-1β (IL-1β) Protein Humans Increased in patients with Biochemical Recurrence Prognostic Recurrence Vs No Recurrence p=0.02 Tissue 25075566
1490 Interferon β (IFNβ) Protein Humans Decreased in patients with Biochemical Recurrence Prognostic Recurrence Vs No Recurrence p=0.008 Tissue 25075566
1491 Interleukin-1β (IL-1β) + Interferon β (IFNβ) Protein Humans Interleukin-1β (IL-1β): Increased in patients with Biochemical Recurrence; Interferon β (IFNβ): Decreased in patients with Biochemical Recurrence Prognostic Recurrence Vs No Recurrence p=0.004 Tissue 25075566
1492 mir-23b miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs No Prostate Cancer p<0.0001 Tissue 25115396
1493 mir-27b miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs No Prostate Cancer p<0.0001 Tissue 25115396
1494 mir-24-1 miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs No Prostate Cancer p<0.0001 Tissue 25115396
1495 mir-27b miRNA Humans Decreased in patients with shorter progression free interval Prognostic Progression Vs No Progression p=0.0346 Tissue 25115396
1496 miR-1290 miRNA Humans NA Prognostic High Risk vs Low Risk (Survival) p<0.0008 Plasma 25129854
1497 miR-1246 miRNA Humans NA Prognostic High Risk vs Low Risk (Survival) p<0.0008 Plasma 25129854
1498 miR-375 miRNA Humans NA Prognostic High Risk vs Low Risk (Survival) p<0.0008 Plasma 25129854
1499 miR-1290 + miR-375 + PSA + ADT miRNA Humans NA Prognostic High Risk vs Low Risk (Survival) p= 0.0016 Plasma 25129854
1500 miR-1290 + miR-375 miRNA Humans NA Prognostic High Risk vs Low Risk (Survival) p<0.05 Plasma 25129854
1515 YWHAZ Protein Humans NA Prognostic Gleason Score ≤ 6 Vs Gleason Score 7 (3+4) Vs Gleason Score 7 (4+3) Vs Gleason Score ≥ 8 p<0.001 Tissue 25156059
1516 YWHAZ Protein Humans Increased expression in patients with PCa specific death Prognostic High Risk vs Low Risk (Survival) Univariate: p=0.004; Multivariate: p = 0.015 Tissue 25156059
1517 YWHAZ Protein Humans Increased expression in patients with Castration Resistant Prostate Cancer (CRPC) Prognostic Castration Resistant Prostate Cancer (CRPC) Vs No CRPC Univariate: p=0.005; Multivariate: p = 0.008 Tissue 25156059
1518 YWHAZ Protein Humans Increased expression in patients with PSA Relapse Prognostic High Risk vs. Low Risk (Relapse Univariate: p=0.005; Multivariate: p = 0.019 Tissue 25156059
1522 Oligophrenin-1 (OPHN1) mRNA Humans Upregulated in Prostate Cancer (Tumor/nonneoplastic prostate (T/N ratio): > 3 fold) Diagnostic Prostate Cancer Vs Non Neoplastic Samples NA Tissue 25170626
1523 Oligophrenin-1 (OPHN1) Protein Humans Upregulated in Prostate Cancer (Tumor/nonneoplastic prostate (T/N ratio): > 3 fold) Prognostic Gleason Score 6-7 Vs Gleason Score 8-9-10 univariate: p=0.0011; Multivariate: 0.0038 Tissue 25170626
1524 Oligophrenin-1 (OPHN1) Protein Humans Upregulated in Prostate Cancer (Tumor/nonneoplastic prostate (T/N ratio): > 3 fold) Prognostic Stage pT2 Vs Stage pT3 univariate: p=0.0099; Multivariate: 0.0104 Tissue 25170626
1525 Yin Yang 1 (YY1) Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs PIN p<0.001 Tissue 25174820
1526 Death Receptor 5 Protein Humans Downregulated in PCa Diagnostic Prostate Cancer Vs PIN p<0.001 Tissue 25174820
1527 Yin Yang 1 (YY1) Protein Humans Downregulated in PCa Prognostic High Grade cancer Vs Low grade Cancer P<0.0001 Tissue 25174820
1528 Death Receptor 5 Protein Humans Downregulated in PCa Prognostic High Grade cancer Vs Low grade Cancer P<0.0001 Tissue 25174820
1529 8-hydroxydeoxyguanosine (8-OHDG) Protein Humans Upregulated in Malignant Tissue Diagnostic Benign Vs Malignant p<0.0001 Tissue 25175169
1530 cytoplasmic-nuclear factor erythroid 2-related factor 2 (c-Nrf-2) Protein Humans Upregulated in Malignant Tissue Diagnostic Benign Vs Malignant p=0.015 Tissue 25175169
1531 Nuclear-nuclear factor erythroid 2-related factor 2 (n-Nrf-2) Protein Humans Upregulated in Malignant Tissue Diagnostic Benign Vs Malignant p=0.016 Tissue 25175169
1532 cytoplasmic-nuclear factor erythroid 2-related factor 2 (c-Nrf-2) Protein Humans Upregulated in Malignant Tissue Prognostic Biochemical Failure Free Survival Vs No Survival Univariate: p=0.28; Multivariate: p=0.019 Tissue 25175169
1533 cytoplasmic-nuclear factor erythroid 2-related factor 2 (c-Nrf-2) Protein Humans Upregulated in Malignant Tissue Prognostic Overall Survival Vs No Survival Univariate: p=0.28; Multivariate: p=0.019 Tissue 25175169
1534 miRNA-21 miRNA Humans Upregulated in PCa( BPH: 1.3 ± 3.6; PCa:4.5 ± 3.6) Diagnostic Prostata Cancer Vs Benign prostatic hyperplasia p=0.003 Serum 25190021
1535 miRNA-221 miRNA Humans Upregulated in PCa( BPH: 1.2 ± 2.5; PCa: 6.9±4.6) Diagnostic Prostata Cancer Vs Benign prostatic hyperplasia p=0.004 Serum 25190021
1536 E Cadherin Protein Humans Downregulated in patients with early relapse Prognostic Biochemical Relapse Vs No Biochemical Relapse for external beam radiotherapy treated (EBRT) p=0.02 Tissue 25227682
1537 Ki-67 Protein Humans Upregulated in patients with early relapse Prognostic Early Relapse Vs No Relapse EBRT cohort: p=0.0006; PADT Cohort: p=0.0004 Tissue 25227682
1539 Anterior gradient 2 Wild Type (AGR2wt) mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p<0.05 Tissue 25237833
1540 Anterior gradient 2 Slice Variant H (AGR2-SV-H) mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p<0.05 Tissue 25237833
1541 Anterior gradient 2 Wild Type (AGR2wt) mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p<0.001 Urine 25237833
1542 Anterior gradient 2 Slice Variant C (AGR2-SV-C) mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p≤0.001 Urine 25237833
1543 Anterior gradient 2 Slice Variant E (AGR2-SV-E) mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p<0.01 Urine 25237833
1544 Anterior gradient 2 Slice Variant F (AGR2-SV-F) mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p<0.01 Urine 25237833
1545 Anterior gradient 2 Slice Variant G (AGR2-SV-G) mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p≤0.001 Urine 25237833
1546 Anterior gradient 2 Slice Variant H (AGR2-SV-H) mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p≤0.001 Urine 25237833
1547 STEAP2 (Six transmembrane epithelial antigen of the prostate) Protein Humans Upregulated in DU145 and PC3 (28 fold) Diagnostic Cancerous Vs Non Cancerous Cell Lines p<0.001 Cell Lines 25248617
1548 STEAP1 (Six transmembrane epithelial antigen of the prostate) mRNA Humans Upregulated in Low Risk PCa (4.45 fold) Diagnostic Low Risk PCa Vs Normal Tissue p = 0.007 Tissue 25248617
1549 STEAP1 (Six transmembrane epithelial antigen of the prostate) mRNA Humans Upregulated in High Risk PCa (8.15 fold) Diagnostic High Risk PCa Vs Normal Tissue p=0.011 Tissue 25248617
1550 STEAP1 (Six transmembrane epithelial antigen of the prostate) mRNA Humans Upregulated in Metastatic PCa (7.45 fold) Diagnostic Metastatic PCa Vs Normal Tissue p=0.011 Tissue 25248617
1551 STEAP2 (Six transmembrane epithelial antigen of the prostate) mRNA Humans Upregulated in Low Risk Localised PCa (5.77 fold) Diagnostic Low Risk Localised PCa Vs Normal Tissue p=0.022 Tissue 25248617
1552 STEAP2 (Six transmembrane epithelial antigen of the prostate) mRNA Humans Upregulated in Locally Advanced PCa (14.10 fold) Diagnostic Localy Advanced PCa Vs Normal Tissue p=0.003 Tissue 25248617
1553 miR-221 miRNA Humans Downregulated in Recurrent Cases (Recurrent Median: 0.25; Control Median: 0.46) Prognostic Recurrence Vs No Recurrence Regulation: p=0.0002; Univariate: p=0.02; Multivariate: p=0.05 Tissue 25252191
1554 miR-21 miRNA Humans Downregulated in Recurrent Cases (Recurrent Median: 1.01; Control Median: 1.54) Prognostic Recurrence Vs No Recurrence p=0.0149 Tissue 25252191
1555 miR-141 miRNA Humans Downregulated in Recurrent Cases (Recurrent Median: 0.39; Control Median: 0.81) Prognostic Recurrence Vs No Recurrence p<0.0001 Tissue 25252191
1556 Chondroitin Sulfate Protein Humans Upregulated in Prostate Cancer Diagnostic Prostate Cancer Vs No Cancer p<0.0001 Tissue 9815775
1557 Chondroitin Sulfate Protein Humans Upregulated in Prostate Cancer Prognostic Progression Vs No Progression p=0.0001 Tissue 9815775
1558 Versican Protein Humans Upregulated in Prostate Cancer Diagnostic Prostate Cancer Vs No Cancer p=0.0006 Tissue 9563891
1559 Decorin Protein Humans Upregulated in Prostate Cancer Diagnostic Prostate Cancer Vs No Cancer p=0.0078 Tissue 9563891
1560 Versican Protein Humans Upregulated in Prostate Cancer Prognostic Progression Vs No Progression p=0.0003 Tissue 9563891
1562 WISP1 Protein Humans Increased with decreased BCR survival Prognostic Biochemical recurrence Vs No Biochemical Recurrence Cohort 1: p = 0.028;Cohort 3: p= 0.042 Tissue 31069142
1563 WISP1 Protein Humans Upregulated with increasing Stage Prognostic pTNM 2 Vs pTNM 3 Vs pTNM 4 p<0.05 Tissue 31069142
1564 WISP1 mRNA Humans Upregulated in Metastatic PCa Prognostic Primary Vs Metastatis Prostate Cancer p=0.03 Tissue 31069142
1565 TMEFF2 mRNA Humans Upregulated in PCa (Log 2 Median Centered Intensity) Diagnostic Normal/ Benign Tissue Vs Primary/Localised Prostate Cancer p<0.05 Tissue 31060542
1566 TMEFF2 mRNA Humans Upregulated in PCa (Log 2 Median Centered Intensity) Prognostic Primary/Localised Vs Metastatic/CRPC Prostate Cancer p<0.05 Tissue 31060542
1567 TMEFF2 mRNA Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p<0.0001 Tissue 31060542
1568 BUB1B; CDC45; CDK1; CENPI; CLSPN; ERCC6L; EXO1; NCAPG; NUSAP1; RAD51; RRM2; mRNA Humans Upregulated in PCa (Log 2 Median Centered Intensity) Diagnostic Normal/ Benign Tissue Vs Primary/Localised Prostate Cancer p<0.05 Tissue 31060542
1569 BUB1B; CDC45; CDK1; CENPI; CLSPN; ERCC6L; EXO1; NCAPG; NUSAP1; RAD51; RRM2; mRNA Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p<0.05 Tissue 31060542
1570 BUB1B+CDC45+CDK1+CENPI+CLSPN+ERCC6L+EXO1+NCAPG+NUSAP1+RAD51+RRM2 mRNA Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p<0.05 Tissue 31060542
1571 Osteopontin (OPN) Protein Humans increased with decreased BRFS Prognostic Biochemical Recurrence Free Survival Vs No Biochemical Recurrence Free Survival p < 0.036 Tissue 31059955
1572 Glucose Transporter 1 (GLUT1) Protein Humans increased with decreased BRFS Prognostic Biochemical Recurrence Free Survival Vs No Biochemical Recurrence Free Survival p < 0.001 Tissue 31059955
1573 Glucose Transporter 1 (GLUT1) Protein Humans increased with decreased DMFS Prognostic Distant Metastasis Free Survival Vs Distant Metastasis Free Survival p = 0.045 Tissue 31059955
1582 Ki-67 Protein Humans NA Prognostic Distant Metastatis Vs No Distant Metastatis p<0.0001 Tissue 25294917
1583 Cox-2 Protein Humans Upregulation Prognostic Distant Metastatis Vs No Distant Metastatis p=0.04 Tissue 25294917
1584 p16 Protein Humans NA Prognostic Distant Metastatis Vs No Distant Metastatis p=0.0065 Tissue 25294917
1585 MDM2 Protein Humans NA Prognostic Distant Metastatis Vs No Distant Metastatis p=0.036 Tissue 25294917
1586 AF087978; uc002llc; EF177379; BC013821; uc001pyz; AK024556; AB116553; BC012900; LOC100506303; LOC100506922y; LOC100287482; XLOC_l2_009441; LOC154822; XLOC_010807; XLOC_002335; XLOC_l2_009136; XLOC_002871; ANKRD20A9Py; FLJ20444; XLOC_003734y; LOC100505666; LOC100506411; XLOC_007697; XLOC_003734y; XLOC_l2_000735; LOC100129480; XLOC_007162; LOC100506802; LOC100507025; XLOC_010813; LncRNA Humans Upregulated in PC3 (Log Fold Change) [AF087978 (5.8 fold) ; uc002llc(4.8 fold) ; EF177379(4.3 fold) ; BC01382(3.8 fold)1 ; uc001pyz(3.7 fold) ; AK024556 (3.7 fold) ; AB116553 (3.5 fold) ; BC012900 (3.5 fold) ; LOC100506303(2.6 fold) ; LOC100506922(3.6 fold); LOC100287482 (3.0 fold); XLOC_l2_009441 (3.3 fold); LOC154822 (3.2 fold) ; XLOC_010807(3.5 fold) ; XLOC_002335 (3.4 fold); XLOC_l2_009136(2.1 fold); XLOC_002871 (2.3 fold); ANKRD20A9P ( 2.0 fold) ; FLJ20444 (4.1 fold); XLOC_003734( 4.0 fold); LOC100505666(2.1 fold); LOC100506411(4.1 fold); XLOC_007697(3.4 fold); XLOC_003734y(3.5 fold) XLOC_l2_000735(4.6 fold); LOC100129480(4.5 fold); XLOC_007162(3.1 fold); LOC100506802(3.4 fold); LOC100507025(5.7 fold); XLOC_010813(3.8 fold;] Diagnostic PC3 Cells Vs prostate epithelial cells p<0.05 Cell Lines 25307116
1587 LOC100506303; LOC100506922; LOC100287482; XLOC_l2_009441; LOC154822; XLOC_010807; XLOC_002335; XLOC_l2_009136; XLOC_002871; ANKRD20A9Py; FLJ20444; XLOC_003734y; LOC100505666; LOC100506411; XLOC_007697; XLOC_003734y; XLOC_l2_000735; LOC100129480; XLOC_007162; LOC100506802; LOC100507025; XLOC_010813; LncRNA Humans Upregulated in LNCaP (log fold change): [LOC100506303(5.1 fold); LOC100506922y(4.9 fold); LOC100287482(4.8 fold) ; XLOC_l2_009441(4.7 fold); LOC154822(4.6 fold); XLOC_010807 (4.5 fold) ; XLOC_002335( 4.5 fold) ; XLOC_l2_009136(4.4 fold) ; XLOC_002871( 4.2 fold) ; ANKRD20A9(4.0 fold); FLJ20444(4.0 fold); XLOC_003734(3.8 fold) ; LOC100505666(3.7 fold) ; LOC10050641( 3.5 fold)1; XLOC_007697(3.3 fold); XLOC_003734y(3.2 fold); XLOC_l2_000735(2.8 fold); LOC100129480(2.4 fold); XLOC_007162(2.2 fold); LOC100506802(2.1 fold) ; LOC100507025(2.1 fold) ; XLOC_010813(2.1 fold) ;] Diagnostic LNCaP Cells Vs prostate epithelial cells p<0.05 Cell Lines 25307116
1588 XLOC_001699; XLOC_005327y; LOC400958; XLOC_008559y; LINC00340; XLOC_000495; RPS18; XLOC_012294; XLOC_l2_008560; XLOC_009911y; LncRNA Humans Upregulated in PCa [Log2 (Tumor/Normal)]: [XLOC_001699 (4.3 fold) ; XLOC_005327y (4.1 fold); LOC400958 (3.9 fold); XLOC_008559y (3.7 fold) ; LINC00340 (3.6 fold) ; XLOC_000495 (3.6 fold) ; RPS18(3.3 fold) ; XLOC_012294 (3.3 fold); XLOC_l2_008560 (3.3 fold); XLOC_009911y (3.2 fold); Diagnostic Prostate Cancer Vs Adjacent Normal p<0.05 Tissue 25307116
1589 SPRY4-IT1 LncRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Adjacent Normal p<0.05 Tissue 25307116
1590 AK024556; XLOC_007697; LOC100287482; XLOC_005327; XLOC_008559; XLOC_009911; LncRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Adjacent Normal p<0.05 Urine 25307116
1592 miRNA-483-5p miRNA Humans Upregulated in PCa Diagnostic Benign Vs Malignant p=0.013 Urine 25445383
1593 miRNA-483-5p+ PSA miRNA Humans Upregulated in PCa Diagnostic Benign Vs Malignant p=0.013 Urine 25445383
1602 Vascular endothelial growth factor A (VEGF-A) Protein Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.016 Tissue 26268996
1603 Vascular endothelial growth factor A (VEGF-A) + Vascular endothelial growth factor Receptor (VEGFR-2) Protein Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.006 Tissue 26268996
1604 Full Length Androgen Receptor (AR-FL) mRNA Humans NA Prognostic Progression-free survival Vs No Progression-free survival p=0.0003 Plasma 31055861
1605 let‐7c miRNA Humans Downregulated in PCa (log 2 fold change: 0.7140) Diagnostic Prostate Cancer Vs Normal Adjacent p<0.05 Tissue 31045265
1606 mir-145 miRNA Humans Downregulated in PCa (log 2 fold change: 0.4020) Diagnostic Prostate Cancer Vs Normal Adjacent p<0.05 Tissue 31045265
1607 mir-221 miRNA Humans Downregulated in PCa (log 2 fold change: 0.5174) Diagnostic Prostate Cancer Vs Normal Adjacent p<0.05 Tissue 31045265
1608 mir-21 miRNA Humans Upregulated in PCa (log 2 fold change: 0.6068) Diagnostic Prostate Cancer Vs Normal Adjacent p<0.05 Tissue 31045265
1609 mir-182 miRNA Humans Upregulated in PCa (log 2 fold change: 0.8817) Diagnostic Prostate Cancer Vs Normal Adjacent p<0.05 Tissue 31045265
1610 mir-145 miRNA Humans Downregulated in Gleason Score Upgradation (Without Upgradation: -0.4831 Vs Upgradation: -1.1202) Prognostic Gleason Score Upgradation Vs No Upgradation p=0.03 Tissue 31045265
1611 mir-221 miRNA Humans Downregulated in Recurrence (Recurrence: −1.7170 Vs No Recurrence: − 0.9129) Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.04 Tissue 31045265
1624 KIF20A mRNA Humans Upregulated in prostate cancer tissues compared with HR: 2.060 Pathways include: Kinesins, Aurora B signaling, Polo-like kinase 1 (PLK1) pathway, M phase pathway, MHC class II antigen presentation Prostate Cancer Vs No Prostate Cancer Diagnostic 498 cases from TCGA-PRAD were analysed along with 52 normal prostate controls were selected for the analysis NA NA 0.8406 (95% CI: 0.6603-0.8256) NA p < 0.0001 1623 NA No NA NA Not validated on independent patient dataset 31031850 2019 CDK1 NA Expression Based mRNA Tissue Humans normal tissues Prognostic Biochemical recurrence Vs No Biochemical Recurrence p < 0.0001 Tissue 31031850
1625 CCNB1 mRNA Humans Upregulated in PCa Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.0166 Tissue 31031850
1626 BUB1 mRNA Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p < 0.0001 Tissue 31031850
1627 CENPA mRNA Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p < 0.0001 Tissue 31031850
1628 AURKB mRNA Humans Upregulated in PCa Prognostic Biochemical recurrence Vs No Biochemical Recurrence p =0.0002662 Tissue 31031850
1629 CCNB2 mRNA Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p < 0.001469 Tissue 31031850
1630 BIRC5 mRNA Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p =0.0001304 Tissue 31031850
1631 AURKA mRNA Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p < 0.0001 Tissue 31031850
1632 BUB1B mRNA Humans Upregulated in PCa Prognostic Biochemical recurrence Vs No Biochemical Recurrence p < 0.0001 Tissue 31031850
1633 TTK mRNA Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p < 0.0001 Tissue 31031850
1634 KIF20A mRNA Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p < 0.0001 Tissue 31031850
1636 CDKN3 mRNA Humans Upregulated in prostate cancer tissues compared with HR: 2.451 Pathways include: T cell receptor regulation of apoptosis Biochemical recurrence Vs No Biochemical Recurrence Prognostic 498 cases from TCGA-PRAD were analysed along with 52 normal prostate controls were selected for the analysis NA NA 0.6493 NA p =0.0002558 1635 NA No NA NA Not validated on independent patient dataset 31031850 2019 KIF2C NA Expression Based mRNA Tissue Humans normal tissues Prognostic Biochemical recurrence Vs No Biochemical Recurrence p < 0.0001 Tissue 31031850
1637 NCAPG mRNA Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p < 0.0001 Tissue 31031850
1638 CDCA8 mRNA Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p =0.0001771 Tissue 31031850
1639 miR-3162-5p miRNA Humans NA Prognostic Gleason grades 4+5 and 5 Vs Gleason grade 4 p=0.04 Tissue 31018918
1641 TGM4; SOSTDC1; MPO; SPRR1A; KLF4; RNU3B1; RNU3B3; RNU3B4; MT-ATP6; MT-ATP8; TMEM170A; LYNX1; IFNL3; PPP1R3G; GPR15; UGT2A3; MED13L; DNAJC10; NPY; XIST; LST1; WNT9A; LRRN3; GPR45; IFIT1; YWHAQ; KIR3DL1; EPPIN; CRLF1; MAL2; MAP3K15; H1FX; mRNA Mice Upregulated in prostate cancer tissues compared with NA Pathway include: Genes were related to 12 pathways: (i) Aryl hydrocarbon receptor (AHR) signaling, (ii) Bone metamorphosis signaling, (iii) Wnt/GSK-3β signaling, (iv) Glucocorticoid receptor signaling, (v) Immune cell signaling, (vi) Gas signaling, (vii) iNOS signaling, (viii) Hypoxia signaling, (ix) Wnt/β-catenin signaling, (x) Cancer metastasis signaling (xi) p38MAPK signaling, and (xii) Oxidative phosphorylation TRAMP mice Vs Non-Transgenic Mice Diagnostic Twenty week old TRAMP mice and non-transgenic littermates tissues were harvested NA NA NA NA p<0.05 1640 Microarrays No NA NA Validated on human patient cohort 30972102 2019 TOX4; RPL38; LSM12; RPL5; HAX1; ALPI; TCTE3; RPL7; MRTO4; HDAC1; UBE2H; KRT26; TNFSF10; DPPA2; PNLDC1; MRPS11; PFDN6; STOML2; VDAC1; RPS8; TDGF1; UBE2E2; GKAP1; RPL10A; RPS15; UMOD; RPL9; RPL30; NPNT; NR1I2; KRTAP16-1; H3F3A; H3F3B; MRPL34; CSE1L; ST6GALNAC1; UBE2Q2; RPS17; RPL35; GMCL1; NIP7; MSL2; EIF4A1; LASP1; LUZP4; EIF1AD; TUBB3; RPL34; RPL17; RPL23; RPL28; KIR3DL2; LMO2; NA; AOC3; H2AFZ; RPL37; TMSB10; AMY2A; AMY2B; PPIA; PPIH; BEGAIN; NT5C3A; RPS28; RPL27; IL24; COPS9; NEK2; SOCS2; UBL5; UBE2D3; VHL; RPL23A; AICDA; LDHA; CNEP1R1; RPL29; SPCS1; RPL41; SP110; PMP22; ARCN1; UQCRB; SLC25A19; UBE2N; SNRPE; ACKR1; RPL21; LEFTY2; RPL31; RPL35A; RPL7A; RPL39; NACA; SP140; MRPL23; VDAC3; VDAC1P5; ATP5L; DIMT1; GMCL1P1; ARFGAP2; RPL22;' NA Expression Based mRNA Tissue Mice normal tissues Diagnostic TRAMP mice Vs Non-Transgenic Mice p<0.05 Tissue 30972102
1642 ATP5L; ARFGAP2; DIMT1; GMCL1; MRPL34; RPL22; SP140; VDAC3 mRNA Mice Upregulated in Gleason Grade 5 Diagnostic TRAMP mice Vs Non-Transgenic Mice p<0.01 Tissue 30972102
1643 KLF4; MPO; SOStdc1; SPRR1A; TGM4 mRNA Mice Downregulated in TRAMP Diagnostic TRAMP mice Vs Non-Transgenic Mice p<0.01 Tissue 30972102
1644 TNFSF; RPL22; EIF4; SLC2A; LMO2/3; KRT; RPS21; RPS19; RPL21; NEK; PPP1R3; mRNA Humans Upregulated in TRAMP Diagnostic prostate cancer vs. benign prostate p<0.05 Tissue 30972102
1645 GPR15; GPR45; TME; TGM4; KLF4; LRRN3; WNT; SPRR1A; TMEM; mRNA Humans Upregulated in TRAMP Diagnostic prostate cancer vs. benign prostate p<0.05 Tissue 30972102
1655 miR‐28; miR‐100; miR‐942; miR‐28‐3p miRNA Humans NA Prognostic Low Grade Vs High Grade Prostate Cancer miR‐28: p=0.016; miR‐100: p=0.025; miR‐942: p=0.025; miR‐28‐3p: p=0.038 Plasma 30958910
1656 miR‐708; miR‐1298; miR‐886‐3p; miR‐374; miR‐376c; miR‐202; miR‐128a; miR‐185 miRNA Humans NA Prognostic Low Grade Vs High Grade Prostate Cancer miR‐708: p<0.001; miR‐1298: p=0.001; miR‐886‐3p:p=0.01; miR‐374:p=0.017; miR‐376c: p=0.031; miR‐202: p=0.035; miR‐128a: p=0.039; miR‐185: p=0.041 Plasma 30958910
1657 MMP2 (Matrix Metalloproteinase-2) mRNA Humans NA Diagnostic Prostate Cancer Vs Normal Prostate p<0.05 Tissue 30917169
1658 BASP1 (Brain Abundant Membrane Attached Signal Protein 1) mRNA Humans Downregulated in High Grade PCa Diagnostic Prostate Cancer Vs Normal Prostate p<0.05 Tissue 30917169
1659 SNHG6 (small nucleolar RNA host gene 6) LncRNA Humans Upregulated in High Grade PCa Diagnostic Prostate Cancer Vs Normal Prostate p<0.05 Tissue 30911973
1660 SNHG6 (small nucleolar RNA host gene 6) LncRNA Humans Downregulated in PCa Prognostic Normal Prostate Vs T2 PCa Vs T3+T4 PCa p<0.001 Tissue 30911973
1661 SNHG6 (small nucleolar RNA host gene 6) LncRNA Humans Upregulated in PCa Prognostic Normal Prostate Vs Gleason Score 6 Vs GS 7 VS GS 8 Vs GS 9+GS10 p<0.001 Tissue 30911973
1662 SNHG6 (small nucleolar RNA host gene 6) LncRNA Humans Upregulated in PCa Prognostic Disease Free Survival Vs No Disease Free Survival p=0.0365 Tissue 30911973
1663 SNHG6 (small nucleolar RNA host gene 6) LncRNA Humans Upregulated in T2 PCa and T3+T4 PCa Diagnostic Normal Cell Lines Vs PCa Cell Lines p<0.001 Cell Lines 30911973
1664 SNHG6 (small nucleolar RNA host gene 6) LncRNA Humans Upregulated in GS 6,7,8,9+10 Diagnostic Prostate Cancer Vs Normal Prostate p<0.05 Tissue 30911973
1665 PLZF (Promyelocytic leukemia zinc finger protein) Protein Humans High expression associated with shorter disease-free survival time Diagnostic Normal Vs Primary and Metastatic PCa NA Tissue 25807461
1694 TTTY15-USP9Y mRNA Humans Upregulated in PCa Diagnostic Positive Vs Negative Biopsy p<0.001 Urine 26008593
1695 TTTY15-USP9Y + PSA mRNA Humans Downregulated in Gleason Pattern 4 and 5 Diagnostic Positive Vs Negative Biopsy p<0.001 Urine 26008593
1696 TTTY15-USP9Y mRNA Humans Downregulated in Gleason Upgrade Patients Diagnostic Positive Vs Negative Biopsy p<0.001 Urine 26008593
1697 hsa-miR-518a miRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p< 0.001 Urine 26126436
1698 hsa-miR-3605 miRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p=0.033 Urine 26126436
1699 hsa-miR-16 miRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p=0.04 Urine 26126436
1700 RUN6-2 miRNA Humans Downregulated in PCa (BPH: 4098.6; PCa: 2670.6) Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p< 0.001 Urine 26126436
1701 hsa-miR-615-3p miRNA Humans Downregulated in PCa (BPH: 8842.4; PCa: 2781.7) Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p< 0.001 Urine 26126436
1702 hsv1-miR-H18 miRNA Humans Downregulated in PCa (BPH: 1030.7; PCa: 619.2) Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p< 0.001 Urine 26126436
1703 hsv2-miR-H9-5p miRNA Humans Downregulated in PCa (BPH: 1030.7; PCa: 619.2) Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p< 0.001 Urine 26126436
1704 hsv1-miR-H18 miRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia Tissue, Urine: p<0.001; Serum: p=0.004 Tissue+Urine+Serum 26126436
1705 hsv2-miR-H9-5p miRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia Tissue, Urine: p<0.001; Serum: p=0.002 Tissue+Urine+Serum 26126436
1706 hsa-miR-615-3p miRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia Tissue: p<0.001; Tissue+Urine+Serum 26126436
1707 hsa-miR-BARTA-4 miRNA Humans Upregulated in PCa (Tissue, Serum, Urine) Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia Tissue: p<0.001; Tissue+Urine+Serum 26126436
1708 hsa-miR-4316 miRNA Humans Upregulated in PCa (Tissue, Serum, Urine) Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia Tissue: p<0.001; Urine: p=0.022 Tissue+Urine+Serum 26126436
1709 hsv1-miR-H18 miRNA Humans Upregulated in PCa (Tissue) Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p<0.05 Tissue+Urine 26126436
1710 hsv2-miR-H9-5p miRNA Humans Upregulated in PCa (Tissue) Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p<0.05 Tissue+Urine 26126436
1711 ERG Protein Humans Upregulated in PCa (Tissue, Serum) Prognostic Recurrence Free Survival Vs No Recurrence Free Survival p=0.04 Tissue 26172920
1712 SPINK1 Protein Humans Upregulated in PCa (Tissue, Urine) Prognostic Recurrence Free Survival Vs No Recurrence Free Survival p=0.004 Tissue 26172920
1713 ERG; SPINK1 Protein Humans Upregulated in PCa (Tissue, Urine) Prognostic Recurrence Free Survival Vs No Recurrence Free Survival p=0.003 Tissue 26172920
1720 FOXM1 (Forkhead Box M1) Protein Humans NA Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p<0.001 Tissue 30719174
1721 FOXM1 (Forkhead Box M1) Protein Humans NA Prognostic Low & Intermediate Risk Vs High Risk p<0.001 Tissue 30719174
1722 FOXM1 (Forkhead Box M1) Protein Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence Univariate: p=0.022; Multivariate: p=0.035 Tissue 30719174
1729 SERPINA5; MFSD2A; ACSL6; MCF2; EMX2; HOXB8; CLDN2; AKR1B1; SPINK2; CYP19A1; mRNA Humans Upregulated in PCa: (PCa: 39.68 ± 30.00; No PCa: 15.04 ± 7.11) Diagnostic Prostate Cancer Vs Normal Adjacent p<0.05 Tissue 30286759
1730 EMX2OS; LINC02137; LINC01116; LINC00839; AL161645.1; AC012123.1; AL354793.1; LINC02385; HOXB‐AS3; AC005674.1; LncRNA Humans Upregulated in High Risk PCa Diagnostic Prostate Cancer Vs Normal Adjacent p<0.05 Tissue 30286759
1731 hsa‐mir‐891a; hsa‐mir‐892a; hsa‐mir‐1224; hsa‐mir‐93; hsa‐mir‐23c; hsa‐mir‐1251; hsa‐mir‐204; hsa‐mir‐323b; hsa‐mir‐200c; hsa‐mir‐96; miRNA Humans Downregulated after surgery (Before Surgery: 31.05 ± 21.01; After Surgery: 23.14 ± 11.1) Diagnostic Prostate Cancer Vs Normal Adjacent p<0.05 Tissue 30286759
1732 SERPINA5; MFSD2A; ACSL6; MCF2; EMX2; HOXB8; CLDN2; AKR1B1; SPINK2; CYP19A1; mRNA Humans Differentially Expressed [Log Fold Change: SERPINA5: (-6.78954); MFSD2A (− 5.97025); ACSL6: (− 4.99597); MCF2: (−5.26855); EMX2: (− 6.79059); HOXB8: (− 6.24965); CLDN2: (−7.91887); AKR1B1: (− 3.87736); SPINK2: (−7.41992); CYP19A1: (−5.40444;] Prognostic High Risk Vs Low Risk PCa p=0.00822 Tissue 30286759
1747 miR-1260 miRNA Humans NA Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p=0.00001 Tissue 30250996
1748 miR-1274a miRNA Humans NA Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p=0.00001 Tissue 30250996
1753 5-hmC (5-hydroxymethylcytosin)+ ERG negative Protein Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence Univariate: p=0.01; Multivariate: p=0.003 Tissue 30818754
1754 AZGP1; C0S; H3K18Ac; H3K4Me2; Ki67; p53; PML Protein Humans NA Prognostic Biochemical Relapse Vs No Biochemical Relapse AZGP1 p= 0.03; C0S: p=0.01; H3K18Ac: p=0.04; H3K4Me2: p=0.05; Ki67: p=0.02; p53: p=0.002; PML: p=0.03 Tissue 30288742
1755 AZGP1; Ki67; PML Protein Humans NA Prognostic Metastatic Relapse Vs No Relapse AZGP1: p=0.002; Ki67: p=0.04; PML:p=0.04 Tissue 30288742
1756 AZGP1 Protein Humans NA Prognostic Prostate Cancer Specific Death Vs No Death p=0.002 Tissue 30288742
1757 AZGP1+Ki67 Protein Humans NA Prognostic Metastatic Relapse Vs No Relapse Discovery: Univariate: p=0.03; Multivariate: p=0.04 Tissue 30288742
1758 AZGP1+Ki67 Protein Humans NA Prognostic Prostate Cancer Specific Death Vs No Death Discovery: Univariate: p=0.005; Multivariate: p=0.03;Validation: Univariate: p=0.05 Tissue 30288742
1762 miR-1825 miRNA Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p<0.001 Serum 30324582
1763 miR-484 miRNA Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p<0.001 Serum 30324582
1764 miR-205 miRNA Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p<0.001 Serum 30324582
1765 miR-141 miRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs No Prostate Cancer p<0.001 Serum 30324582
1766 let-7b miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs No Prostate Cancer p<0.001 Serum 30324582
1767 miR-1825 miRNA Humans Downregulated in PCa Prognostic Stage T1-T2 Vs Stage T3-T4 p<0.05 Serum 30324582
1768 let-7b miRNA Humans Upregulated in PCa Prognostic Stage T1-T2 Vs Stage T3-T4 p<0.05 Serum 30324582
1769 miR-205 miRNA Humans Downregulated in PCa Prognostic Bone Metastasis Vs No Bone Metastasis p<0.05 Serum 30324582
1770 PCA3 mRNA Humans Upregulated in Stage T3-T4 Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia NA Blood 30334974
1771 hK2 mRNA Humans Downregulated in Stage T3-T4 Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia NA Blood 30334974
1772 miR-141 miRNA Humans Upregulated in Bone Metastasis Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia NA Blood 30334974
1773 tPSA+ hK2+ PCA3+ miR-141 miRNA Humans NA Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia NA Blood 30334974
1821 AMBP; (cDNA FLJ50830, highly similar to AMBP); (unnamed protein product); (Isoform 2 of Calmodulin-regulated spectrin-associated protein 1-like 1 (CAMSAP1L1); cDNA FLJ51445, highlysimilar to AMBP protein; Ribosomal RNA upstream binding transcription factor (Fragment, UBTF); Basementmembrane-specific heparan sulfate proteoglycan coreprotein (HSPG2); Ferritin heavy chain (FTH1); Transthyretin; 13 kDa protein; Unknown (protein for IMAGE:3934797); Putative beta-actin-like protein 3 F7 Factor VII active sitemutant immunoconjugate; C11orf54 Aminoacylase-1 (ACY1); Ferritin Light chain (FTL) Coactosin-like protein (COTL1); Protein Humans Methylated in PCa Diagnostic Prostate Cancer Vs Controls and Benign Prostatic Hyperplasia p<0.05 Urine 30610587
1822 BUB1 mRNA Humans Methylated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1823 TPX2 mRNA Humans Methylated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1824 NCAPG mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1825 UBE2C mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1826 MELK mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1827 CCNA2 mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1828 CCNB1 mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1829 CDK1 mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1830 E2F2 mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1831 DLGAP5 mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1832 TMEM206 mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1833 CDKN3 mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1834 SHMT2 mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1835 SRD5A2 mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1836 CSRP1 mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1837 PGM5 mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1838 NFIB mRNA Humans Downregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1839 HEATR5B (HEAT repeat containing 5B); DDC (Dopa decarboxylase, transcript variant 6); TAS1R3 (Taste 1 receptor member 3); XIAP (X-linked inhibitor of apoptosis, transcript variant 2); mRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Normal Adjacent p<0.05 Tissue 30890858
1840 GABPB1-AS1 (GABPB1 antisense RNA 1); DDC (Dopa decarboxylase, transcript variant 6); HEATR5B (HEAT repeat containing 5B); CARD11 (Caspase recruitment domain family member 11, transcript variant 2); mRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Normal Adjacent p<0.05 Tissue 30890858
1841 GABPB1-AS1 (GABPB1 antisense RNA 1); KRT5 (Keratin 5); NCS1 (Neuronal calcium sensor 1, transcript variant 2); COL17A1 ( Collagen type XVII alpha 1 chain); ANXA1 (Annexin A1); LGALS3BP (Galectin 3 binding protein); mRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs Normal Adjacent p<0.05 Tissue 30890858
1842 MT1IP (Metallothionein 1I, pseudogene (MT1IP), transcript variant 1); TRPT1 (tRNA phosphotransferase 1 (TRPT1), transcript variant 6); CHFR (Checkpoint with forkhead and ring finger domains, E3 ubiquitin protein ligase (CHFR), transcript variant 2); ZNF830 (Zinc finger protein 830); REXO1L2P (RNA exonuclease one homolog (S. cerevisiae)-like 2); SLC25A21 (SLC25A21 antisense RNA 1); mRNA Humans Differentially Expressed Prognostic Tumor Stage T1C Vs T2 p<0.05 Tissue 30890858
1843 FXR2 (Fragile X mental retardation, autosomal homolog 2); GADD45GIP1 (Growth arrest and DNA-damage-inducible, gamma interacting protein 1); STX4 (Syntaxin 4, transcript variant 1); CALCOCO2 (Calcium binding and coiled-coil domain 2, transcript variant 1); BEST4 (Bestrophin 4); URI1 (Prefoldin-like chaperone, transcript variant 3); DCP2 (Decapping mRNA 2, transcript variant 3); mRNA Humans Differentially Expressed Prognostic Tumor Stage T2 Vs T2a p<0.05 Tissue 30890858
1844 RASSF4 (Ras association (RalGDS/AF-6) domain family member 4); SIRPA (Signal-regulatory protein alpha (SIRPA), transcript variant 3); COMP (Cartilage oligomeric matrix protein); SOD3 (Superoxide dismutase 3, extracellular); DIDO1 (Death inducer-obliterator 1, transcript variant 3); PRELP (Proline/arginine-rich end leucine-rich repeat protein, transcript variant 1); mRNA Humans Differentially Expressed Prognostic Tumor Stage T2a Vs T2b p<0.05 Tissue 30890858
1845 BGN (Homo sapiens biglycan); RASSF4 (Ras association (RalGDS/AF-6) domain family member 4); USP21 (Ubiquitin-specific peptidase 21, transcript variant 3); NR1D1 (Nuclear receptor subfamily 1 group D, member 1); ANGPTL2 (Angiopoietin-like 2); mRNA Humans Differentially Expressed Prognostic Tumor Stage T2b Vs T2c p<0.05 Tissue 30890858
1846 SMAP2 (Small ArfGAP2 (SMAP2), transcript variant 2); TMSA (Prothymosin, alpha (PTMA), transcript variant 1); YY1AP1 (YY1 associated protein 1 (YY1AP1), transcript variant 6); DOCK9 (Dedicator of cytokinesis 9 (DOCK9), transcript variant 2); KITLG (KIT ligand (KITLG), transcript variant b); mRNA Humans Differentially Expressed Prognostic Tumor Stage T2c Vs T3a p<0.05 Tissue 30890858
1847 FAM133DP (Family with sequence similarity 133 member D pseudogene); SAMM50 (Sorting and assembly machinery component 50 homolog, protein coding); OR4F13P (Olfactory receptor family 4 subfamily F member 13 pseudogene); mRNA Humans Differentially Expressed Prognostic Tumor Stage T3a Vs T3b p<0.05 Tissue 30890858
1848 IKZF3 (IKAROS family zinc finger 3 (Aiolos), transcript variant 12); USP13 (Ubiquitin-specific peptidase 13 (isopeptidase T-3)); CLASP1 (Cytoplasmic linker associated protein 1, transcript variant 3); CEP112 (Centrosomal protein 112kDa, transcript variant 3); TSEN15 (tRNA splicing endonuclease subunit, transcript variant 1); FLVCR2 (Feline leukemia virus subgroup C cellular receptor family, member 2,transcript variant 2); GOLGA8B (Golgin A8 family, member B, transcript variant 1); ZNF438 (Zinc finger protein 438, transcript variant 1); SCARNA22 (Small Cajal body-specific RNA 22); LPPR1 (Lipid phosphate phosphatase-related protein type 1, transcript variant 2); PTGFR (Prostaglandin F receptor (FP), transcript variant 1); NREP (Neuronal regeneration related protein, transcript variant 1); mRNA Humans Differentially Expressed Prognostic Tumor Stage T2c Vs T3/4 p<0.05 Tissue 30890858
1849 miR-30c-5p miRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p<0.05 Urine 30728149
1850 miR- 222-3p*+ miR-24-3p+ miR-30c-5p miRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p<0.05 Urine 30728149
1851 miR- 222-3p*+ miR-24-3p+ miR-30c-5p+PSA miRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p<0.05 Urine 30728149
1852 miR-425-5p miRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Adjacent Normal p<0.001 Tissue 30720162
1853 miR-425-5p miRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Adjacent Normal p<0.001 Cell Lines 30720162
1854 miR-424 miRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p=0.043 Tissue 30345533
1855 miR-572 miRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p= 0.031 Tissue 30345533
1856 miR-572+ miR-424 miRNA Humans Upregulated in PC3 and DU145 Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p= 0.031 Tissue 30345533
1857 miR-572+ miR-424+ miR-1 + miR133b miRNA Humans Downregulated in Recurrent PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p= 0.031 Tissue 30345533
1875 KNG1 (Kininogen-1); Protein Humans Methylated in PCa Diagnostic Prostate Cancer Vs Benign Prostatic hyperplasia p<0.05 Urine 30237853
1876 PD-L2 (Programmed death ligand 2) mRNA Humans Methylated in PCa Prognostic Biochemical Recurrence Free Survival Vs No Biochemical Recurrence Free Survival p=0.01 Tissue 30321406
1877 PD-L2 (Programmed death ligand 2) mRNA Humans Methylated in PCa Prognostic Distant Metastatic Free Survival Vs No DMFS Survival p=0.01 Tissue 30321406
1878 PD-L2 (Programmed death ligand 2) mRNA Humans Upregulated in PCa: []; Downregulated in PCa: [] Prognostic Prostate Cancer Specific Survival Vs No PCSS Survival p<0.001 Tissue 30321406
1894 ASAP1 DNA (Copy Number variations) Humans NA Prognostic Gleason Grade 4 in Gleason Score 7 p<0.01 Tissue 30611450
1895 HDAC9 DNA (Copy Number variations) Humans NA Prognostic Gleason Grade 4 in Gleason Score 7 p<0.01 Tissue 30611450
1896 CHD1 DNA (Copy Number variations) Humans NA Prognostic Gleason Grade 4 in Gleason Score 7 p<0.01 Tissue 30611450
1897 RB1 DNA (Copy Number variations) Humans Upregulated in Agressive PCa Prognostic Gleason Grade 4 in Gleason Score 7 p<0.01 Tissue 30611450
1898 PTEN DNA (Copy Number variations) Humans Upregulated in Agressive PCa Prognostic Gleason Grade 4 in Gleason Score 7 p<0.01 Tissue 30611450
1899 MYC DNA (Copy Number variations) Humans Upregulated in Agressive PCa Prognostic Gleason Grade 4 in Gleason Score 7 p<0.01 Tissue 30611450
1900 ASAP1 DNA (Copy Number variations) Humans Upregulated in Agressive PCa Prognostic GP3 in GS7 Vs GP3 in GS6 p<0.01 Tissue 30611450
1901 HDAC9 DNA (Copy Number variations) Humans Upregulated in Agressive PCa Prognostic GP3 in GS7 Vs GP3 in GS6 p<0.01 Tissue 30611450
1902 CHD1 DNA (Copy Number variations) Humans Upregulated in Agressive PCa Prognostic GP3 in GS7 Vs GP3 in GS6 p<0.01 Tissue 30611450
1903 RB1 DNA (Copy Number variations) Humans Upregulated in Agressive PCa Prognostic GP3 in GS7 Vs GP3 in GS6 p<0.01 Tissue 30611450
1904 PTEN DNA (Copy Number variations) Humans Upregulated in Agressive PCa Prognostic GP3 in GS7 Vs GP3 in GS6 p<0.01 Tissue 30611450
1905 MYC DNA (Copy Number variations) Humans Upregulated in Agressive PCa Prognostic GP3 in GS7 Vs GP3 in GS6 p<0.01 Tissue 30611450
1906 AFP; AKR1C1; AKR1C3; AKR1C4; C1orf229; C5orf28; C5orf34; CCNE1; DNMT1; E2F3; ENSA; FBXO4; G6PD; KPNA2; LETM2; LGSN; MRPS30; OPLAH; OR4K15; OR4L1; PAIP1; SKP1; SPEF2; WDR70; ZNF124; ZNF280A; ZNF324B; ZNF669; ZNF695; mRNA Humans Upregulated in Agressive PCa Prognostic Primary Prostate Cancer Vs Metastatic Prostate Cancer p<0.05 Tissue 30401717
1907 ANO7; NSA2; BOK; PDE8B; CECR6; PER3; CNNM1; PPP1R7; CNTNAP3; SCAMP1; COX15; SEMA4G; DMGDH; SLC7A8; DUSP1; TMEM18; EPHA7; TRIM8; FAM20C; TSLP; FOXC1; WDR41; ZNF658; GABRG3; GLB1L3; GLOD4; KCNMB1; LOC100128239; LOXL4; MTERFD2; NCAM1; NDN; mRNA Humans Upregulated in Agressive PCa Prognostic Primary Prostate Cancer Vs Metastatic Prostate Cancer p<0.05 Tissue 30401717
1908 ADAM12; AURKA; AURKB; C7orf49; CDCA8; CENPF; CIT; DNMT3B; DYRK2; FANCD2; FGD1; GDAP1; GPI; GTSE1; HNRNPUL1; IPO9; KIF23; LIG1; NCAPH; NHSL1; PEG10; SKP2; TMEM65; TOP2A; TPX2; UBE2T; mRNA Humans Upregulated in Agressive PCa Prognostic Primary Prostate Cancer Vs Metastatic Prostate Cancer p<0.05 Tissue 30401717
1909 ALDH1A3; APH1B; ATAD1; CTBS; CTSO; DHRS7; ESR1; FOXC1; MEIS2; NR4A1; PDE8B; RPS27L; SEC62; SPCS3; ZMAT1; mRNA Humans Upregulated in Metastatic PCa Prognostic Primary Prostate Cancer Vs Metastatic Prostate Cancer p<0.05 Tissue 30401717
1910 HSP27; prohibitin; GSTP1; fibrinogen β chain; ALDH6A1; A1AT; HSP60; Protein Humans Downregulated in Metastatic PCa Diagnostic Metastatic Prostate Cancer Vs No Prostate Cancer NA Tissue 30396985
1911 HSP27 Protein Humans Upregulated in Metastatic PCa Prognostic Survival Vs No Survival p=0.007 Tissue 30396985
1912 Prohibitin Protein Humans Upregulated in Metastatic PCa Prognostic Survival Vs No Survival p<0.001 Tissue 30396985
1913 ALDH6A1 Protein Humans Upregulated in Metastatic PCa: [HSP27 (2.01 fold); prohibitin (1.88 fold); GSTP1 (1.18 fold); fibrinogen β chain (2.68 fold); ALDH6A1 (2.89 fold);Downregulated in Metastatic PCa [A1AT (0.84 fold) ; HSP60 (0.19 fold);] Prognostic Survival Vs No Survival p<0.001 Tissue 30396985
1914 Prohibitin+ HSP27+ALDH6A1 Protein Humans Upregulated in Metastatic PCa: [HSP27 (2.01 fold); prohibitin (1.88 fold); GSTP1 (1.18 fold); fibrinogen β chain (2.68 fold); ALDH6A1 (2.89 fold);]Downregulated in Metastatic PCa [A1AT (0.84 fold) ; HSP60 (0.19 fold);] Prognostic Survival Vs No Survival NA Tissue 30396985
1915 Prohibitin+ HSP27 Protein Humans Upregulated in Metastatic PCa: [HSP27 (2.01 fold); prohibitin (1.88 fold); GSTP1 (1.18 fold); fibrinogen β chain (2.68 fold); ALDH6A1 (2.89 fold);] Downregulated in Metastatic PCa [A1AT (0.84 fold) ; HSP60 (0.19 fold);] Prognostic Survival Vs No Survival NA Tissue 30396985
1916 Prohibitin+ALDH6A1 Protein Humans Upregulated in Metastatic PCa: [HSP27 (2.01 fold); prohibitin (1.88 fold); GSTP1 (1.18 fold); fibrinogen β chain (2.68 fold); ALDH6A1 (2.89 fold);Downregulated in Metastatic PCa [A1AT (0.84 fold) ; HSP60 (0.19 fold);] Prognostic Survival Vs No Survival NA Tissue 30396985
1917 CAV1; TP53; MAGEA11; CALM1; EGFR; UBE2I; CALR; SMAD3; FHL2; HDAC1; APP; MYC; JUN; ESR1; GNB2L1; HIPK3; SMAD2; APPBP2; CDC2; BRCA1; RB1; SMAD1;PXN; XRCC6; IL6ST; STAT3; DLG1; AES; TRAF6; FLNA; TRIM29; PCAF; REPS2; AKT1; PRKCA; RAF1; HLA-B; TRAF2; SMARCA4; MAPK1; CHGB; RANBP9; CCND1; GSK3B; HSPA1A; BCL2; VCL; RAI17; TGFBR1; SELENBP1; Protein Humans Upregulated in Metastatic PCa: [HSP27 (2.01 fold); prohibitin (1.88 fold); GSTP1 (1.18 fold); fibrinogen β chain (2.68 fold); ALDH6A1 (2.89 fold);]Downregulated in Metastatic PCa [A1AT (0.84 fold) ; HSP60 (0.19 fold);] Diagnostic Prostate Cancer Vs Normal Prostate NA Tissue 22654636
1918 CAV1; MAGEA11; CALM1; CALR; TP53; FHL2; EGFR; APP; JUN; SMAD3; SMAD2; ESR1; RB1; HIPK3; BRCA1; SMAD1; GNB2L1; XRCC6; UBE2I; HDAC1; CDC2; AES; STAT3; IL6ST; APPBP2; PCAF; REPS2; FLNA; RAF1; MYC; MAPK1; TRAF6; CCND1; SMARCA4; HLA-B; TRAF2; RANBP9; PIAS4; GSK3B; TRIM29; FOS; IDE; SRC; PXN; SLC25A4; SP1; NR5A1 YWHAG; AKT1; CCNE1; Protein Humans Upregulated in Metastatic PCa: [HSP27 (2.01 fold); prohibitin (1.88 fold); GSTP1 (1.18 fold); fibrinogen β chain (2.68 fold); ALDH6A1 (2.89 fold);]Downregulated in Metastatic PCa [A1AT (0.84 fold) ; HSP60 (0.19 fold);] Prognostic Prostate Cancer Vs Lymph Node Metastasis NA Tissue 22654636
1919 miR-17* miRNA Humans Upregulated in Metastatic PCa: [HSP27 (2.01 fold); prohibitin (1.88 fold); GSTP1 (1.18 fold); fibrinogen β chain (2.68 fold); ALDH6A1 (2.89 fold);Downregulated in Metastatic PCa [A1AT (0.84 fold) ; HSP60 (0.19 fold);] Diagnostic Prostate Cancer Vs Benign Prostatic hyperplasia p=0.040 Serum 25786615
1920 miR-200b* miRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs Benign Prostatic hyperplasia p=0.045 Serum 25786615
1921 miR-210 miRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs Benign Prostatic hyperplasia p=0.003 Serum 25786615
1922 miR-297 miRNA Humans Upregulated in PCa [mean PC/mean]: (2.27 fold) Diagnostic Prostate Cancer Vs Benign Prostatic hyperplasia p=0.031 Serum 25786615
1923 miR-375 miRNA Humans Upregulated in PCa [mean PC/mean]: (2.13 fold) Diagnostic Prostate Cancer Vs Benign Prostatic hyperplasia p=0.009 Serum 25786615
1924 miR-501-3p miRNA Humans Upregulated in PCa [mean PC/mean]: (2.02 fold) Diagnostic Prostate Cancer Vs Benign Prostatic hyperplasia p=0.015 Serum 25786615
1925 miR-551b miRNA Humans Upregulated in PCa [mean PC/mean]: (2.30 fold) Diagnostic Prostate Cancer Vs Benign Prostatic hyperplasia p=0.017 Serum 25786615
1926 miR-562 miRNA Humans Upregulated in PCa [mean PC/mean]: (14.66 fold) Diagnostic Prostate Cancer Vs Benign Prostatic hyperplasia p=0.01 Serum 25786615
1927 miR-562+ miR-210 miRNA Humans Upregulated in PCa [mean PC/mean]: (2.12 fold) Diagnostic Prostate Cancer Vs Benign Prostatic hyperplasia NA Serum 25786615
1928 miR-562+ miR-210+ miR-501-3p miRNA Humans Upregulated in PCa [mean PC/mean]: (17.39 fold) Diagnostic Prostate Cancer Vs Benign Prostatic hyperplasia NA Serum 25786615
1929 miR-562+ miR-210+ miR-501-3p+ miR-375 miRNA Humans Upregulated in PCa [mean PC/mean]: (2.72 fold) Diagnostic Prostate Cancer Vs Benign Prostatic hyperplasia NA Serum 25786615
1930 miR-562+ miR-210+ miR-501-3p+ miR-375+ miR551b miRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign Prostatic hyperplasia NA Serum 25786615
1931 let-7a* miRNA Humans Upregulated in PCa Prognostic Disseminated PCa VS Localised PCa p=0.012 Serum 25786615
1932 miR-200b* miRNA Humans Upregulated in PCa Prognostic Disseminated PCa VS Localised PCa p=0.028 Serum 25786615
1933 miR-210 miRNA Humans Upregulated in PCa Prognostic Disseminated PCa VS Localised PCa p=0.01 Serum 25786615
1934 miR-297 miRNA Humans Upregulated in PCa [mean PC/mean]: (2.34 fold) Prognostic Disseminated PCa VS Localised PCa p=0.038 Serum 25786615
1935 miR-375 miRNA Humans Upregulated in PCa [mean PC/mean]: (2.34 fold) Prognostic Disseminated PCa VS Localised PCa p=0.014 Serum 25786615
1936 miR-501-3p miRNA Humans Upregulated in PCa [mean PC/mean]: (2.34 fold) Prognostic Disseminated PCa VS Localised PCa p=0.028 Serum 25786615
1937 miR-562 miRNA Humans Upregulated in PCa [mean PC/mean]: (2.34 fold) Prognostic Disseminated PCa VS Localised PCa p=0.03 Serum 25786615
1938 miR-616 miRNA Humans Upregulated in PCa [mean PC/mean]: (2.34 fold) Prognostic Disseminated PCa VS Localised PCa p=0.05 Serum 25786615
1939 let-7a*+ miR-210 miRNA Humans Upregulated in PCa [mean PC/mean]: (2.34 fold) Prognostic Disseminated PCa VS Localised PCa NA Serum 25786615
1940 let-7a*+ miR-210+ miR-562 miRNA Humans Upregulated in PCa [mean PC/mean]: (2.34 fold) Prognostic Disseminated PCa VS Localised PCa NA Serum 25786615
1941 let-7a*+ miR-210+ miR-562+ miR-616 miRNA Humans Upregulated in PCa [mean PC/mean]: (2.34 fold) Prognostic Disseminated PCa VS Localised PCa NA Serum 25786615
1942 let-7a*+ miR-210+ miR-562+ miR-616+ miR-297 miRNA Humans Upregulated in PCa [mean PC/mean]: (2.34 fold) Prognostic Disseminated PCa VS Localised PCa NA Serum 25786615